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ABSTRACT 
Physiology and Pathophysiology of Retinoid and Lipid Storage  
in Mouse Hepatic Stellate Cell Lipid Droplets 
Diana N. D’Ambrosio 
 
 Retinoids are important mediators of many physiological processes in the body, including 
vision, reproduction, embryonic development, immunity and bone growth.  Thus, the storage and 
metabolism of retinoids in the body has immediate implications for the overall health and 
metabolic homeostasis of the animal.  This thesis research focused on two retinoid metabolites: 
retinyl ester, the form in which retinoids are stored, and retinoic acid, the transcriptionally active 
retinoid metabolite.  Approximately 70% of retinoid in the body is stored in the liver, and, of this 
fraction, 80-90% is stored in the hepatic stellate cell (HSC) lipid droplets as retinyl ester.  These 
lipid droplets are a distinguishing feature of the HSC, and they have recently been proposed to be 
specialized organelles for the storage of retinoid based on their unique retinoid content and 
responsiveness to dietary retinoid status.  It is also known that the ability to synthesize and store 
retinyl ester in HSCs is necessary for the presence of HSC lipid droplets.  Interestingly, it is well 
established that, with the progression of liver disease in human patients, there is a progressive 
loss of total hepatic retinoid content.  As hepatic disease progresses, the HSCs transition from a 
quiescent to an activated phenotype, accompanied by the loss of their lipid droplet and retinoid 
content.  The ultimate goal of this dissertation was to further elucidate the factors that regulate 
HSC retinoid storage as retinyl esters in lipid droplets and to define the factors that regulate HSC 
lipid droplet genesis and dissolution.   
 The first aim of this research was to investigate the heterogeneity of HSCs and their lipid 
droplets in healthy, uninjured liver.  Our observations suggest that the HSC population in a 
healthy, uninjured liver is heterogeneous.  One subset of the total HSC population, which 
expresses early markers of HSC activation, may be primed and ready for rapid response to acute 
liver injury.  We show that these “pre-activated” HSCs have: (i) increased expression of typical 
markers of HSC activation; (ii) decreased retinyl ester levels, accompanied by reduced 
expression of the enzyme needed for hepatic retinyl ester synthesis (LRAT); (iii) decreased 
triglyceride levels; (iv) increased expression of genes associated with lipid catabolism; and (v) an 
increase in expression of the retinoid-catabolizing cytochrome, CYP2S1    
The second aim of this research was to investigate HSC lipid droplet formation and 
maintenance in healthy, but genetically-modified liver: specifically, we studied HSC lipid 
droplets in the LRAT KO mouse model, a system where HSC lipid droplets do not form.  Our 
findings indicate that there are not global differences in retinoid-related gene expression, 
suggesting that the formation and maintenance of HSC lipid droplets is likely regulated entirely 
by the synthesis and storage of retinyl ester and not by more profound changes in retinoid 
metabolism.  Our data also shows that the LRAT KO HSCs have significant differences in   
expression of genes related to lipid metabolism; overall, lipid biosynthesis is down-regulated and 
lipid catabolism is up-regulated in LRAT KO HSCs, which likely contributes to the complete 
absence of lipid droplets in the HSCs of these animals.  Importantly, we show for the first time, 
to our knowledge, that the lipid droplet-associated proteins may be post-transcriptionally 
regulated.        
A final aim of this research was to investigate HSC lipid droplet dissolution in HSC 
activation and hepatic fibrosis, systems where HSC lipid droplets form, but are subsequently lost.  
We employed two standard models of HSC activation, the in vivo model of carbon tetrachloride 
(CCl4) treatment and the in vitro model, the culture of purified HSCs on plastic cell culture 
dishes.  Additionally, we studied the effects of hypervitaminosis A since there is evidence in the 
literature that dietary vitamin A toxicity can cause hepatic fibrosis.  Our studies suggest that, 
despite being unable to synthesize and store retinyl ester in lipid droplets, LRAT KO mice are 
not more susceptible than WT to the development of diet- or chemically-induced hepatic fibrosis.  
We found that, while the culture of HSCs on plastic results in the typical hallmark events of HSC 
activation, including the upregulation of Col1a1, the decrease in retinyl ester and the loss of lipid 
droplets, it does not regulate gene expression as HSC activation does in vivo.  Thus, all future 
studies on HSC activation and its effects on retinoid storage should be conducted in vivo.  We 
also present preliminary data on the alterations in the lipidome of activated HSCs, specifically 
with regard to the potent lipid signaling molecules, endocannabinoids, sphingolipids and 
ceramides.  Our findings allow us to hypothesize that endocannabinoids and sphingolipids may 
function in activated HSCs as mediators of apoptosis.  Importantly, this study demonstrates the 
ability to detect these lipids in very small aliquots of in vivo-activated HSCs and provides a 
strong foundation upon which all future studies may be built.   
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I.  Introduction 
Retinoids (vitamin A and its metabolites, both natural and synthetic) are essential to 
many physiological processes, including reproduction, embryonic development, bone growth, 
immunity and vision [1].  These processes are regulated by the biologically active metabolite of 
vitamin A, retinoic acid.  Retinoic acid is a potent transcriptional regulator and, as such, 
regulates the transcription of over 500 genes via interactions with the retinoid nuclear receptors.  
This class of nuclear receptors includes the retinoic acid receptors and the retinoid X receptors, 
which are ligand-inducible transcription factors that belong to the steroid/thyroid hormone 
receptor superfamily [1].  The retinoic acid receptors (RARα, RARβ, and RARγ) bind to 
elements that activate transcription in response to all-trans-RA and 9-cis-RA, and retinoid X 
receptors (RXRα, RXRβ, and RXRγ) bind and activate transcription in response to 9-cis-RA.  
RARs associate with the RXRs to form heterodimers that bind to regulatory regions, usually 
present in the promoters of specific target genes, called RAREs (Retinoic Acid Response 
Elements) and directly regulate gene expression in the presence of appropriate ligand (Figure 1).   
Retinoid metabolism is complex and involves many different retinoid forms, in addition 
to retinoic acid, including retinyl esters, retinol, retinal, and oxidized and conjugated metabolites 
of both retinol and retinoic acid.  Furthermore, retinoid metabolism involves many carrier 
proteins and enzymes that are specific to retinoid metabolism, as well as other proteins which 
may be involved in mediating triglyceride and/or cholesterol metabolism.  This literature review 
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will focus on recent advances in the understanding of retinoid metabolism that are relevant to 
this dissertation research.  
 
II.  Metabolism of Dietary Retinoid within the Gastrointestinal (GI) Tract 
Retinoid metabolism within the GI tract occurs predominantly within the proximal 
portion of the small intestine and involves metabolic events that occur both in the lumen, as well 
as within the enterocyte [2-4].  These events are summarized in Figure 2 and are discussed 
below.  For optimal retinoid absorption, fat must be consumed along with the newly ingested 
retinoid.  This fat is needed to facilitate retinoid entry into enterocytes from the lumen of the gut.  
In addition, a fat load is needed to allow for optimal chylomicron formation, since retinoids, like 
other dietary lipids, enter the body as a component of nascent triglyceride-rich chylomicrons.  
The intestine is the primary tissue within the body where dietary proretinoid carotenoids, 
like β-carotene, are converted to retinoid.  Dietary proretinoid carotenoids, as well as non-
proretinoid carotenoids like lycopene and lutein, are incorporated into nascent chylomicrons and 
thus enter into the general circulation and the body. 
 
II A.  Dietary Forms and Metabolism in the Lumen of the Intestine  
Retinoid arrives from the diet either as preformed retinoid, consisting predominantly of retinol 
and retinyl ester, or as proretinoid carotenoids, which can be converted to retinoid within the 
intestine and other tissues.  The major dietary proretinoid carotenoids that contribute 
significantly in Western populations towards meeting dietary retinoid needs are α-carotene, β-
carotene and β-cryptoxanthin [5].  
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The key digestive processes that occur within the lumen of the intestine include the physical 
release of dietary retinoids and proretinoid carotenoids from the food matrix and their 
emulsification with dietary fatty acids and bile acids.  Emulsification with free fatty acids and 
bile salts is required to facilitate uptake of the highly insoluble retinoids and carotenoids into 
enterocytes from the lumen [2-4].  
Dietary retinol is taken up directly from the lumen into the enterocyte; however, dietary 
retinyl esters must first undergo enzymatic hydrolysis within the lumen or at the enterocyte brush 
border to allow for uptake of the hydrolysis product retinol [2-4].  The identities of pancreatic 
enzymes that act in a physiologically significant manner in retinyl ester hydrolysis within the 
lumen were explored systematically in the last decade using both induced mutant mice and 
biochemical approaches [6, 7].  Weng et al. reported studies of dietary cholesteryl ester and 
dietary retinyl ester absorption in wild type (WT) and carboxyl ester lipase (CEL) knockout mice 
[6].  These authors showed that, compared to WT mice, mice totally deficient in CEL absorbed 
only about 50% of the cholesterol provided as cholesteryl ester.  Although earlier published work 
had proposed that CEL acted importantly within the lumen to catalyze retinyl ester hydrolysis, 
WT and Cel-deficient mice absorbed similar amounts of retinol when it was provided in a 
gavage as retinyl ester.  Based on these findings, Weng et al. concluded that enzymes other than 
CEL must participate in the hydrolysis of dietary cholesteryl esters and retinyl esters within the 
GI tract [6].  This group of investigators subsequently reported studies that involved the 
separation and partial purification of pancreatic CEL and pancreatic triglyceride lipase (PTL) by 
DEAE-chromatography [7].  For both rats and mice, pancreatic retinyl ester hydrolase (REH) 
activity, measured by in vitro assay, was attributed mainly to PTL and, to a quantitatively lesser 
extent, to CEL.  Purified human PTL was reported to exhibit similar enzymatic characteristics 
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for both triglyceride  hydrolysis and retinyl ester hydrolysis.  Based on these biochemical data, it 
was concluded that PTL is the major pancreatic REH activity in rats and mice and is a 
catalytically active REH in humans, as well [7].  
Purified horse PTL was reported by Reboul et al. to hydrolyze retinyl ester when provided 
either in triglyceride-rich lipid droplets, mixed micelles or vesicles [8].  It was further reported 
by these investigators that purified dog pancreatic lipase-related protein 2 (PLRP2), but not 
purified horse pancreatic lipase related protein 1 (PLRP1), catalyzes retinyl ester hydrolysis [8].  
PLRP2-catalyzed retinyl ester hydrolysis required the presence of pancreatic colipase in order for 
activity to be observed.  PLRP2 showed activity towards retinyl ester that had been incorporated 
into mixed micelles, but not emulsions.  Based on these data, it was proposed that PTL and 
PLRP2 act synergistically within the lumen to catalyze dietary retinyl ester hydrolysis, 
enhancing the overall efficiency of retinoid absorption [8]. 
 
II B.  Metabolism and Processing within the Intestinal Mucosa 
 The intestine is the primary site of proretinoid carotenoid metabolism in the body.  
Dietary proretinoid carotenoids are taken up intact into the enterocyte, where they can undergo 
conversion to retinoid or be packaged unmodified into chylomicrons.  During the past decade, 
considerable research activity has been focused on carotenoid uptake into, and conversion to 
retinoid, within the intestine.  Similarly, there has been considerable progress made towards a 






1.  Uptake Into and Efflux from the Enterocyte 
 Both in vivo studies, involving the use of mutant mouse models, and in vitro cell culture 
experiments have established scavenger receptor class B, type I (SR-B1) as a key a mediator for 
uptake of β-carotene from the intestinal lumen into the enterocyte [9-11].  Van Bennekum et al. 
studied cholesterol and β-carotene uptake by WT and SR-B1 knockout mice and concluded that 
SR-B1 is required for β-carotene absorption, at least for mice consuming a high fat diet [9].  
These authors further showed that both SR-B1 and the plasma membrane fatty acid transporter 
CD36 can facilitate absorption of dietary cholesterol, but van Bennekum et al. were unable to 
establish whether SR-B1 acts essentially in vivo in facilitating this cholesterol uptake [9].  No 
evidence was obtained that CD36 acts in facilitating β-carotene absorption.  SR-B1 expression in 
transfected COS-7 cells [9] and in intestinal Caco-2 cells [10] was found to confer on these cells 
the ability to take up β-carotene from mixed bile salt micelles, phospholipid small unilamellar 
vesicles, and triglyceride emulsions, thus, providing further evidence for a role for SR-B1 in β-
carotene absorption.  In addition to facilitating mucosal uptake of the proretinoid carotenoid β-
carotene, SR-B1 also acts in facilitating uptake into the enterocyte of the non-proretinoid 
carotenoids lycopene and lutein [12, 13]. 
Retinol uptake into cultured intestinal Caco-2 cells has been reported by During and Harrison 
to occur via both a saturable process, when retinol was provided at concentrations below 10 µM, 
and a nonsaturable process at higher retinol concentrations [10].  Expression of SR-B1 is not 
required for retinol uptake into Caco-2 cells, since knockdown of SR-B1 expression with small 
inhibitory RNAs (siRNAs) failed to influence retinol uptake by the cells [10].  Interestingly, 
inhibition of expression of the cholesterol efflux transporter ATP-binding cassette, sub-family A, 
member 1 (ABCA1) in Caco-2 cells through use of either siRNAs or the drug glyburide, which 
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inhibits transport activity of ATP-binding cassette family members including ABCA1, 
diminished retinol efflux from the basolateral surface of the polarized cultures of Caco-2 cells 
[10].  These findings led to the proposal that retinol efflux from enterocytes is probably partially 
facilitated by the basolateral cholesterol transporter ABCA1.  However, later studies by Reboul 
et al., making use of both Caco-2 cells and Abca1-deficient mice, failed to confirm this earlier 
observation [14].  Although Reboul et al. were able to convincingly demonstrate a role for 
ABCA1 in facilitating absorption of both α- and γ-tocopherol, their data provide no support for 
the idea that ABCA1 contributes to retinoid efflux, in nascent chylomicrons, from enterocytes 
[14]. 
 
2.  Enzymatic Conversion of Proretinoid Carotenoid to Retinoid 
 The enzymes involved in converting proretinoid carotenoids to retinoid were long a 
matter of heated research controversy [3, 4].  From studies undertaken in the late 1950s and early 
1960s, it was clear that enzymes existed within mammalian tissues that are able to cleave β-
carotene, either symmetrically at its central 15,15' carbon-carbon double bond, forming two 
molecules of retinaldehyde, or asymmetrically at other carbon-carbon double bonds, forming two 
products of unequal chain length (Figure 3).  Largely owing to technical difficulties in purifying 
and cloning these enzymes, from the 1970s through the 1990s, there was considerable debate as 
to whether only the central cleavage reaction contributed to retinoid formation or whether 
asymmetric cleavage also gave rise to quantitatively significant retinoid formation.  This 
controversy was resolved in the last decade with the cloning and study of cDNA for two gene 
products, Bcmo1 and Bcmo2, which encode enzymes able to catalyze central and asymmetric β-
carotene cleavage, respectively.  cDNAs for Bcmo1 have now been cloned for the chicken [15], 
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mouse [16-18], rat [19], and human [20, 21], as well as for the fruit fly [22] and zebrafish [23].  
Kiefer et al. reported cloning cDNAs for Bcmo2 from the fruit fly, zebrafish, and the mouse and 
human [24]; whereas, Hu et al. reported cloning the ferret cDNA [25].  It is now established that 
only the Bcmo1 gene product, which encodes an enzyme able to catalyze the central cleavage of 
β-carotene, is significant within the body for mediating retinoid formation from dietary 
proretinoid carotenoids [26, 27]. 
Two structurally related proteins, β-carotene-15,15'-monooxygenase (BCMO1), encoded by 
Bcmo1, and β-carotene-9',10'-monooxygenase (BCMO2), encoded by Bcmo2, are the sole 
mammalian enzymes known to cleave carotenoids.  BCMO1 and BCMO2 are highly 
homologous to each other, with mouse BCMO1 and BCMO2 sharing 39% sequence identity.  
Each has a high degree of sequence homology to the retinal protein RPE65, which catalyzes the 
isomerization of all-trans-retinoid to the 11-cis-isomer for use in the visual cycle.  The older 
literature, based on the study of only partially purified enzyme, referred to BCMO1 as β-
carotene-15,15'-dioxygenase, rather than as a monooxygenase [2-4].  However, a reevaluation of 
the reaction mechanism for this enzyme, employing recombinant protein, indicated that it acts 
through a monooxygenase, rather than a dioxygenase mechanism [28].  Biochemical data 
obtained by different laboratories regarding the properties and expression of mammalian 
BCMO1 are in general agreement [15-21].  BCMO1 is a soluble, Fe+2-containing, 63 kDa 
protein.  It is expressed in the small intestine (at higher levels more proximal to the stomach), 
liver, kidney, lungs, skin, testis, the retinal pigment epithelium within the eye, and in a number of 
embryonic tissues.  
The biochemical properties and expression of BCMO2 have been less extensively studied 
than those of BCMO1.  Like BCMO1, BCMO2 contains Fe+2 and has a cytoplasmic localization 
  
8
within the cell [24, 25].  Both recombinant mouse and ferret BCMO2 catalyze cleavage of β-
carotene at its 9'10' carbon-carbon double bond, and both will catalyze lycopene cleavage at its 
9'10' carbon-carbon double bond [24, 25].  In the mouse, Bcmo2 is expressed in small intestine, 
liver, kidney, spleen, brain, and heart [24].  A similar tissue distribution has been reported for the 
ferret [25]. 
 
3.  Enterocyte Esterification of Retinol 
 Newly absorbed dietary retinol within the enterocyte must be esterified prior to its 
packaging as retinyl ester in nascent chylomicrons.  The older literature had indicated that the 
intestine possesses two distinct enzyme activities able to synthesize retinyl esters from retinol [2-
4].  One of these, lecithin:retinol acyltransferase (LRAT), catalyzes the transesterification of 
retinol employing a fatty acyl group present in the A1 position of a membrane phosphotidyl 
choline molecule.  The other, acyl-CoA:retinol acyltransferase (ARAT), catalyzes the fatty acyl-
CoA-dependent esterification of retinol.  Studies by O'Byrne et al. using Lrat-deficient mice 
established that, for mice receiving a physiologic dose of retinol (6 µg), LRAT-catalyzed retinol 
esterification accounted for approximately 90% of intestinal retinyl ester formation [29].  
Chylomicrons isolated from the dosed Lrat-deficient mice contained some retinyl ester, which 
was presumably synthesized by an intestinal ARAT, and relatively high levels of the free alcohol 
retinol, which were not observed in chylomicrons obtained from WT mice.  Subsequent studies 
by Wongsiriroj et al. established that the enzyme diacylglycerol acyltransferase 1 (DGAT1), 
which catalyzes triglyceride synthesis from diacylglycerol and fatty acyl-CoA, acts as a 
physiologically significant ARAT in the mouse intestine [30].  Normally, for a physiological 
dose of retinol, DGAT1 accounts for approximately 10% of the retinol esterified in the intestine. 
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However, the contribution DGAT1 makes to intestinal retinol esterification becomes 
considerably greater upon administration of a large pharmacologic dose of retinol (1000 µg) 
[30].  Under physiologic conditions, LRAT and DGAT1 account for all retinol esterification 
within the enterocyte since no retinyl esters could be detected in chylomicrons isolated from 
Lrat/Dgat1-double knockout mice given a physiologic dose of retinol.  However, when 
Lrat/Dgat1-double knockout mice were administered a pharmacologic dose of retinol, some 
retinyl ester could be detected in chylomicrons isolated from these mice, indicating the existence 
of other minor ARAT activities that can become active in response to excessive retinol intake 
[30].  In summary, LRAT accounts for the great majority of retinyl ester formed in the enterocyte 
upon consumption of normal dietary levels of retinoid; DGAT1, an intestinal ARAT, accounts 
for the remaining esterification activity. 
 
4.  Cellular Retinol-Binding Protein, Type II (CRBPII) 
 Retinoids are very insoluble in water and consequently within the aqueous environment 
of the body they are usually found bound to specific retinoid-binding proteins (see Table 1 
below for a listing of retinoid-binding proteins).  In the adult, CRBPII is reported to be expressed 
solely in the intestinal mucosa and is proposed to facilitate optimal retinol absorption from the 
diet [31].  Within the enterocyte, CRBPII represents 0.4-1.0% of the total cytosolic protein [32].  
To investigate the physiological role of CRBPII, Li and colleagues generated and studied CrbpII-
deficient mice [33].  When maintained on a retinoid-enriched diet, the knockout mice were found 
to have reduced (by 40%) hepatic retinoid stores, but the mutant mice grew and reproduced 
normally.  However, when maternal dietary retinoid levels were reduced to marginal levels 
during the latter half of gestation, a 100% mortality rate, within 24 hours after birth, was 
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observed for these litters [33].  These studies convincingly demonstrate that CRBPII acts to 
ensure adequate delivery of retinol to the developing fetus when dietary retinoid is limiting.  
Subsequent investigations making use of CrbpII-deficient mice bred into the Lrat-deficient 
background (lacking both CrbpII and Lrat) established that CRBPII metabolically channels 
retinol to LRAT for retinyl ester synthesis [30].  However, it could not be demonstrated 
experimentally that CRBPII directly prevents retinol from being acted upon in vivo by intestinal 
DGAT1 or other intestinal ARAT activities, as had been proposed in the older literature [2-4]. 
 
III.  Chylomicrons and Their Metabolism in the Circulation 
For uptake of dietary retinoid, retinyl ester is packaged along with other dietary lipids into 
nascent chylomicrons, which are secreted into the lymphatic system [2-4].  As mentioned above, 
dietary carotenoid that has not undergone conversion to retinoid is also incorporated into the 
nascent chylomicrons.  After entering the general circulation, the nascent chylomicrons undergo 
a process of remodeling that involves primarily the hydrolysis of triglyceride by lipoprotein 
lipase (LpL) and the acquisition of apolipoprotein E (apoE) from the circulation, resulting in the 
formation of chylomicron remnants. 
It has long been established that 66-75% of dietary retinoid (chylomicron and chylomicron 
remnant retinoid) is taken up by the liver where it is stored in hepatic stellate cells (HSCs), with 
the remainder being cleared by peripheral tissues [34].  However, the significance of this early 
observation for understanding retinoid metabolism has been greatly underappreciated.  Many 
general reviews and textbooks describe how tissues acquire needed retinoid as retinol bound to 
its specific binding protein, retinol-binding protein (RBP [35], also referred to as RBP4 in the 
literature).  But these general texts often fail to consider the contribution that postprandial 
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retinoids, present in chylomicrons and their remnants, make to tissue retinoid pools.  Yet, 25-
33% of all the dietary retinoid that is absorbed by the intestine is delivered via chylomicrons and 
their remnants to tissues other than the liver.  The physiological importance of the postprandial 
retinoid delivery pathway is underscored by the general good health of humans who lack RBP 
[36], as well as Rbp-deficient mice [37].  Both humans and mice that lack RBP are 
physiologically normal.  Thus, if these humans or animal models are provided retinoid regularly, 
at normal levels in the diet, the postprandial retinoid delivery pathway is sufficient to meet tissue 
requirements for retinoid.  It should be noted for completeness that the circulation also contains 
low levels of retinoic acid, which can contribute significantly to tissue retinoic acid pools [38]. 
The processes through which chylomicron/chylomicron remnant retinoid is absorbed by 
peripheral tissues are only now starting to be explored.  LpL can hydrolyze retinyl ester present 
in chylomicrons, and it has been proposed that retinyl ester hydrolysis facilitates retinol uptake 
by peripheral tissues [39].  For many tissues, there is now growing evidence that LpL facilitates 
uptake of postprandial retinoid into tissues.  Studies involving the use of different perturbations 
to LpL activity and/or levels within tissues have established that LpL acts to modulate 
postprandial retinoid uptake by skeletal muscle, heart and adipose tissue [39, 40], mammary 
tissue and milk [41, 42], and probably lung [43]. 
 
IV.  Hepatic Retinoid Metabolism 
The liver is the major site of retinoid metabolism and storage in the body [2-4].  There are 
two hepatic cell types important to these processes: the parenchymal cells (also known as 
hepatocytes) and the stellate cells (also known as fat-storing cells, lipocytes, Ito cells, and 
perisinusoidal cells).  The hepatocytes comprise approximately 66% of cells in the liver and 
contain 90% of the total protein mass [44-46].  The hepatic stellate cells (HSCs) are relatively 
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much smaller and less abundant.  The HSCs comprise only 6-8% of cells in the liver and contain 
1% of hepatic protein [44-46].  It is well-established that hepatocytes are involved centrally in 
the uptake and processing of retinol in the liver, and that HSCs play a central role in hepatic 
retinoid storage.  This section of the review will report on recent advances in our understanding 
of retinoid metabolism in hepatocytes and HSCs, including the uptake and processing of 
chylomicron retinyl ester by the hepatocyte, transfer of retinoid to the HSC, storage of retinoid in 
the HSC and hepatic retinol mobilization. 
 
IV A.  Uptake and Processing of Chylomicron Retinyl Ester by the Hepatocyte 
 
1.  Hepatic Chylomicron Remnant Receptors   
When the retinyl ester-containing chylomicron remnant arrives at the liver, it passes into the 
space of Disse (located between the endothelium and the hepatocyte) in a process referred to as 
sieving [47].  Only remnants of appropriate size can pass through, while larger particles, 
including whole chylomicrons, are excluded.  Once inside, the remnant is taken up exclusively 
by hepatocytes by one of two possible receptor-mediated pathways.  The topic of receptor-
mediated remnant uptake has been extensively and well reviewed by Cooper, and the reader is 
referred to this work for more detail [48].  Cooper recounts that one receptor-mediated pathway 
involves direct uptake by the low density lipoprotein (LDL) receptor, which has a high affinity 
for the apoE-rich chylomicron remnant particles, and internalization via endocytosis.  If the LDL 
receptor is absent, down-regulated or saturated, the remnants may be sequestered in the space of 
Disse by binding to heparin sulfate proteoglycans (HSPGs), mediated by apoE.  The remnants 
may also be sequestered through binding to hepatic lipase, which is enhanced by the presence of 
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apoB.  The remnants may eventually be transferred to LDL receptors as they become available 
or, if the remnants acquire enough apoE, transferred to an alternative receptor, the LDL receptor-
related protein (LRP).  LpL, acquired by the remnants during their formation, can facilitate 
uptake of remnants by LRP.  It has not yet been established the extent to which each receptor 
contributes to chylomicron remnant-retinyl ester removal, but it likely depends on the metabolic 
state of the animal, which in turn can influence the amount of apoE being secreted.  
The importance of HSPGs in chylomicron remnant uptake was demonstrated by Zeng et al. 
who showed that remnant binding to the hepatocyte is dependent on both the expression of 
HSPG core proteins and the functionality of HSPG heparin sulfate chains [49].  Remnant binding 
in HepG2 cells was significantly decreased by antisense oligonucleotide knockdown of HSPG, 
antibodies to heparin sulfate, heparinase treatment and by various disruptions of the heparin 
sulfate chains, including inhibition of glycosylation.  More recently, it’s been shown in vivo that 
the primary HSPG core protein involved in hepatic clearance of remnants is syndecan-1, which 
facilitates lipoprotein binding in the space of Disse [50].  
Though less understood, evidence for a third hepatic remnant uptake pathway is emerging.  
Studies in normal and apoE-deficient mice fed low- or high-fat diets showed that plasma 
clearance of chylomicron remnants is delayed with non-lipolyzed particles and is inhibited by 
lactoferrin, which blocks LRP [51].  When lipolysis was restored with the addition of hepatic 
lipase, no difference in uptake was observed between the two diet groups or in the presence and 
absence of apoE.  This provided evidence for an apoE-independent pathway that functions 
through LRP.  This idea was further investigated by Out et al., who proposed a mechanism 
involving interactions between remnant phospholipids and a receptor on the surface of 
hepatocytes, SR-BI [52].  In SR-BI-deficient mice, triglyceride-rich chylomicron-like particles 
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associate significantly less with isolated hepatocytes compared to WT mice, with a concomitant 
delay in postprandial triglyceride clearance [52].  Adenovirus-mediated hepatic overexpression 
of SR-BI significantly decreased serum cholesterol, phospholipids and TG [53].  While a role for 
SR-BI in chylomicron remnant metabolism in the liver is likely, it remains to be determined if 
and how it may interact with the other receptor systems. 
 
2.  Retinyl Ester Hydrolysis in the Hepatocyte 
 Upon entry into the hepatocyte, the retinyl ester is associated with early endosomes and 
undergoes rapid hydrolysis [54].  The hydrolysis of retinyl ester is carried out by a number of 
enzymes referred to in the literature as REHs, carboxylesterases and/or lipases.  
The first well-characterized REH was the bile salt-dependent CEL (see above for more details 
regarding CEL actions in the intestine), which is a potent bile salt-dependent REH in vitro [55, 
56].  Hepatic CEL was found to have very close similarity to pancreatic CEL in terms of mRNA 
sequence, enzymatic activity and antibody recognition [57].  Like pancreatic CEL, hepatic CEL 
is also a secreted enzyme, so it was first hypothesized to be involved in retinyl ester hydrolysis in 
the space of Disse [58].  However, it was shown that lack of CEL expression does not affect 
uptake of dietary chylomicron remnant-retinyl ester in the liver, and furthermore, the livers of 
CEL-deficient mice display similar REH activity compared to wild type livers [59].  The 
presence of REH activity in the liver distinct from CEL was confirmed by the discovery of 
neutral, bile acid-independent REH activity in rat liver homogenates that localized to the 
microsomal fraction, consistent with a role in retinyl ester hydrolysis in the plasma membrane 
and/or endosome, and was not cross-reactive with antibodies to the pancreatic enzyme [60].  It 
was later found that this activity was stimulated by the presence of apo-CRBPI at physiological 
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concentrations, suggesting apo-CRBPI may be a regulator of retinyl ester hydrolysis in vivo [61].  
Acidic bile salt-independent REH activity has also been observed in rat liver plasma membrane 
and endosomal fractions [62].  It has been postulated that the neutral REH acts on chylomicron 
remnant-retinyl ester at the cell surface and when it enters the early endosome, and as the pH 
drops in the late endosome, retinyl ester hydrolysis is continued by the acidic REH [63].  
Another group of enzymes proposed to be important to retinyl ester hydrolysis in the liver is 
the carboxylesterases.  Although over 30 liver carboxylesterases with various oxyester substrates 
have been identified, most of these enzyme activities are thought to arise as the gene products of 
five major loci in linkage group V and are referred to as ES-2, ES-3, ES-4, ES-10 and ES-15 
[64].  Of these five enzymes, ES-2, ES-4 and ES-10 have been shown specifically to possess 
REH activity in the liver in vitro [65, 66].  ES-4 functions primarily as a thioesterase to catalyze 
the hydrolysis of long-chain acyl Co-A [65], but it has also been shown to hydrolyze retinyl 
palmitate [67].  ES-2 and ES-10 have been shown to function as neutral bile salt-independent 
REHs.  Sun et al. purified REH activity from rat liver microsomal fractions that reacted with 
antibodies against ES-2, showed substrate preference for retinyl palmitate and had a pH optimum 
of 7 [66].  Similarly, they were able to purify REH activity that corresponded to the protein size 
and amino acid sequence of ES-10 and also demonstrated immunoreactivity to antibodies 
directed against ES-10.  More recently, ES-22 has been reported to be a hepatic REH.  Schreiber 
et al. identified ES-22 as a hepatocyte-expressed esterase that localizes to the ER [68].  These 
investigators showed that ES-22 specifically hydrolyzes retinyl palmitate, but not triolein or 
cholesteryl oleate.  Additionally, overexpression of ES-22 inhibited the accumulation of retinyl 
esters in Cos-7 cells.  
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A number of in vitro studies have also identified some well characterized lipases that possess 
REH activity, including hepatic lipase [69], LpL [39, 40], PTL [7, 8], and hormone sensitive 
lipase (HSL) [70].  Mello et al. have shown that, of these, only hepatic lipase and LpL are 
expressed in the liver (mRNA levels of PTL and HSL in all liver cell types were very low) [71].  
Hepatic lipase is exclusively expressed in hepatocytes and is the only secreted lipase expressed 
in these cells [71].  It is secreted by the hepatocyte into the space of Disse, where it can function 
in the binding and uptake of chylomicron remnants and possibly in the hydrolysis of 
chylomicron remnant retinyl ester, though there is currently no direct evidence for the latter 
possibility.  LpL is expressed at very low levels in hepatocytes and HSCs, but its expression is 
induced 32-fold in activated HSCs [71].  Thus, Mello et al. propose that it is unlikely LpL 
functions in the hydrolysis of newly absorbed hepatic chylomicron remnant-retinyl ester, but 
rather may have a role in the hydrolysis of lipid droplet retinyl esters in activated HSCs [71].  
How this might occur is unclear, given that LpL is a secreted enzyme, and there is no evidence 
for it acting intracellularly.  A summary of proposed REHs in hepatocytes can be found in Table 
2.  
     The physiological significance of the many lipid hydrolases and carboxylesterases in the liver 
remains to be identified.  However, this uncertainty is true for many other tissues in the body as 
well; in vivo retinyl ester hydrolase activity has only been determined for a number of these 
enzymes.  For example, it is clear that PTL and PLRP2 are physiologically significant retinyl 
ester hydrolases in the intestine.  As discussed in further detail below, LpL-catalyzed retinyl ester 
hydrolysis is important for facilitating postprandial retinol uptake into adipose tissue, heart and 
skeletal muscle.  And similarly, it is known that HSL catalyzes retinyl ester hydrolysis in 
adipocytes to allow for retinol mobilization into the circulation.  With these exceptions, the 
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identities of most other physiologically significant retinyl ester hydrolases remain obscure.  It is 
likely that several other enzymes will be shown to have physiologically significant and distinct 
roles in catalyzing this reaction.  With respect to the liver, we speculate that this may include 
hepatic lipase in hepatocytes and HSL in HSCs.  Much work remains to elucidate the roles of 
these many enzymes in the various tissues that function in the uptake and metabolism of retinoid 
in the body.         
 
IV B.  Transfer of Retinol from Hepatocytes to HSCs 
After the chylomicron retinyl ester is hydrolyzed to retinol within the hepatocyte, it is 
then transferred to the HSC where it is re-esterified and stored in lipid droplets.  This transfer 
occurs primarily in times of sufficient or excess retinoid intake, so that these retinoid stores may 
be called upon and mobilized in times of vitamin A deficiency.  The mechanism of transfer has 
not been the focus of more recent research and thus, is not fully understood.  A couple of 
possibilities exist and are discussed below. 
 
1.  RBP-Mediated Transfer 
Early studies suggested that this transfer is mediated by retinol-binding protein (RBP).  
Blomhoff et al. reported that antibodies against RBP completely blocked the transfer of retinol 
from hepatocytes to HSCs [72].  Following loading of hepatocytes in vivo by intravenous 
injection of [3H]retinyl ester-labeled chylomicrons, livers were perfused in situ with either a 
control buffer or a buffer containing an excess of antibodies against RBP.  In both groups, the 
radioactivity recovered 10 min after loading was significantly higher in hepatocytes than in 
HSCs; after 40 min of perfusion, the control group showed significantly higher 3H-cpms 
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associated with the HSCs, while the HSCs from the livers perfused with the RBP antibodies still 
had less 3H-cpms than hepatocytes.  A similar study by Senoo et al. showed that antibodies to 
RBP blocked its transfer from HepG2 cells to rat HSCs, when the cells were co-cultured [73].  
This study also showed that RBP could be internalized by cultured HSCs when the cells were 
incubated with human RBP.  RBP was first observed to be associated with vesicles close to the 
cell surface and membrane and was later found deeper in the cytoplasm within endosomes.  The 
findings that RBP is able to be bound and internalized by HSCs and that antibodies to RBP 
inhibited transfer of retinol into HSCs was taken to suggest that RBP mediates this transfer.  
However, the generation of Rbp-deficient mice allowed this hypothesis to be tested directly, 
and the results are not in agreement with these earlier proposals.  Quadro et al. showed that, in 3- 
and 13-week-old mice, there is no statistical difference in hepatic total retinol levels between WT 
and Rbp-deficient mice; thus, the absence of RBP does not impair hepatic uptake of retinol [37].  
It was later demonstrated that there is no quantitative or qualitative differences in the lipid 
droplets present in liver sections from Rbp-deficient compared to WT mice, suggesting that 
retinol transfer to HSCs for storage is unaffected by the absence of RBP [74].  These studies 
provide strong evidence that RBP does not act in an essential manner in the transfer of retinol 
from hepatocytes to HSCs.  
 
2.  CRBPI-Mediated Transfer 
 The involvement of CRBPI in the transfer process has been suggested by data from 
Ghyselinck et al. [75], whose studies of CrbpI-deficient mice suggest that CRBPI may mediate 
the transfer of retinol from hepatocytes to HSCs [75].  CrbpI-deficiency was found to result in 
significantly lower hepatic retinyl ester levels, with mutant mice having a 50% reduction in 
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levels of retinyl palmitate, the main retinyl ester form found in the liver.  Light microscopy also 
revealed that the HSCs of CrbpI-deficient mice are characterized by a reduction in both the 
number and size of lipid droplets.  This suggests a decrease in retinyl ester synthesis that likely 
occurs due to impaired delivery of retinol to the retinyl ester-synthesizing enzyme LRAT, which 
is highly expressed in HSCs [76].  These studies clearly indicate that CRBPI is necessary for 
assuring efficient retinol esterification and storage in vivo.  Future studies are needed to confirm 
how the presence and absence of CRBPI affects total retinol levels specifically in hepatocytes 
and HSCs.  
 
IV C.  Storage of Retinoid in the HSC as Retinyl Ester in Lipid Droplets 
 
1.  The Role of HSC Lipid Droplets in Retinoid Storage 
The most distinguishing feature of the HSC is the presence of numerous retinyl ester-
containing lipid droplets in the cytoplasm, which have recently been proposed to be specialized 
organelles for retinoid storage [76].  This idea arises from numerous studies showing the unique 
retinoid content of these droplets, their responsiveness to dietary retinoid status, their dependence 
on the synthesis of retinyl ester, and their loss in different types of hepatic disease.  Taken 
together, these studies have demonstrated a strong regulatory role of retinoids in HSC lipid 
droplet physiology.  This will be discussed below in more detail. 
 
2.  Esterification of Retinol in the HSC 
After transfer from the hepatocyte to the HSC, retinol is esterified back to retinyl ester for 
storage in HSC lipid droplets.  Once in the HSC, retinol is bound by CRBPI and transferred to 
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LRAT for esterification [77].  The binding of retinol to CRBPI is necessary for its transport in 
the aqueous environment of the cytosol and has been proposed to prevent acyl CoA-dependent 
enzymes in the liver from catalyzing retinyl ester formation [77].  Both LRAT and CRBPI are 
enriched in HSCs [3, 4, 85], and both proteins are needed to assure optimal HSC accumulation of 
retinoid stores.  
LRAT is the only known enzyme capable of esterifying retinol in the liver in vivo.  Earlier in 
vitro studies suggested that an unidentified ARAT(s) may work in conjunction with LRAT to 
catalyze retinyl ester formation [78].  As mentioned above, DGAT1 has been shown to 
participate in retinol esterification in vitro [29, 79, 80] and in the intestine and skin in vivo [30, 
81].  Thus, DGAT1 became a candidate for in vivo esterification of retinol in the liver, as well.  
However, the generation and study of Lrat-deficient mice fail to support both possibilities.  
O’Byrne et al. show that the livers of Lrat-deficient mice have undetectable levels of retinyl ester 
and are completely void of lipid droplets [29].  These studies not only proved that LRAT is the 
only retinol esterifying enzyme present in the liver, but also that LRAT and/or its product retinyl 
ester is necessary for HSC lipid droplet formation.  Around the same time, Liu and Gudas 
reported that disruption of the Lrat gene makes mice more susceptible to retinoid-deficiency 
[82].  After maintenance on a retinoid-deficient diet for 6 weeks, Lrat-deficient mice had 
significantly lower serum retinol levels than WT mice and undetectable levels of retinol in a 
number of tissues studied, including the liver.  Thus, Liu and Gudas proposed that Lrat-deficient 






3.  HSC Lipid Droplet Content and Effects of Dietary Retinoid Status 
 Moriwaki et al. reported the lipid composition of lipid droplets isolated from primary rat 
HSCs [83].  In rats maintained on a control diet, the mean percent lipid composition consisted 
approximately of 40% retinoid lipid and 60% non-retinoid lipid, broken down as follows: 39.5% 
retinyl ester, 31.7% triglyceride, 15.4% cholesteryl ester, 6.3% phospholipid, 4.7% cholesterol 
and 2.4% free fatty acids.  The retinyl esters present in these droplets possess only long chain 
fatty acyl moieties, with retinyl palmitate followed in abundance by retinyl stearate, retinyl 
oleate and retinyl linoleate [84].  In the same study, the rats were maintained on four additional 
experimental diets containing either low or high retinol and low or high triglyceride.  The 
investigators found that HSC lipid droplet retinyl esters, as well as other lipids, are decreased in 
response to a low retinol diet, and both retinoid and non-retinoid lipids are elevated in response 
to a high retinol diet; however, neither retinoid nor non-retinoid content is affected by low or 
high fat diets.  This data was taken to indicate that the lipid composition of HSC lipid droplets is 
strongly influenced by dietary retinoid status, but not by dietary triglyceride intake. 
 
4.  HSC Lipid Droplets in Hepatic Disease 
 Following acute liver injury, a wound healing response is initiated, which ultimately 
returns the liver to its healthy state [44-46].  However, when the liver is confronted with chronic 
injury, the result is often hepatic fibrosis, which is the formation of excess fibrous connective 
tissue as a reparative process to contain the site of injury.  The most common causes of hepatic 
fibrosis include chronic hepatitis B and C infection, alcoholism, non-alcoholic fatty liver disease 
(NAFLD), and bile duct obstruction.  Further progression of disease will lead to cirrhosis and 
eventually hepatocellular carcinoma.  Seminal work by Leo and Lieber established that with this 
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progression of liver disease in human subjects is the progressive depletion of hepatic retinoid 
[85].  These investigators found that there is a near 5-fold decrease in total hepatic retinol levels 
with the development of alcoholic hepatitis, and another approximate 4-fold decrease with the 
development of cirrhosis.  It remains unclear whether this loss of hepatic retinoid content is a 
causative agent or simply a consequence of disease. 
As a result of injury, HSCs undergo a process of activation in which they transition from a 
quiescent state to a myofibroblastic phenotype [86, 87].  Activated HSCs are characterized by 
increased synthesis of extracellular matrix (ECM) and thereby become fibrogenic and 
proliferative [86, 87].  There are currently several in vivo models of HSC activation, including 
carbon tetrachloride injection and bile duct ligation, and one commonly studied in vitro model, 
the culture of primary HSCs on plastic.  It has been demonstrated that the changes in gene 
expression that accompany HSC activation and the loss of HSC retinyl ester lipid droplets are 
regulated differently in the in vitro model and the in vivo models [88].  Thus, the study of HSC 
activation can only be studied in the context of the disease model employed.  
Two hypotheses have been proposed to account for the loss of retinyl ester lipid droplets in 
hepatic disease.  One theory is that HSC activation results in a “toxic burst” of transcriptionally 
active retinoids from the lipid droplet stores and, acting through the retinoic acid receptors and 
the retinoid X receptors (all of which are expressed in HSCs), lead to the altered gene expression 
patterns seen with activation [89, 90].  The other proposes that the retinoid stores in these lipid 
droplets play a protective role, such that their presence buffers against hepatic insult [91].  When 
these stores are absent, an injury to the liver will result in fibrosis and hepatic disease.  This 
second hypothesis seems unlikely considering Lrat-deficient mice are not predisposed to 
developing spontaneous hepatic fibrosis [29].  However, more definitive studies need to be 
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conducted before the linkage between the loss of HSC retinoid stores and hepatic disease can be 
determined. 
 
IV D.  Mobilization of Retinol from Hepatic Stores to Peripheral Tissues 
 
1.  Hydrolysis of HSC Lipid Droplet Retinyl Ester 
 As mentioned above, HSC lipid droplet retinyl ester stores must be mobilized in times of 
dietary retinoid-insufficiency to supply peripheral tissues with retinoid needed for maintaining 
various essential biological functions.  Mobilization requires that the retinyl ester first be 
hydrolyzed back to retinol.  It is currently not known which lipases are involved in the hydrolysis 
of HSC retinyl ester, but there are several candidate enzymes based on their REH activity and/or 
expression in HSCs (Table 2).  As discussed above, ES-2, ES-4 and ES-10 are three hepatic 
carboxylesterases shown to have REH activity [65, 66].  Mello et al. show that ES-4 and ES-10 
are expressed in HSCs, albeit at very low levels compared to hepatocytes [71].  Their REH 
activity and expression in HSCs make ES-4 and ES-10 strong candidates for HSC lipid droplet 
retinyl ester hydrolases.  Another candidate for HSC retinyl ester hydrolysis is adipose 
triglyceride lipase (ATGL).  ATGL is the key enzyme for triglyceride hydrolysis in adipocytes 
[92], and its lipase activity in vivo is dependent on coactivation by CGI-58 [93].  Earlier studies 
suggested ATGL does not have REH activity, but these studies were done in the absence of CGI-
58 [92].  Mello et al. found that ATGL is expressed highly in HSCs and propose that, in the 
presence of CGI-58, will have REH activity [71].  However, this possibility has not yet been 




2.  Role of RBP in Hepatic Mobilization of Retinol 
 Upon hydrolysis of HSC lipid droplet retinyl ester, retinol is thought to be transferred 
back to the hepatocyte, where it is bound by its specific transport protein, RBP.  RBP is a 21 kDa 
protein with a single binding site for one molecule of all-trans-retinol, and the hepatocyte is the 
major (though not exclusive) site of RBP synthesis in the body [95].  Once bound by RBP, the 
retinol-RBP complex enters the bloodstream for transport to peripheral tissues.  Secretion of 
RBP by the hepatocyte is highly regulated by the retinoid status of the animal, such that RBP 
secretion is blocked in times of dietary deficiency and restored upon retinol-repletion [94].  
The importance of RBP in maintaining retinoid homeostasis in the body was demonstrated by 
Quadro et al. through generation of Rbp-deficient mice [37].  These investigators show that, in 3- 
and 13-week-old mice, there is no statistical difference in hepatic total retinol levels between WT 
and Rbp-deficient mice; thus, the absence of RBP does not impair hepatic uptake and 
accumulation of retinol.  However, when these investigators measured hepatic and serum retinol 
levels in 5-month-old mice, they found that hepatic retinol and retinyl ester levels were 
significantly higher in Rbp-deficient compared to WT mice and, additionally, serum total retinol 
levels were significantly lower.  These data indicate that Rbp-deficient mice can acquire hepatic 
retinol stores, but these cannot be mobilized.  It was later shown using transgenic mice that 
express human RBP that extrahepatically synthesized RBP cannot be taken up by hepatocytes 
and cannot function in the mobilization of hepatic retinol stores [74].  Only RBP synthesized in 
the liver can mobilize hepatic retinol stores. 
In the blood, RBP is found in a 1:1 protein-protein complex with a 55-kDa serum protein, 
transthyretin (TTR) [95].  The retinol-RBP-TTR complex is the predominant transport molecule 
through which retinol is delivered to peripheral tissues in the fasting circulation.  In the absence 
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of TTR, plasma retinol and RBP levels are only approximately 5% of those that are observed in 
matched WT mice [95].  It has been established that the association of RBP with TTR prevents 
filtration of the relatively small RBP molecule through the kidney glomeruli [96].  Studies by 
van Bennekum et al. employing Ttr-deficient mice have demonstrated the importance of TTR in 
maintaining normal levels of retinol and RBP in the circulating plasma.  Subsequent studies 
established that, when a physiologic dose of human retinol-RBP was injected intravenously into 
Ttr-deficient mice, it was cleared more rapidly from the plasma and accumulated more rapidly in 
the kidneys of Ttr-deficient than WT mice [96].  These data were taken by the authors to indicate 
that the reduced levels of retinol and RBP in the circulations of Ttr-deficient mice arise, at least 
in part, due to increased filtration of the retinol-RBP complex.  Other studies of Ttr-deficient 
mice showed that the livers of these mutants have similar levels of retinol and retinyl ester 
compared to WT mice, but 60% higher levels of RBP protein [97].  These data indicated that 
TTR does not have a role in hepatic uptake or storage of dietary retinol, but suggested it may 
play a role in hepatic secretion of RBP.  However, van Bennekum et al. were unable to establish 
directly that the absence of TTR affects RBP secretion from hepatocytes [96].  These 
investigators showed that cultured primary hepatocytes isolated from Ttr-deficient mice 
accumulated RBP in their culture media to the same degree as hepatocytes from WT mice; thus, 
RBP was being secreted from hepatocytes at the same rate in the presence and absence of TTR.  
 
V.  Uptake of Retinoids by Extrahepatic Tissues 
 In the fasting state, >95% of retinoid in the circulation is found as retinol bound to RBP 
(i.e. as retinol-RBP).  The remainder of circulating retinoid in the fasting circulation is comprised 
of a variety of low abundance species, including retinyl esters associated with lipoproteins (very 
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low density lipoprotein (VLDL), low density lipoprotein (LDL), and high density lipoprotein 
(HDL)) and retinoic acid bound to albumin.  In the postprandial state, chylomicron retinyl ester 
is elevated and can quantitatively predominate over retinol-RBP [4].  In this section, recent 
advances in our understanding of how retinol-RBP is taken up in extra-hepatic tissues will be 
discussed, as well as insights into mechanisms associated with the uptake of retinol from 
postprandial, chylomicron-remnant derived, retinyl ester (summarized in Figure 4). 
 
V A.  Uptake of Retinol-RBP from the Blood by Extrahepatic Tissues 
While the spontaneous transfer of free retinol across the phospholipid bilayer is a 
possibility supported by experimental evidence, the existence of a cell-surface receptor for RBP 
has been postulated since the mid-1970’s (extensively reviewed in [4]).  In 2007, Kawaguchi et 
al. identified and studied a transmembrane-spanning protein STRA6 (stimulated by retinoic acid 
6) that acts as a receptor for RBP in many, but not all, tissues (since it is not expressed in all 
retinoid metabolizing tissues) [98].  These authors demonstrated that (i) RBP can bind to STRA6 
with high affinity, (ii) STRA6-transfected cells efficiently take up retinol, especially if LRAT is 
expressed within the cells, (iii) RNAi knockdown of STRA6 suppresses retinol uptake, and (iv) 
STRA6 is expressed in tissues consistent with its function as an RBP receptor.  These 
experiments provide strong evidence that STRA6 can function as an RBP receptor and mediate 
the cellular uptake of retinol.  Interestingly, a synergy exists between STRA6 and LRAT 
expression, such that cells expressing both proteins uptake relatively more retinol than cells 
expressing either protein individually [98, 99].  This phenomenon indicates that conversion of 
retinol into retinyl ester by LRAT within the cell maintains the driving force for STRA6-
mediated retinol uptake.  This suggests a model whereby circulating retinol-RBP binds to 
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STRA6 located on the cell surface, facilitating uptake of retinol and its conversion to retinyl ester 
by LRAT. 
The concept of STRA6-mediated cellular uptake of retinol has been extended to include 
STRA6-mediated efflux of retinol from the cell by von Lintig and colleagues.  Cell culture 
experiments have shown that STRA6-expressing cells, preloaded with retinol, release more 
retinol into the culture medium than cells which do not express STRA6, a process which is RBP-
dependent [99].  In vivo evidence of STRA6-mediated retinol efflux comes from observations 
made in the developing mouse embryo [100].  Embryonic STRA6 expression is upregulated in 
response to maternal dietary retinoid-excess.  Similarly, STRA6 levels were elevated in Lrat-
deficient mouse embryos, where intracellular retinol levels would be higher because of the 
incapacity to convert retinol to retinyl ester.  These data are taken to indicate that STRA6 is 
upregulated to facilitate export of excessive levels of retinol from the cell [100].  These findings 
suggest that STRA6 acts as a bidirectional transporter of retinol, with intracellular retinol 
concentrations determining the polarity of transport. 
The notion that STRA6 acts as a bidirectional retinol transporter is attractive, as it resolves a 
theoretical paradox with regard to STRA6 expression [101].  If one accepts that STRA6 
facilitates retinol uptake and that its expression is stimulated by retinoic acid, then in times of 
excess retinoic acid, STRA6 expression would increase and drive more potentially toxic retinoid 
into the cell.  This detrimental scenario is avoided if we accept that STRA6 also facilitates retinol 
export.  Here, excess retinoic acid and the associated increase in STRA6 would channel retinol 
out of the cell, thereby protecting it.  It is possible that STRA6 functions at a basal level to 
import retinol into the cell to maintain intracellular retinoid homeostasis, and in times of retinol 
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excess within the cell it can be upregulated and function in retinol export, protecting the cell 
from a potentially cytotoxic build up of retinoid. 
The hypothesis that STRA6 expression is driven by retinoic acid is supported by studies in 
several cell lines [102-105].  But data from in vivo measurements of STRA6 expression are not 
in good agreement.  High maternal dietary retinoid intake is associated with increased embryonic 
STRA6 expression [100], and retinoic acid has been shown to increase STRA6 expression in the 
lungs of neonatal rats [106].  However, these data conflict with observations from chick 
embryos, in which retinoic acid soaked beads had no effect on STRA6 expression [107].  If we 
consider the opposite extreme of retinoid nutriture, the data are also contradictory.  Mouse 
embryos from dams deprived of dietary retinoid showed no change in STRA6 expression [100], 
whereas retinoid-deficient quail embryos upregulate STRA6 [107].  It is likely that control of 
STRA6 expression is tightly regulated at both the gene and protein levels, and depends on the 
cellular context and retinoid status of the animal.  
Irrespective of debate regarding the physiological function of STRA6, a role in cellular 
retinoid homeostasis is pointed to by the severe congenital abnormalities associated with STRA6 
mutations in humans.  Postulated loss-of-function mutations in STRA6 have been found in more 
than 20 individuals with syndromic anophthalmia/microphthalmia, in association with variable 
malformations of the heart, lungs, and diaphragm (Microphthalmic syndrome 9, OMIM 601186) 
[108-115].  Significantly, retinoid signaling is known to be important in the development of the 
eye [116, 117], lungs [118, 119], heart [120, 121], and diaphragm [122, 123].  Further, 
malformations in these tissues are commonly found as part of the maternal retinoid-deficiency 
syndrome [124].  The parallel between the effects of maternal retinoid-deficiency and STRA6 
mutation supports the concept that STRA6 is needed for maintaining cellular retinoid 
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homeostasis during organogenesis.  Interestingly, there is a discrepancy between the severe 
outcome of STRA6 mutation in humans, and mutations of RBP, which yield only a mild clinical 
phenotype [36, 37], leading some authors to speculate that STRA6 may have other unknown 
functions in addition to it being an RBP receptor [101].  
 
V B.  Extrahepatic Uptake of Chylomicron Retinyl Ester 
 As mentioned above, nascent chylomicrons from the intestine are rapidly metabolized in 
the general circulation, yielding smaller lipoprotein particles called chylomicron remnants.  It has 
been well established that while ~75% of postprandial retinyl ester is taken up by the liver, the 
remaining ~25% is taken up by extra-hepatic tissues, including white adipose tissue, skeletal 
muscle, heart, lungs, and kidneys [34, 40, 59].  The physiological importance of postprandial 
retinyl ester uptake into extra-hepatic tissues was initially unclear; however, a growing body of 
evidence suggests that this source can be an important factor in maintaining retinoid homeostasis 
in specific tissues. 
A physiologic role for uptake of postprandial retinyl ester was highlighted in mice lacking 
RBP [37].  Despite having only trace levels of circulating retinol and having an impaired ability 
to mobilize hepatic retinol, Rbp-deficient mice are viable and fertile.  These mice do have a 
transient visual defect, though this resolves with age.  The relatively benign phenotype of these 
mice led the authors to hypothesize that retinoid homeostasis was being maintained by uptake of 
postprandial retinoid.  Investigation of Rbp-deficient mice revealed that the mutant mice have a 
relatively high concentration of circulating retinyl ester in the chylomicron/VLDL plasma 
fraction, supporting the hypothesis that chylomicron-derived retinyl esters were important in 
maintaining their good health [125].  It was also found that the eye is particularly poor at taking 
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up chylomicron-derived retinyl ester; this suggests why vision was impaired in these animals, 
whereas other organ systems were unaffected because of their ability to readily uptake 
postprandial retinyl ester [126].  Study of Rbp-deficient mice also indicated that these mice can 
use postprandial retinyl ester to support normal embryogenesis [125].  This concept was 
investigated in more depth showing that retinyl ester is important for the establishment of fetal 
retinoid stores, whereas retinol-RBP has a more direct role in embryogenesis and organogenesis 
[127].  
The contribution of postprandial retinyl ester uptake has also been studied in other tissues.  In 
the lactating mammary gland, a contribution of retinyl ester into milk retinoid has been shown in 
non-human primates and rodents [41, 128-130].  The magnitude of this contribution is thought to 
reflect dietary retinoid intake, such that with increasing levels of retinoid consumed in the diet, 
the proportion of chylomicron-derived retinyl ester in the milk relative to retinol-RBP, also 
increases.  In the extreme, it has been shown that chylomicron retinyl ester uptake can 
completely compensate for Rbp-deficiency in mammary tissue, such that the retinoid content of 
milk in Rbp-deficient mice is identical to age- and diet matched WT mice [42].  Another tissue in 
which the contribution of postprandial retinyl ester uptake is thought to be important is the lung 
[43].  Studies in rats have shown that the retinoid content of the lung is reduced in 9 week old 
rats that were raised on a retinoid-deficient diet.  Neonatal retinoid supplementation of these 
animals was sufficient to normalize serum and liver retinoids levels, but lung levels remained 
low.  This finding can be interpreted to indicate that the lung requires a direct contribution of 
postprandial retinoid to accumulate retinoid stores, presumably from chylomicrons [43]. 
In addition to understanding the physiological significance of postprandial retinyl ester 
uptake, the biochemical mechanisms involved are of interest.  It was hypothesized in the mid-
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1990s that LpL may have a physiological role in the hydrolysis of chylomicron retinyl ester, 
thereby facilitating its uptake [39].  In a series of in vitro experiments, these authors 
demonstrated that LpL can catalyze the hydrolysis of retinyl ester in its four most abundant 
forms (retinyl palmitate, retinyl oleate, retinyl stearate, and retinyl linoleate).  Triglycerides were 
the preferred substrate for LpL, though when the majority of triglycerides were hydrolyzed 
(~75%), retinyl ester hydrolysis was observed.  Also, the inclusion of apolipoprotein C-II, a 
known LpL activator [131], further enhanced the LpL-catalyzed hydrolysis of retinyl ester.  
These experiments, coupled with the observation that hydrolysis of retinyl ester to retinol by LpL 
was associated with increased retinoid uptake by BFC-1β adipocytes, strongly suggested that 
LpL may have a physiological role in the extrahepatic uptake of retinoid [39].   
In vivo evidence in support of this hypothesis came from experiments in which the tissue 
levels of LpL expression were experimentally manipulated [40].  Specifically, mice over-
expressing LpL in skeletal muscle show increased uptake of chylomicron retinoid into their 
skeletal muscle.  Similarly, double-mutant mice, over-expressing human LpL in skeletal muscle, 
but containing a null mutation in the murine LpL gene, show decreased levels of uptake in the 
heart.  In another series of experiments, LpL activity was modulated in rats by fasting.  In the 
fasting rat, adipose tissue LpL activity is decreased, and heart and skeletal muscle activity is 
increased.  Accordingly, fasted animals had decreased retinyl ester uptake in the adipose tissue 
and increased uptake in the heart and skeletal muscle, relative to control.  A further dissection of 
LpL-facilitated uptake of chylomicron retinyl ester in the heart has recently been undertaken 
[132].  These authors show that uptake of chylomicron derived retinyl ester is significantly 
reduced in mice with a heart-specific deletion of LpL.  Uptake was unaffected in CD36 knock-
out mice and LpL/CD36 double knock-out mice, suggesting that this fatty-acid transporter is not 
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essential for retinol uptake into the heart.  Taken together these results indicate that, at least in 
skeletal muscle, heart, and adipose tissue, LpL expression and activity closely reflect the tissue’s 
ability to take up chylomicron retinyl ester, such that increased expression is associated with 
increased uptake, and vice versa.   
Interestingly, while LpL appears to facilitate chylomicron retinyl ester uptake in these tissues, 
other tissues which take up postprandial retinyl ester were unaffected by manipulations of LpL 
expression/activity, such as the kidneys and lungs.  This indicates that an unidentified, LpL-
independent mechanism, exists to mediate the extra-hepatic uptake of chylomicron retinyl ester.  
Another interesting finding of these studies was the observation that steady-state tissue retinoid 
levels were unchanged.  Despite increased uptake in some tissues, there was no quantitative 
change in tissue retinoid levels.  This could suggest that the increase in retinoid uptake was not 
matched by an increase in the capability to store retinoid within the cell, and the excess retinoid 
taken up was redistributed throughout the body.  This indicates that the retinoid-storage capacity 
of a tissue, given normal dietary retinoid intake levels, resides within the tissue.  In addition to 
skeletal muscle, heart, and adipose tissue, LpL has also been shown to be an important mediator 
of chylomicron retinoid uptake in mouse and rat mammary tissue [41, 42]. 
It is evident that extrahepatic tissues can take up postprandial retinyl ester from chylomicrons 
and that in Rbp-deficiency this is sufficient to maintain normal retinoid homeostasis provided 
dietary retinoid is sufficient.  The mechanisms which mediate retinyl ester uptake in the 






VI.  HSCs and Liver Fibrogenesis 
 Hepatic fibrosis is a reversible wound-healing response characterized by the 
accumulation of ECM following liver injury.  If the insult is acute, these changes are transient, 
and liver architecture is restored to its normal composition.  However, if the injury is sustained, 
accumulation of ECM persists, leading to a progressive substitution of liver parenchyma by scar 
tissue.  This process results in cirrhosis, the end stage of fibrosis, which has a mortality rate of 
around 30,000 deaths per year in the United States [133].  HSC activation represents a critical 
event in fibrosis because these cells are the primary source of ECM in liver upon injury.  This 
section of the review will discuss the mechanisms underlying HSC activation, including ECM 
remodeling, regulation by cytokines, control of gene transcription, and interactions with the cells 
of the immune system (summarized in Figure 5). 
 
VI A.  ECM and Cellular Alterations in Liver Fibrogenesis 
The ECM is a tightly organized molecular network that provides functional and structural 
integrity for liver parenchyma.  In a normal liver, there is a balance between ECM synthesis and 
degradation.  However, during chronic liver injury, ECM synthesis exceeds ECM degradation, 
and hepatic fibrosis develops as a result of the progressive thickening of fibrotic lesions and 
cross-linking of collagen [134].  In addition to an increase in quantity of ECM, the quality of the 
ECM also changes in liver injury, and these alterations to the ECM and the cells within 
collectively impair hepatic function [134].   
The liver consists of hepatocytes (the parenchymal or epithelial cells) and 
nonparenchymal cells, including endothelial cells, Kupffer cells, and HSCs.  Sinusoids, the space 
where hepatic blood flow occurs, are lined with endothelial cells (as well as Kupffer cells), and 
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fenestrations between each endothelial cell allow for metabolic exchange between the blood and 
the hepatocytes.  The hepatocytes, separated from the sinusoids by the space of Disse, have 
microvilli, which also allow for proper metabolic exchange.  In a normal liver, the HSCs lie in 
the space of Disse and produce mainly collagens IV and VI (basement membrane collagens) 
[135].  Upon injury, the HSCs become activated, become proliferative and motile, and secrete 
large amounts of ECM, mainly in the form of fibrillar collagens I and III [135].  This deposition 
of ECM in the space of Disse leads to the loss of both the endothelial fenestrations and 
hepatocyte microvilli, resulting in the impairment of metabolic exchange and the development of 
portal hypertension, a process termed “capillarization” [136].   
The interaction between the ECM and its surrounding cells is bi-directional and mediated 
primarily by specific membrane adhesion receptors.  Among these receptors are the integrins, 
ADAM (a disintegrin and metalloprotease) molecules and discoidin domain receptors (DDRs).  
In vitro-activated HSCs have been shown to express integrins α1β1, α2β1, α5β1, and α6β4; 
whereas, in vivo-activated HSCs have been shown to upregulate α2β1, α6β4, αVβ8, and α5β1 
[137].  Furthermore, ADAMSTS-13 [138] and DDR2 [139, 140] have been implicated in liver 
fibrogenesis.  Increased production of collagen I during HSC activation induces DDR2, which 
ultimately stimulates the proliferation of HSCs [139, 140]. 
 
VI B.  Stages of HSC Activation 
 HSC “activation” refers to the conversion of a resting vitamin A-rich cell to one that is 
proliferating, contractile and fibrogenic [137].  As described in detail by Friedman, activation 
consists of two major phases: initiation and perpetuation [137].  Initiation, also called the 
“preinflammatory stage,” refers to the early changes in gene expression and phenotype that 
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render the cells responsive to other cytokines and stimuli [137].  Initiation results mainly from 
paracrine stimulation from neighboring cell types, including endothelial cells, Kupffer cells, and 
hepatocytes.  Upon injury, endothelial cells have been found to secrete fibronectin, which can 
then activate HSCs [141].  Kupffer cell infiltration contributes to HSC activation through the 
actions of cytokines and the release of reactive oxygen species [142].  Moreover, damaged 
hepatocytes are a potent source of lipid peroxides and apoptotic fragments [143, 144].    
 Perpetuation results from the effects of these stimuli on maintaining the activated 
phenotype in HSCs.  This stage involves both paracrine and autocrine stimulation, and it 
involves six discrete changes in HSC behavior: (i) proliferation; (ii) chemotaxis; (iii) 
fibrogenesis; (iv) contractility; (v) matrix disruption; and (vi) retinoid loss [137].  Proliferation is 
characterized by the increased expression of mitogens, the most prominent of which is platelet-
derived growth factor (PDGF) [145], which leads to an increased number of HSCs.  Chemotaxis 
is characterized by the increased migration of HSCs towards cytokine chemoattractants [146], 
which also is mediated by PDGF [147].  The fibrogenic role of HSCs has already been 
discussed; this involves the increased production of ECM components, particularly collagen I 
[135].  Transforming growth factor beta (TGF-β) is the most potent stimulus for increased 
collagen I production, as well as for increased production of other matrix components, including 
fibronectin and proteoglycans [148].  Contractility of HSCs is thought to be a major contributor 
to the increase in portal resistance in hepatic fibrosis.  Activated HSCs upregulate the expression 
of the cytoskeletal protein alpha smooth muscle actin (α-SMA), which confers a contractile 
phenotype; thus, activated HSCs impede portal blood flow by constricting individual sinusoids 
and contracting the fibrotic liver [149].  A major determinant of progressive fibrosis is the 
inability to degrade the increased scar matrix.  In a normal liver, there is a balance between 
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expression of matrix metalloproteinases (MMPs), responsible for breaking down ECM, and 
tissue inhibitors of MMPs (TIMPs).  Activated HSCs undergo decreased expression of MMPs 
and increased expression of TIMPs [137].  MMP-1, which is the main protease responsible for 
the degradation of collagen I, is not detected in activated HSCs [150].  The final feature of 
activated HSCs is retinoid loss.  While a resting, quiescent HSC stores large amounts of retinoid, 
in the form of retinyl ester, activated HSCs are known to have higher levels of retinol, indicating 
that activated HSCs undergo increased retinyl ester hydrolysis [151].  The loss of HSC retinyl 
ester in hepatic disease has been discussed in greater detail above, in section III C. 
 
VI C.  Role of Cytokines and Signaling Pathways in HSC Activation 
 Cytokines are a family of proteins that include chemokines, interferons, interleukins, 
growth factors, adipokines, and soluble neurohumoral ligands (endocannabinoids).  Cytokines 
released by activated HSCs fall into two main categories: inflammatory and fibrogenic [152].  
The most important growth factors implicated in HSC activation are PDGF and TGF-β [152].  
All PDGF isoforms (A, B, C, and D) are upregulated during HSC activation and correlate with 
the degree of fibrosis [153, 154].  PDGFs signal through the PDGF receptors, involving the 
PI3K/AKT signaling pathway [155].  TGF-β has three major isoforms (1, 2, and 3), but TGF-β1 
is the principal form associated with liver fibrosis.  TGF-β1 signals via the Smad signaling 
pathway, which enhances transcription of both procollagens I and III [156].  Vascular endothelial 
growth factor (VEGF), a known modulator of angiogenesis, is also upregulated during HSC 
activation, stimulating HSC proliferation, migration, and collagen production [157].  VEGF and 
various other growth factors function through the MAPK signaling pathway.   
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The primary adipokines implicated in liver fibrogenesis are adiponectin, which is 
antifibrogenic, and leptin, which is profibrogenic [152].  Adiponectin acts through stimulation of 
AMPK signaling, which inhibits processes that consume ATP (i.e. mitosis) [158].  Leptin, on the 
other hand, directly modulates HSC activation through the obese (ob) gene receptor ObRb, 
which acts through the JAK/STAT signaling pathway, and the stimulation of TGF-β production 
in endothelial and Kupffer cells [159, 160].  The JAK/STAT pathway is also stimulated by a 
number of other cytokines, including the interferons IFN-α/β and IFN-γ (which activate STAT1) 
and the interleukins IL-6 and IL-22 (which activate STAT3) [152].  Binding of cytokines to their 
receptors activates receptor-associated tyrosine kinases (JAK1, JAK 2, JAK3), which then 
interact with the STAT proteins.  Phosphorylation of the STAT proteins causes the complexes to 
translocate to the nucleus, where they regulate target gene transcription.  STAT1 is known to 
suppress expression of both PDGF and TGF-β and, therefore, inhibits HSC proliferation [161]. 
Upregulation of endocannabinoids and their receptors have been associated with chronic 
hepatic fibrosis.  The endogenous endocannabinoids anandamide (AEA) and 2-
arachidonylglycerol (2-AG) signal through the cannabinoid receptors, CB1 and CB2.  It has been 
shown that treatment of cultured primary HSCs with AEA and 2-AG, at lower concentrations, 
blocked HSC proliferation and, at higher concentrations, induced HSC apoptosis [162, 163].  
These effects were reported to be specific to HSCs, with no effect on primary cultures of 
hepatocytes, and are similar to necrosis, involving the rapid depletion of ATP and induction of 
ROS production.  Furthermore, one of these studies directly measured hepatic 2-AG levels in 
BDL- and CCl4-induced fibrosis, and they found that 2-AG is elevated 3-fold in both models 
[163].  Both studies conclude that AEA and 2-AG are potential anti-fibrogenic tools in the 
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treatment of hepatic fibrosis.  The two CB receptors, however, have been shown to have opposite 
effects: CB1 is fibrogenic [164], while CB2 is profibrogenic [165].  
 
VI D.  Regulation of Gene Transcription in Activated HSCs 
 Liver fibrogenesis is accompanied by a series of changes in gene expression patterns that 
collectively give rise to the proliferative, contractile, and fibrogenic phenotype of activated 
HSCs, as discussed throughout section V.  Here, transcriptional regulation of gene expression 
will be considered, with a discussion of the key transcription factors implicated in HSC 
activation. 
 A family of transcription factors that have been shown to have diverse impacts in HSC 
activation is the CCAAT/enhancer binding protein (C/EBP) family.  C/EBPα is a negative 
regulator of HSC activation and hepatic fibrosis.  Its overexpression has been associated with 
decreased ECM and α-SMA production, decreased HC proliferation, and enlargement of HSC 
lipid droplets [166].  Furthermore, its expression declines with HSC activation [166].  C/EBPβ, 
however, promotes fibrosis.  It increases collagen I synthesis, induces HSC proliferation, and 
prevents apoptosis of activated HSCs [167].   
A number of other transcription factors, belonging to various families, have been shown 
to promote fibrogenesis.  MyoD, belonging to the basic helix-loop-helix family of transcription 
factors, is myogenic and promotes the contractile phenotype of activated HSCs [168].  Mef2, a 
member of the MADS (MCM1,AG,DEFA,SRF)-box family, increases expression of α-SMA and 
collagen I and stimulates HSC proliferation [169].  Activator protein (AP)-1 (not classified into a 
specific transcription factor family) enhances the transcription of TIMP-1, IL-6, and TGF-β1 
[170].  AP-2 has been found to upregulate transcription of collagen I in activated HSCs [171].  
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Transcription factors falling into the nuclear receptor family are mainly involved in 
maintenance of the quiescent phenotype in HSCs.  The nuclear receptors regulate the expression 
of target genes following ligand activation in the cytoplasm and subsequent translocation to the 
nucleus.  One such family are the PPARs (peroxisome proliferator-activated receptors), which 
play a significant role in the regulation of lipid and glucose metabolism.  All isoforms, including 
-α, -β/δ, and -γ are expressed in HSCs, but PPAR-γ is the most studied with respect to liver 
fibrogenesis.  Overexpression of PPAR-γ in activated HSCs inhibits collagen I expression via 
suppression of the proximal alpha (I) collagen promoter, blocks TGF-β signaling (through 
inhibition of Smad3 inhibition), reduces HSC proliferation, and increases HSC lipid droplets 
[172-174].  The retinoic acid receptors (RARs) and retinoid X receptors (RXRs) each have -α, -
β, and –γ isoforms, and all are expressed in HSCs.  The role of these receptors in liver 
fibrogenesis is less clear, but their expression has been found to be down-regulated in activated 
HSCs [175].  The farnesoid X receptor (FXR) is activated by bile acids and reduces expression 
of collagen I and TIMP-1 in HSCs, with no affect on α-SMA expression or HSC proliferation 
[176].  The pregnane X receptor (PXR) is activated by pregnelone-16-α-carbonitrile and has 
been shown to prevent HSC activation and fibrosis in rats following CCl4 exposure [177]. 
 
VI E.  Interaction of Activated HSCs with Immune Pathways 
 There is an expanding literature showing that bidirectional interactions between the cells 
of the immune system and HSCs mediate liver fibrogenesis.  HSCs can be regulated by immune 
cells and, in turn, can modulate immune cell behavior.   
Kupffer cells are the liver’s resident macrophages, constituting approximately 15% of the 
total liver cell population.  These cells function in phagocytosis, antigen presentation, and 
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secretion of soluble factors that can mediate the inflammatory response [178].  Upon activation, 
Kupffer cells secrete a large number of proinflammatory and fibrogenic factors, which can drive 
HSC activation [178].  Toll-like receptors (TLRs) are a family of mammalian transmembrane 
pattern-recognition receptors that distinguish pathogen-associated motifs; their main ligand is 
lipopolysaccharide (LPS), which is an endotoxin found in the outer membrane of gram-negative 
bacteria that elicits strong immune responses in animals, including the release of 
proinflammatory cytokines [178].  Kupffer cells express TLR4 and are targets of LPS.  Activated 
HSCs also express TLR4, and upon binding of LPS, secrete cytokines that activate IκB 
kinase/NF-κB and JNK [179].  LPS also downregulates the TGF-β pseudoreceptor BAMBI in 
quiescent HSCs, promoting TGF-β signaling and enhancing fibrogenesis [180].  TLR9 is another 
TLR expressed by HSCs and, upon activation, increases collagen production and promotes HSC 
activation [181].  Furthermore, TLR9-deficient mice have been found to have reduced hepatic 
fibrosis in experimental models of liver injury [182].   
 Other immune cells found to regulate HSCs in liver fibrogenesis are natural killer cells 
and natural killer T cells.  Natural killer cells confer a protective role by inducing HSC apoptosis 
and secreting antifibrogenic mediators [183, 184].  Natural killer T cells have been shown to 
have the opposite affect, acting as profibrogenic mediators, though a direct affect on HSCs has 
not been demonstrated.  Depletion of natural killer T cells in mice treated with CCl4 seemingly 
protects against the development of liver fibrosis [185].                    
 
VI F.  Resolution of HSC Activation and Liver Fibrogenesis 
 In experimental models of liver fibrosis, cessation of the causative agent results in 
fibrosis regression, revealing the potential reversibility of hepatic fibrosis.  The key events in 
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fibrosis resolution involve the apoptosis and senescence of fibrogenic cells, which ultimately 
results in the reduction of ECM (though, not necessarily in the return to normal liver histology) 
[152].  The switch from survival to apoptotic mode is thought to be mediated by the upregulation 
of a number of factors shown to induce apoptosis or inhibit HSC proliferation.  Many of these 
factors have been previously discussed and include FXR, C/EBPβ, the endogenous cannabinoids 
AEA and 2-AG, and adiponectin.  Senescence is a stable form of cell-cycle arrest that is 
mediated by progressive telomere shortening and activation of a DNA damage response [186].  
Senescence of HSCs has been characterized by the induction of p53, p21, and p16 and by the 




















Major Retinoid Ligands Tissue Localization 
RBP RBP4 Lipocalin all-trans-retinol Many, with high levels in liver 
and adipose 
IRBP RBP3 - all-trans-retinol 
11-cis-retinal 
Retina 
CRBPI RBP1 iLBP all-trans-retinol 
all-trans-retinal 
Many, with high levels in liver, 
kidney, testis, eye, lung 
CRBPII RBP2 iLBP all-trans-retinol 
all-trans-retinal 
Small intestine 
CRBPIII RBP7 iLBP all-trans-retinol Heart, muscle, adipose, mammary 
CRABPI RBP5 iLBP all-trans-retinoic acid Ubiquitous expression, with high 
levels in brain, skin and testes 
CRABPII RBP6 b iLBP all-trans-retinoic acid Primarily skin; also found in 
mammary, uterus, kidney, 
prostate and olfactory epithelium 
CRALBP RLBP1 CRAL_Trio 11-cis-retinal 
11-cis-retinol 
9-cis-retinal 
RPE, retina, ciliary body, cornea, 
pineal gland, optic nerve, brain 
 
a
 The nomenclature for the retinoid-binding proteins in the literature is inconsistent 
between species.  Thus, for clarity, this table contains alternative names for each protein in 




 Only human CRABPII is designated RBP6; mouse CRABPII is not referred to as RBP6. 









Table 1-2. Proposed Hepatic Retinyl Ester Hydrolases (REHs). 
 
Protein Hepatic Cell Type 
Bile salt-dependent REH 
(identified to be CEL) 
Hepatocyte 
Neutral, Bile salt-independent REH Hepatocyte 
Acidic, Bile salt-independent REH Hepatocyte 
ES-2 Hepatocyte 
ES-4 Hepatocyte > HSC 
ES-10 Hepatocyte > HSC 
ES-22 Hepatocyte 
Hepatic Lipase Hepatocyte 

























Figure 1-1.  Transcriptional regulation by the retinoid nuclear receptors.  Retinoic acid 
(RA) regulates gene transcription acting through the family of nuclear receptors referred to as 
retinoic acid receptors (RARs) and the retinoid X receptors (RXRs), which are ligand-inducible 
transcription factors that belong to the steroid/thyroid hormone receptor superfamily.  In the 
presence of appropriate RA ligand, the RARs associate with the RXRs to form heterodimers that 
bind to regulatory regions, usually present in the promoters of specific target genes, called 






































Figure 1-2. General scheme for the uptake and metabolism of dietary retinoids and 
proretinoid carotenoids within the intestine.  Dietary proretinoid carotenoids, like β-carotene, 
are taken up into the enterocyte through a process that involves SR-B1. Once inside the 
enterocyte, β-carotene can be acted upon by BCMO1 and either converted to retinal, which binds 
CRBPII, or can be incorporated intact and unmodified along with dietary fat and cholesterol into 
nascent chylomicrons. The retinal produced from β-carotene cleavage must undergo reduction to 
retinol. This is catalyzed by one or more not well-characterized retinal reductases. Upon 
conversion to retinol, the retinol formed from dietary proretinoid carotenoids is metabolically 
indistinguishable from retinoid arriving in the diet as preformed retinoid. Dietary retinyl ester is 
either hydrolyzed in the lumen of the intestine by PTL or PLRP2 or undergoes hydrolysis at the 
intestinal brush border catalyzed by a brush border REH. Retinol taken into the enterocyte binds 
to CRBPII and is esterified to retinyl ester. In response to a physiological challenge of retinol, 
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LRAT will catalyze approximately 90% of retinyl ester formation, while the intestinal acyl-
CoA:retinol acyltransferase, DGAT1, catalyzes the remainder of retinyl ester formation. The 
resulting retinyl ester is then packed along with dietary fat and cholesterol into nascent 


























Figure 1-3.  Cleavage of Beta-Carotene.  Carotenoids can undergo cleavage either 












Figure 1-4.  Uptake of retinoids into extrahepatic tissues.  Retinoids in the circulation are 
present in several forms, including retinol bound to RBP (holo-RBP), retinyl esters in 
lipoproteins (primarily chylomicrons, but also VLDL, LDL, and HDL), and retinoic acid bound 
to albumin. The mechanisms that mediate cellular uptake of retinyl ester and retinoic acid are not 
fully understood. However, it has been established for certain tissues that LpL can hydrolyse 
retinyl ester to retinol, which can then be taken up by tissues and cells. The transmembrane 
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Figure 1-5.  Factors regulating hepatic stellate cell (HSC) activation in liver fibrogenesis.  
As HSCs transition from quiescent, lipid droplet-rich cells to an activated, myofibroblast-like 
phenotype, they undergo regulation by a number of factors.  Extracellular matrix (ECM) 
components and cytokines play an important role in initiating fibrosis development and 
perpetuating HSC activation.  Transcription factors control the rate of gene expression.  Bi-
directional interactions between HSCs and the cells of the immune system, primarily Kupffer 
cells, natural killer cells, and natural killer T cells, contributes significantly to fibrogenesis by the 
secretion of proinflammatory and profibrogenic molecules.  Graphics adapted from Senoo 2004 





Distinct Populations of Hepatic Stellate Cells in the Mouse Liver Have Different Capacities 
for Retinoid and Lipid Storage 
 
ABSTRACT 
Hepatic stellate cell (HSC) lipid droplets are specialized organelles for the storage of retinoid, 
accounting for 50-60% of all retinoid present in the body.  When HSCs activate, retinyl ester 
levels progressively decrease and the lipid droplets are lost.  The objective of this study was to 
determine if the HSC population in a healthy, uninjured liver demonstrates heterogeneity in its 
capacity for retinoid and lipid storage in lipid droplets.  To this end, we utilized two methods of 
HSC isolation, which leverage distinct properties of these cells, including their vitamin A content 
and collagen expression.  HSCs were isolated either from wild type (WT) mice in the C57BL/6 
genetic background by flotation in a Nycodenz density gradient, followed by fluorescence 
activated cell sorting (FACS) based on vitamin A autofluorescence, or from collagen-green 
fluorescent protein (GFP) mice by FACS based on GFP expression from a GFP transgene driven 
by the collagen I promoter.  We show that GFP-HSCs have: (i) increased expression of typical 
markers of HSC activation; (ii) decreased retinyl ester levels, accompanied by reduced 
expression of the enzyme needed for hepatic retinyl ester synthesis (LRAT); (iii) decreased 
triglyceride levels; (iv) increased expression of genes associated with lipid catabolism; and (v) an 
increase in expression of the retinoid-catabolizing cytochrome, CYP2S1.  Conclusion:  Our 
observations suggest that the HSC population in a healthy, uninjured liver is heterogeneous.  One 
subset of the total HSC population, which expresses early markers of HSC activation, may be 




Retinoids (vitamin A and its metabolites, both natural and synthetic) are essential to 
many physiological processes, including reproduction, embryonic development, bone growth, 
immunity and vision [1].  Seventy percent of retinoid in the body is stored in the liver [3, 4], and, 
of this fraction, 90-95% is stored in lipid droplets within hepatic stellate cells (HSCs) [44].  
These lipid droplets are a distinguishing feature of HSCs and have been proposed to be 
specialized organelles for retinoid storage due to their retinoid content and responsiveness to 
dietary retinoid status [76].  Retinyl esters comprise approximately 40% of the lipids present in 
these droplets, more than any other single lipid species [83, 84].  And while the remaining 60% 
is all non-retinoid lipid species, including triglyceride, cholesterol ester, cholesterol, 
phospholipid and free fatty acid, there is considerable data in the literature suggesting that the 
formation and maintenance of these lipid droplets are retinoid-dependent processes [76]. 
Moriwaki et al. showed that the lipid composition of HSC lipid droplets is strongly 
regulated by dietary retinoid status, but not by dietary triglyceride intake [83].  HSC lipid droplet 
retinoid lipid species are decreased in response to a low retinol diet and both retinoid and non-
retinoid lipids are elevated in response to a high retinol diet; however, neither retinoid nor non-
retinoid content is affected by low or high fat diets.  Other data that are highly suggestive of the 
role of retinoids in these droplets relates to the enzyme lecithin:retinol acyltransferase (LRAT), 
which is the only known enzyme in the liver capable of synthesizing retinyl ester.  O’Byrne et al. 
showed that the HSCs of wild type (WT) mice have large, distinct lipid droplets, but the cells of 
LRAT-null mice have none [29].  Thus, the ability to synthesize and store retinyl ester in HSCs 
is necessary for the presence of HSC lipid droplets.   
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It is well-established that when HSCs activate, in response to a hepatic insult or disease, 
the HSCs loose their lipid droplet content and undergo a simultaneous decrease in retinyl ester 
levels.  Leo and Lieber found that there is a nearly 5-fold decrease in total hepatic retinol levels 
with the development of alcoholic hepatitis and another approximately 4-fold decrease with the 
development of cirrhosis [85].  It has also been shown in cultured HSCs that retinyl ester stored 
in HSC lipid droplets is first hydrolyzed and then released into the media as retinol [151].  As 
HSCs transition from a quiescent to a myofibroblastic phenotype, they undergo increased 
extracellular matrix production, including increased synthesis of collagen I, and become 
fibrogenic [86, 87].  It has not yet been unequivocally determined whether the loss of HSC lipid 
droplets is a cause or consequence of activation. 
We are interested in understanding the factors that regulate HSC retinoid storage as 
retinyl esters in lipid droplets and the factors that regulate HSC lipid droplet genesis and 
dissolution.  In this study, we employ two methods of HSC isolation, which leverage distinct 
properties of these cells.  One method relies on HSC lipid droplet vitamin A content and the 
other on HSC expression of collagen I.  It was recently shown that the changes in gene 
expression that accompany HSC activation and the loss of retinyl ester lipid droplets are 
regulated differently in the in vitro and in vivo models of activation [88].  Similarly, a goal of this 
study is to determine whether different methods of HSC isolation will yield phenotypically 
distinct populations of cells and how this may reflect heterogeneity of HSCs in the liver at a 
given time.  We are particularly interested in how these populations compare with regard to their 





MATERIALS AND METHODS 
Animals.  WT and collagen-green fluorescent protein (GFP) mice were used, with both strains 
congenic for the C57BL/6 genetic background.  The collagen-GFP mice have been previously 
described [188].  Briefly, a gene construct was made containing 3,122 bp of the α1 (I) collagen 
(Col1a1) gene promoter, plus enhancer elements (DNase I-hypersensitive sites), linked to the 
GFP reporter gene [188].  The construct is referred to by Yata et al. as pCol9GFP-HS8,9 [188].  
Hepatic expression of collagen I is predominantly in HSCs [189, 190], and its expression is 
increased as the cells become activated [191, 192].  Thus, GFP expression from this transgene 
can be used to identify and isolate HSCs.  All mice used in the study were males between 90 and 
120 days of age at the time of sacrifice.  Animals were allowed ad libitum access to water and a 
standard nutritionally complete rodent chow diet (W. F. Fisher and Sons, Inc., Somerville, NJ).  
All mice were maintained on a 12-h dark-light cycle, with the period of darkness between 7:00 
a.m. and 7:00 p.m. in a conventional barrier facility.  The animal experiments described in this 
report were conducted in accordance with the National Research Council's Guide for the Care 
and Use of Laboratory Animals and were approved by the Columbia University Institutional 
Committee on Animal Care (IACUC Protocol # AC-AAAA9687).   
Hepatic Fibrosis Induction.  WT C57BL/6 mice were given weekly injections of either 0.5 µl 
carbon tetrachloride (CCl4) per gram body weight administered in corn oil or an equivalent 
volume of corn oil alone for 4 weeks and then sacrificed.  Liver tissue was collected and stored 
immediately at –80 °C prior to analysis.  
Hepatocyte Isolations.  Livers were perfused in situ with EGTA for 5 min and collagenase D 
(0.5 mg/ml, Roche Diagnostics, Indianapolis, IN) for 15 min, respectively, at a flow rate of 5 
ml/min.  After perfusion, the partially digested liver was excised, the digest passed through a 
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100 µm nylon mesh to remove undigested materials, and resuspended in Dulbecco’s Modified 
Eagle Medium (DMEM; Gibco, Grand Island, NY) containing 1% penicillin/streptomycin.  
Hepatocytes were separated from the non-parenchymal cells and debris by centrifugation at 4 °C 
in the following sequence: twice for 5 min at 20g, once for 10 min at 50 g, and twice again for 
five min at 20 g.  The supernatant was aspirated and the hepatocytes present in the pellet were 
resuspended in DMEM.  Cell yields were determined by counting on a hemacytometer. 
HSC Isolations.  Primary mouse HSCs were isolated according to established protocols [84, 
193, 194].  Briefly, livers were perfused in situ with EGTA for 5 min, pronase E (0.4 mg/ml, 
EMD Chemicals Inc., Gibbstown, NJ) for 5 min and collagenase D (0.5 mg/ml, Roche 
Diagnostics) for 8 min, respectively, at a flow rate of 5 ml/min.  After excision of the liver from 
the body, the liver digests were filtered through a cell strainer and washed with Gey’s Balanced 
Salt Solution (Sigma, St. Louis, MO) containing DNase I (2mg/ml, Roche Diagnostics).  For the 
WT C57 mice, HSCs were purified from the remainder of non-parenchymal cells and 
hepatocyte-derived debris by floatation through 9% (w/v) Nycodenz (Axis-Shield PoC AS, Oslo, 
Norway) in Gey’s Balanced Salt Solution (without NaCl).  Subsequently, the cells were 
separated by FACS using FACS Calibur (Becton Dickinson, Franklin Lakes, NJ), and vitamin A 
auto-fluorescent cells were collected based on their emission at 460 nm.  This method of HSC 
isolation yields approximately 10% of the total HSCs estimated to be in the liver.  For the 
collagen-GFP mice, parenchymal cells and debris were separated from non-parenchymal cells by 
centrifugation at 50g for 2 minutes.  The remaining non-parenchymal cell suspension was then 
separated by FACS, and GFP-positive cells were collected based on their emission at 530 nm.  
This method of HSC isolation yields approximately 10% of the total HSCs estimated to be in the 
liver.     
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Isolation of RNA and cDNA synthesis.  RNA was isolated from HSCs using the Qiagen 
RNeasy kit (Qiagen, Valencia, CA).  cDNA synthesis and amplification were performed using 
the NuGEN WT-Ovation Pico RNA Amplification kit (NuGEN, San Carlos, CA).  The resulting 
cDNA was then purified using the Qiagen QIAquick PCR Purification kit (Qiagen).  cDNA 
fragmentation and labeling were performed using the NuGEN FL-Ovation cDNA Biotin Module 
V2 kit (NuGEN).         
DNA Microarray Analysis.  Array analysis was conducted on the Affymetrix Mouse Genome 
430 2.0 Array (Affymetrix, Santa Clara, CA) and analyzed using the GeneSifter gene expression 
analysis suite (Geospiza, Seattle, WA).  Individual gene expression values were normalized to 
the median.  Significant changes in gene expression between sample sets were identified by a 
Student’s t-test and subsequent Benjamini–Hochberg correction, with a p-value of 0.05 as the 
criterion for statistical significance.  All microarray data are MIAME compliant and are 
deposited as ArrayExpress accession E-MEXP-3231.   
Quantitative Real-Time PCR.  Differential gene expression was confirmed by quantitative real-
time polymerase chain reaction (qRT-PCR) using commercially available primer-probe sets 
(Table 1, Applied Biosystems, Foster City, CA).  qRT-PCR was performed on a LightCycler 
480 (Roche Diagnostics).   
Immunohistochemistry.  Liver tissue samples from collagen-GFP mice were collected into 10% 
formalin.  Immunohistochemistry was conducted by the Herbert Irving Comprehensive Cancer 
Center Histology Service using standard protocols.  Desmin expression was localized using an 
anti-desmin monoclonal mouse anti-human antibody at a dilution of 1:400 (Dako, Carpinteria, 
CA, clone D33, IR606), and GFP was localized using an anti-GFP rabbit polyclonal antibody at 
a dilution of 1:500 (Invitrogen, Carlsbad, CA, A-11122).  Fluorescent images were captured at 
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40X magnification using a Zeiss Axiovert 200M Microscope with Apotome (Zeiss, Göttingen, 
DE), and images were taken using an AxioCam MRm camera (Zeiss).     
Primary HSC Culture.  HSCs were isolated from WT and collagen-GFP mice as described 
above.  Approximately 0.5x106 cells were resuspended in DMEM containing 10% fetal bovine 
serum and 1% penicillin/streptomycin, seeded on 35 mm glass bottom dishes (MatTek Co., 
Ashland, MA) and incubated at 37 °C overnight.  Phase contrast and fluorescent images were 
captured using an FSX100 Olympus Microscope (Olympus America Inc., Center Valley, PA). 
Reverse-phase HPLC Analysis.  Liver and HSC retinyl ester levels were determined by 
procedures described previously [29].  Briefly, 200 mg liver tissue was homogenized in 2 ml of 
PBS (10 mM sodium phosphate, pH 7.2, 150 mM sodium chloride) using a Polytron homogenizer 
(Brinkmann Instruments, Westbury, NY) and 200 µl aliquots were taken for further analysis.  For 
HSCs, aliquots of 100,000 cells were resuspended in 1 ml PBS.  All samples were then treated 
with an equal volume of absolute ethanol containing a known amount of retinyl acetate as an 
internal standard, and the retinoids present in the homogenates were extracted into hexane.  The 
extracted retinoids were separated on a 4.6 × 250 mm Ultrasphere C18 column (Beckman, 
Fullerton, CA) preceded by a C18 guard column (Supelco, Bellefonte, PA), using 70% 
acetonitrile, 15% methanol, 15% methylene chloride as the running solvent flowing at 1.8 
ml/min.  Retinol and retinyl esters (retinyl palmitate, oleate, linoleate, and stearate) were 
detected at 325 nm and identified by comparing the retention times and spectral data of 
experimental compounds with those of authentic standards.  Concentrations of retinol and retinyl 
esters in the tissues were quantitated by comparing integrated peak areas for each retinoid against 
those of known amounts of purified standards.  Loss during extraction was accounted for by 
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adjusting for the recovery of the internal standard added immediately after homogenization of 
the cells and tissues. 
Triglyceride Analysis.  Approximately 200 mg of liver or 0.5x106 HSCs were homogenized in 1 
ml of PBS using a Polytron homogenizer.  The lipids in the homogenates were then extracted 
into chloroform:methanol (2:1 v/v), and the lower, chloroform phase was collected.  The upper 
phase was re-extracted with an additional volume of chloroform:methanol to ensure complete 
triglyceride recovery, and the pooled chloroform phases were evaporated under N2.  
One milliliter of 2% Triton X-100 in chloroform for liver or 50 µl for HSCs was then added to 
the samples, and the chloroform was re-evaporated under N2.  For liver, triglycerides were 
solubilized for colorimetric assay through addition of 1 mL of deionized water into the glass 
tubes.  Employing a Matrix Plus Chemistry Reference Standard (Verichem Laboratories Inc., 
Providence, RI), according to the manufacturer’s instructions, a colorimetric triglyceride assay 
using the Infinity Triglyceride Reagent (Thermo Fisher Scientific Inc., Middletown, VA) was 
performed in a 96-well plate for 5 µl of each liver sample.  For HSCs, 200 µl of Triglyceride 
Reagent was added directly to the dried-down samples, and the entire volume was read in the 
colorimetric assay.  Color development was measured on a Multiskan Plus Microtiter Plate 
Reader at 520 nm. 
Western Blot Protein Analysis.  HSC proteins were analyzed by Western blot assay.  For all 
proteins analyzed, 5 µg of total protein was separated on 10% SDS–PAGE gels and transferred 
onto polyvinylidene fluoride membrane (Millipore Immunobilon-P Transfer Membrane) at 100V 
for 1 h at 4°C.  The membranes were then incubated with 10% milk blocking buffer for 1 h at 
room temperature (RT), followed by overnight incubation at 4°C with the following primary 
antibodies: alpha smooth muscle actin (1:100, rabbit polyclonal, Abcam, Cambridge, MA, 
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ab5694), adipose differentiation related protein (1:500, rabbit polyclonal, Abcam, ab52356), 
CYP2S1 (1:500, rabbit polyclonal, Abcam, ab69650), CYP2E1 (1:500, rabbit polyclonal, 
Abcam, ab28146) and LRAT (1:500, mouse monoclonal, gift from Dr. Krzysztof Palczewski, 
Department of Pharmacology, Case Western Reserve University).  The secondary antibody 
incubations were for 1 h at RT with either a donkey horseradish peroxidase-conjugated anti-
rabbit IgG antiserum (1:10,000, GE Healthcare, Piscataway, NJ, cat# NA934V) or goat 
horseradish peroxidase-conjugated anti-mouse IgG antiserum (1:10,000, EMD Chemicals Inc., 
Gibbstown, NJ, cat# 401215).  Immunoblots were developed using the ECL system (Thermo 
Scientific, Rockford, IL).  
CYP2S1 adenovirus construction, purification and infection.  Mouse CYP2S1 was PCR 
amplified from mouse liver cDNA and ligated into the pAdTrack-CMV plasmid using XhoI and 
NotI restriction sites.  AdTrack was linearized with PmeI and electroporated into pAdEasy-1- 
containing competent BJ5183-AD-1 bacteria (Stratagene, La Jolla, CA).  Recombinants were 
screened using kanamycin and, after linearization with PacI, transfected into HEK293 cells.  
After 10 days, cells were lysed, and another round of HEK293 cells was infected to obtain cell 
lysates that were purified on a CsCl density gradient.  For CYP2S1 overexpression experiments, 
primary mouse HSCs isolated from WT mice in a mixed genetic background were infected with 
AdCYP2S1 or AdGFP control virus at a multiplicity of 3830 particles/cell approximately 24 
hours after isolation for 48 hours. 
Statistical Analysis.  All data are presented as means ± S.D.  A Student’s t-test was used to 
analyze for statistically significant differences between groups.  Groups were considered to be 





Methods of HSC Isolation.  To obtain a relatively vitamin A-enriched population of HSCs, we 
conducted FACS on HSCs obtained by conventional Nycodenz flotation of cells present in a 
pronase digest of a liver.  Vitamin A autofluoresces at 460 nm upon excitation at 350 nm, so 
exposure to this excitation wavelength allowed us to collect a population of cells that is enriched 
in vitamin A.  This population of lipid droplet- and vitamin A-enriched HSCs will be referred to 
subsequently as AF-HSCs.  The second method of HSC isolation used in this study capitalizes on 
transgene GFP expression driven by the Col1a1 promoter in these mice [188] and data indicating 
that expression of collagen I in the liver occurs predominantly in the HSCs [189, 190] 
(contributions from other hepatic populations are beginning to be recognized and include portal 
fibroblasts, bone marrow-derived cells, and epithelial cells that transition to mesenchymal cells 
[152]).  We performed FACS on digests of non-parenchymal cells and collected GFP-positive 
cells based on their excitation at 488nm.  This GFP-expressing population of HSCs will be 
referred to as GFP-HSCs.  To confirm that GFP expression is confined to HSCs, we performed 
immunohistochemistry using antibodies to GFP and the HSC marker desmin [195].  We show 
that GFP expression is found only in the HSCs, with GFP expression co-localizing with desmin 
expression, and is not found in the other major cell types in the liver (Figure 2A-C).  We further 
analyzed the integrity of these populations by qRT-PCR using desmin mRNA expression as a 
marker of HSC purity, and we show that the two different methods of HSC isolation yield cell 
populations with equivalent desmin expression (Figure 1A).     
Microarray Analysis Overview.  For this study, we performed gene microarray analysis on 
populations of AF-HSCs isolated from 6 mice and GFP-HSCs isolated from 5 mice.  cDNA 
purified from these populations was run on Affymetrix Mouse Genome 430 2.0 Arrays, covering 
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over 45,000 transcripts in the mouse genome, and data was analyzed using GeneSifter software.  
The quality of the samples used is demonstrated by the box plot and scatter plot summaries of 
the AF and GFP groups, which show that the spread of all the array data points is identical in 
both groups (Figure 1B and 1C).  Five thousand three hundred sixty three probe sets were more 
than 2-fold up- or down-regulated in the GFP-HSCs compared to AF-HSCs (Table 2).  As a 
second-stage filter and an analysis with biological implications, the list of transcripts with 
significant differential expression between AF- and GFP-HSCs was screened against > 200 
known KEGG (Kyoto Encyclopedia of Genes and Genomics) pathways.  This analysis identified 
15 KEGG pathways where a significant number of genes were either up- or down-regulated 
(Table 3).  Significance at the pathway level was defined as a z-score with an absolute value 
greater than 2.  As described by Walewski et al.,  a positive z-score greater than or equal to 2 
indicates that a significant number of genes in the list of differentially expressed genes are 
significantly up- or down-regulated in the experimental group in that particular pathway [196].  
Notably, a number of the enriched KEGG pathways identified by this study have a direct or 
indirect relationship with the extracellular matrix (ECM), which is a target of deregulation in 
HSCs that are in the early stages of activation [86].  These pathways are classified as cellular 
adhesion molecules (CAMs), ECM-receptor interaction, focal adhesions, and gap junctions 
(Table 3). 
GFP-HSCs are phenotypically similar to HSCs undergoing early activation.  As a result of 
activation, HSCs undergo increased collagen I production and a simultaneous loss of their retinyl 
ester-containing lipid droplets [190, 191].  Because we have selected for a population of HSCs 
that express Col1a1, we were interested in whether GFP-HSCs would display characteristics of 
activated HSCs.  The array suggests that a number of markers of HSC activation are elevated in 
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the GFP-HSCs, including alpha smooth muscle actin (Acta2), platelet-derived growth factor C 
(Pdgfc), transforming growth factor beta 2 (Tgfb2), and endothelin (Edn1) (Table 4).  Elevated 
expression of all markers was confirmed by qRT-PCR; however, only Acta2 up-regulation was 
found to be significant (Figure 3A).  Elevated protein levels of ACTA2 are also shown by 
western blot analysis (Figure 3B). 
 The elevated levels of markers of HSC activation prompted us to then examine whether 
the GFP-HSCs have less retinyl ester and triglyceride, which are the two predominant lipid 
species present in quiescent HSC lipid droplets [83].  We found that, while the livers of the WT 
and collagen-GFP mice have comparable levels of both lipid species (Figures 4A and 4C), the 
GFP-HSCs have significantly less retinyl ester (Figure 4B) and triglyceride (Figure 4D).  To 
further assess lipid droplet content in these cells, AF- and GFP-HSCs were isolated by FACS and 
cultured overnight on glass plates.  Lipid droplet quantity and size were assessed by phase 
contrast and fluorescent microscopy (Figure 5A and 5B).  We found that GFP-HSCs have on 
average more lipid droplets per cell than AF-HSCs (Figure 5C); however, these droplets are 
smaller in size, determined by the average diameter of lipid droplets per cell measured in 
microns (Figure 5D).  We also calculated the theoretical lipid droplet volume per cell, assuming 
a lipid droplet is a perfect sphere.  Total lipid droplet volume per cell is the same in both 
populations (Figure 5E), and furthermore, the lipid droplet-associated protein adipose 
differentiation related protein (ADRP) is also expressed at equivalent levels in both AF- and 
GFP-HSCs (Figure 5F).             
Changes in retinoid- and lipid-related gene expression.  To better understand the lower levels 
of retinyl ester and triglyceride in GFP-HSCs, we focused our array analysis on retinoid- and 
lipid-related gene expression.  The retinoid and lipid nuclear receptors were of high interest, as 
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this group of genes represents a major route of gene regulation with many downstream effectors.  
The array data indicated that levels of the retinoid X receptor alpha (Rxra), retinoic acid receptor 
alpha and gamma (Rara and Rarg) and the peroxisome proliferator activated receptor alpha 
(Ppara) are lower in GFP-HSCs (Table 5).  However, qRT-PCR analysis did not confirm 
significant differences in the expression of these genes in this population of cells (Figure 6).  
Similarly, the array suggested differential expression in the retinol- and fatty acid binding 
proteins, specifically retinol binding protein (Rbp4), cellular retinol binding protein 1 (Rbp1) and 
fatty acid binding protein 4 (Fabp4) (Table 6).  qRT-PCR analysis of mRNA levels confirmed 
that Fabp4 has significantly higher expression in the GFP-HSCs (Figure 7).  The array 
additionally suggested that there may be significant gene transcriptional changes relating to lipid 
metabolism underlying the altered lipid content in the GFP-HSCs.  There is elevated expression 
of two triglyceride lipases, diacylglycerol lipase, beta (Daglb) (Table 7) and arylacetamide 
deacetylase (Aadac) (Table 8).  A number of phospholipases exhibited higher expression in the 
GFP-HSCs, including various members of the A and C subfamilies (Table 8).  Notably, the array 
showed that carboxylesterase 3 (Ces3) expression is 82-fold higher in the GFP-HSCs (Table 8), 
and this elevation was confirmed by qRT-PCR of Ces3 mRNA levels (Figure 8).  This is 
interesting in light of the fact that a number of carboxylesterases have been proposed to be 
hepatic retinyl ester hydrolases [65, 66].  Also, we found via qRT-PCR analysis that lipoprotein 
lipase (LpL) mRNA expression is elevated in the GFP-HSCs (Figure 8).       
Cytochrome-mediated retinoid catabolism.  Since it is well established that HSC retinoids are 
lost upon cell activation, we hypothesized that the lower levels of retinyl ester in GFP-HSCs is a 
consequence of either increased mobilization of retinol from the HSCs or increased retinoid 
catabolism within the HSCs.  Our data suggest that the first hypothesis is unlikely since we 
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observe no differential expression of the retinoid-binding proteins in the GFP-HSCs (Figure 7), 
which are responsible for inter- and intracellular transport of retinoid in the body.  To investigate 
the second hypothesis, we considered changes in gene expression in cytochrome P450 enzymes.  
The cytochromes (CYPs) are known to metabolize both exogenous compounds, including 
chemicals in the environment, carcinogens and drugs, and also endogenous compounds, 
including retinoids [197].  The array suggests that a number of CYPs are differentially expressed 
in GFP-HSCs (Table 9).  However, we are specifically interested in CYPs that are known to 
metabolize retinoids and/or are proposed to play a role in HSC activation.  Of the twenty seven 
CYPs shown to be differentially expressed on the array, two meet these criteria: Cyp2s1, which 
has 32-fold higher expression in GFP-HSCs, and Cyp2e1, which has approximately 3-fold higher 
expression in GFP-HSCs (Table 9).  We confirmed higher levels of Cyp2s1 and Cyp2e1 mRNA 
(Figure 9A) and in CYP2S1 protein (Figure 9B) in GFP-HSCs compared to AF-HSCs.  
CYP2E1 protein was unchanged (Figure 9B).   
CYP2S1 is a recently-identified cytochrome enzyme that has been shown to be expressed 
highly in the lung, small intestine and spleen and to be inducible by dioxin, which acts via the 
aryl hydrocarbon receptor [198, 199].  It has also been reported to both metabolize and be 
induced by all-trans-retinoic acid [200].  The literature does not definitively establish the 
expression of CYP2S1 in the liver; CYP2S1 expression has been detected in the liver, albeit at 
very low levels [201, 202].  More recently, CYP2S1 was shown to be expressed in human HSCs 
[203].  To further elucidate the expression of CYP2S1 in the mouse liver, we isolated both 
hepatocytes and HSCs and measured mRNA levels of 6 CYPs, which were chosen based on their 
known liver expression, roles in retinoid metabolism and/or proposed roles in hepatic disease.  
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We found that while Cyp2e1 is more highly expressed in hepatocytes, Cyp2s1 is highly enriched 
in HSCs (Figure 10A).   
Having shown Cyp2s1 to be highly expressed in HSCs and elevated in collagen-
expressing HSCs relative to the non-collagen-expressing population, we became interested in 
whether this cytochrome might play a role in the early events of hepatic fibrosis, when HSCs 
activate and lose their lipid droplet content.  To address this question, we injected WT C57 mice 
around 3 months of age with either CCl4 (0.5 µl/g body weight) or corn oil vehicle control once a 
week for 4 weeks and assessed changes in mRNA expression of the 6 CYPs discussed above.  
We found that hepatic levels of Cyp26a1 and Cyp2s1 were both elevated when mice were treated 
with CCl4, by approximately 4-fold in each case (Figure 10B).  Thus, we identify Cyp2s1 as the 
only retinoid-catabolizing CYP that is both highly expressed in HSCs and induced in CCl4-
mediated HSC activation.   
These findings led us to hypothesize that CYP2S1 plays a role in the catabolism of HSC 
retinoid content, contributing to the lower retinyl ester and lipid droplet content in both collagen-
expressing HSCs and HSCs activated in vivo by CCl4 exposure.  To directly demonstrate that 
CYP2S1 plays a role in the hydrolysis of retinyl ester in activated HSCs, we generated a 
recombinant adenovirus overexpressing CYP2S1 in HEK293 cells, with overexpression 
confirmed by qRT-PCR analysis of Cyp2s1 mRNA levels (Figure 11A).  After purification of 
the recombinant adenovirus from HEK293 cells, primary isolates of HSCs were transfected and 
cultured on plastic dishes for 48 hours.  Retinoid content was assessed by RP-HPLC analysis.  
Our data show that the HSCs transfected with AdCYP2S1 have significantly decreased levels of 
retinyl ester and significantly elevated levels of retinol relative to HSCs transfected with AdGFP 




The idea that there is heterogeneity and plasticity in the HSC population in the liver is not 
new, but has not previously been well-studied.  Studies in the early 1990s introduced this idea, 
utilizing the HSC marker desmin to show that there is a population of desmin-negative, lipocyte-
like cells in the liver [204] and that these HSCs are vitamin A-deficient [205].  Our study extends 
these earlier reports and the proposition that not all HSCs in the liver are equivalent by using 
different methodologies to isolate two distinct populations of HSCs from the liver and to 
characterize their morphological and biochemical properties.  The different methods of cell 
isolation we used take advantage of distinct properties of these cells: the first method relies on 
HSC lipid droplet vitamin A content and the second on HSC collagen I gene expression.   
The standard method of HSC isolation employs a Nycodenz density gradient to separate 
non-parenchymal cells from a liver digest where hepatocytes have been destroyed by exposure to 
pronase [84, 193, 194].  The low buoyant density of the numerous lipid droplets present in the 
HSCs (see Figure 5) allows these cells to float to the top of the gradient and thereby be separated 
from the other less lipid-rich cell types present in the liver.  To obtain a vitamin A-enriched 
population of HSCs, we additionally conducted FACS on the nycodenz-purified cells.  Vitamin 
A autofluoresces upon excitation at 350 nm, so exposure to this wavelength of light allowed us 
to collect a population of cells that is enriched in vitamin A.  We also employed a second FACS-
based method to isolate HSCs.  This involved the use of collagen-GFP mice in which GFP 
expression is driven by the Col1a1 promoter [188].  Our data confirm that collagen I expression 
in the liver is confined to the HSCs, with GFP expression co-localizing exclusively with desmin-
positive cells.  Our data additionally show that the GFP-based method of HSC isolation yields a 
population of cells with equivalent desmin expression to the conventional Nycodenz-based 
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method.  Thus, we demonstrate for the first time a novel method of HSC isolation that yields 
cells of identical purity to cells isolated by the conventional Nycodenz-based method. 
 When a liver is confronted with acute injury, a wound-healing response is initiated which 
ultimately returns the liver to its healthy state; however, when the liver is confronted with 
chronic injury, the result is often hepatic fibrosis, which is the production of excess fibrous 
connective tissue as a reparative process to contain the site of injury [86, 87].  In the early stages 
of hepatic fibrosis, the HSCs undergo a process of activation, whereby they transition from a 
quiescent, lipocyte-like state to a myofibrosblastic, contractile phenotype.  Activated HSCs 
express high levels of COL1a1 and ACTA2, which are key components of the extracellular 
matrix.  Other key proliferative, fibrogenic and contractile stimuli in hepatic fibrosis are PDGF-
C, TGF-β and EDN1, respectively [206].  Induction of ACTA2 is the single most reliable marker 
of HSC activation because it is absent from other resident liver cells in either normal or injured 
liver; furthermore, its expression connotes a contractile phenotype [46].  Our data show that 
GFP-HSCs have significantly elevated levels of both ACTA2 mRNA and protein, indicating that 
this is a population of HSCs in early activation.  Because the livers from which these cells were 
isolated were not experimentally injured or chemically induced, these findings suggest that there 
is a population of pre-activated HSCs in the liver under physiological conditions.  This idea 
supports earlier studies in transgenic mice, in which GFP was driven by the collagen I promoter 
and red fluorescent protein (RFP) was driven by the Acta2 promoter [207].  It was shown that 
there are mixed populations of activated HSCs, such that some populations expressed GFP or 
RFP alone and some expressed both.  
Lipid droplets are indispensable, metabolically active organelles found ubiquitously 
across species (including plants, animals and yeasts) and also within different animal cell types 
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(adipocytes, macrophages, hepatocytes, hepatic stellate cells, etc.) [208].  Thus, lipid droplets are 
versatile and diverse.  Lipid droplets found in different cell types have different lipid and protein 
compositions.  Cell-specific localization combined with unique composition dictates regulation 
of lipid droplet formation and maintenance in a cell type-specific manner.  There is a strong 
correlation between the predominant lipid species in the droplet and the enzyme(s) responsible 
for synthesis of the lipid.  For instance, an adipocyte lipid droplet, which is composed primarily 
of triglyceride synthesized by DGAT1 (diacylglycerol acyltransferase 1) and/or DGAT2, will not 
be formed when these two enzymes are not expressed [209].  Similarly, the HSC lipid droplet 
has a unique retinoid and lipid content, not found in other cell types in the body [83, 84].  The 
retinyl ester content is dependent on expression of LRAT, which is the only hepatic enzyme 
capable of retinyl ester synthesis in vivo [29].  We show that when LRAT expression is 
diminished, these lipid droplets are smaller in size, suggesting degradation.  Importantly, it is 
also established that as HSCs undergo activation, they lose their retinyl ester-containing lipid 
droplets; though it is not known if this loss is a cause or consequence of the activation process.  
Thus, our findings correlate strongly with the events known to occur in the early stages of HSC 
activation.  LRAT expression is low, retinyl ester levels are decreased, and there are marked 
alterations in the HSC lipid droplets.    
Our observations regarding the different lipid droplet content in the GFP-HSCs 
additionally allows us to hypothesize about the events taking place in the very early stages of 
HSC activation.  It is important to emphasize that the GFP-HSCs have not been experimentally 
induced, so we distinguish these cells as “pre-activated” HSCs: they are not fully activated, but 
they display characteristic features of such cells, including decreased retinyl ester levels and 
elevated expression of ACTA2 mRNA and protein.  A priori, we would expect the early events 
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of HSC activation to follow one of the following three scenarios: (i) lipid droplets progressively 
decrease in number, eventually leading to the complete loss of droplets; (ii) lipid droplets 
progressively decrease in size, eventually leading to the complete loss of droplets; or (iii) lipid 
droplets are initially broken-down into many more, smaller droplets – increase in number, 
decrease in size - and then they progressively decrease in number until none remain in the cell.  
Interestingly, our data provide strong evidence for the third, more complex scenario.  We show 
that the GFP-HSCs, a population of uninduced but collagen-expressing cells, have more lipid 
droplets than the AF-HSCs, and these droplets are smaller in size, as determined by a decrease in 
average diameter.  Our data is in good agreement with other studies investigating lipid droplet 
dissolution in other cellular systems.  It is known that in the first several hours of hormone-
stimulated lipolysis in 3T3-L1 adipocytes, the lipid droplets present in these cells are fragmented 
and dispersed into microlipid droplets, which significantly increases the surface area available 
for lipase activity [210-212].  A similar pattern of lipid droplet dissolution was reported for rat 
adipocytes, in which lipolysis was stimulated by electroporation of a constitutively active β-1 
adrenergic receptor into the fat pads of the animals [213].  It will be necessary for future studies 
to confirm this sequence of events in HSCs directly with real-time tracking of lipid droplet 
remodeling in response to HSC activation.  It will also be necessary to define the contribution of 
the lipid droplet-associated proteins, such as ADRP, to these processes.  Our data shows ADRP 
protein expression is not different in the GFP-HSCs, but its distribution in the cell and on the 
lipid droplets might be changed as a consequence of the beginning stages of lipolysis.              
 Our data also establish decreased triglyceride levels, along with the differential 
expression of many lipid metabolism-related genes, in GFP-HSCs.  This is not surprising since 
triglyceride is the second most predominant lipid species in HSC lipid droplets (31.7%), only 
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slightly less than retinyl ester (39.5%) [83, 84].  It is likely that when retinyl esters are lost as a 
result of activation, the HSC lipid droplet is targeted and signaled to breakdown, and thus, 
synthesis of the non-retinoid lipids is down-regulated.  This is analogous to the idea discussed 
above that when the predominant lipid found in a particular droplet is not synthesized, the 
droplet will not form.  In the case of the GFP-HSCs we are studying, some retinyl ester is still 
being made since LRAT is still expressed; thus, the droplets are present, but they are smaller in 
size.  The decrease in HSC triglyceride levels could be a consequence of either decreased 
triglyceride synthesis or increased triglyceride catabolism.  The array data suggest that 
triglyceride synthesis is not markedly different in the GFP-HSCs.  There are no genes involved 
in triglyceride biosynthesis with significant differential expression in the GFP-HSCs.  DGAT1 
and DGAT2 are known triglyceride synthesizing enzymes in the liver [214, 215], but expression 
levels of both are the same in the two HSC populations (data not shown).  There are, however, 
many differences in expression in genes involved with triglyceride breakdown, classified as 
either lipases or esterases.  We observe increased expression of two triglyceride lipases and a 
number of phopholipases.  Phospholipids comprise approximately 6% of lipids in HSC lipid 
droplets [83, 84]; thus, the increase in phopsholipid catabolism supports the idea that when 
retinyl ester is low, the non-retinoid lipids are degraded, as well.  We also observe a large 
increase in expression of Ces3.  This is interesting in light of the fact that other carboxylesterases 
have recently been proposed as potential retinyl ester hydrolases in HSCs, including ES-4 and -
10 [71, 216].  Our findings suggest that Ces3 might be a retinyl ester hydrolase in activated 
HSCs, but more work will need to be done to confirm its HSC expression and role in retinyl ester 
hydrolysis.  Similarly, we find elevated levels of LpL in the GFP-HSC population.  Mello et al. 
have shown that LpL is expressed at very low levels in hepatocytes and HSCs, but its expression 
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is induced 32-fold in activated HSCs [71].  Thus, the elevated levels of LpL provide further 
evidence that the GFP population are pre-activated HSCs.  Overall, the highly altered lipid 
metabolism in the GFP-HSCs is very interesting since we still do not know much about the 
specific lipid species that populate HSC lipid droplets, particularly with regard to the exact fatty 
acyl compositions of the lipids in these cells.  All we currently have is a fairly crude 
understanding of the breakdown of retinyl ester, triglyceride, cholesterol, phospholipids, and free 
fatty acids [83, 84].  Thus, future work in this area will prove to be very exciting with the 
potential of using the newly-emerging field of lipidomics and the use of LC/MS/MS for these 
characterizations. 
 The cytochrome P450’s are a superfamily of enzymes known to metabolize both 
exogenous compounds, including chemicals in the environment, carcinogens and drugs, and also 
endogenous compounds, including retinoids [197].  We were interested in studying six 
cytochromes in particular, based on either their expression in the liver and/or proposed roles in 
different types of liver disease.  The CYP26s (including CYP26A1, B1 and C1) are thought to be 
the major retinoid-catabolizing CYPs in the body [217-220].  They are known to metabolize all-
trans-retinoic acid and additionally, to be retinoic acid-inducible.  CYP26A1 and B1 are 
expressed in the mouse liver, but C1 is not.  CYP2E1 is notable for its role in alcoholic liver 
disease and for its release of reactive oxygen species, which are known to promote fibrogenesis 
in HSCs [221, 222].  CYP2S1 is a relatively newly-identified CYP and thus is not well-studied; 
however, it has been reported to metabolize retinoic acid [198-200].  The last two, CYPs 2C37 
and 2C39, have liver-specific expression [223].  Additionally, 2C39 has been reported to 
metabolize retinoic acid [224].  Of these six CYPs, only CYP2S1 was shown on the array, by 
qRT-PCR and by western blot to be elevated in the GFP-HSCs.  Previous reports in the literature 
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suggest that CYP2S1 has very low expression in the liver [201, 202].  Our data show that Cyp2s1 
is highly enriched in the HSCs, which comprise only 6-8% of cells in the liver and contain 1% of 
hepatic protein [44, 46].  Thus, expression in whole liver homgenates will be masked by the 
presence of hepatocytes, Kupffer cells and endothelial cells.  Furthermore, we show that Cyp2s1 
expression is elevated in vivo by carbon tetrachloride-mediated induction of hepatic fibrosis.  
Thus, we proposed that CYP2S1-mediated retinoid catabolism may play a role in the loss of lipid 
droplets and retinyl ester content in HSCs undergoing activation in the early stages of hepatic 
fibrosis. 
To determine if CYP2S1 plays a direct role in the hydrolysis of retinyl ester in activated 
HSCs, we overexpressed this protein as a recombinant adenovirus and transfected primary 
isolates of HSCs.  We show that cells overexpressing CYP2S1 have decreased retinyl ester and 
increased retinol content, providing very strong evidence that these HSCs are undergoing 
increased retinyl ester hydrolysis.  These findings not only implicate CYP2S1 as a mediator of 
HSC activation, but additionally define a novel role of this previously under-studied cytochrome 
in retinyl ester hydrolysis.  As with other retinoid-catabolizing cytochromes, CYP2S1 is known 
to metabolize all-trans-retinoic acid; however, the ability to use other retinoid metabolites as 
substrates has not been found for these enzymes.  Our data suggest that CYP2S1 uses retinyl 
ester, in addition to retinoic acid, as a substrate.  Future studies will need to employ enzyme 
activity assays to determine the exact retinoid substrates of CYP2S1 and the contribution of the 
various retinoid-binding proteins, including CRBPs and CRABPs, to these processes.       
In conclusion, using FACS-based methods of HSC isolation, we show that there are 
distinct populations of HSCs in a normal mouse liver.  The GFP-isolated HSCs have altered lipid 
droplet content and display distinct biochemical properties, determined by differential gene and 
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protein expression profiles and differential capacities for retinyl ester and triglyceride storage in 
their lipid droplets.  Specifically, we show that the GFP-HSCs have: (i) increased expression of 
typical markers of HSC activation; (ii) significantly decreased retinyl esters, accompanied by 
reduced LRAT protein expression; (iii) significantly less triglycerides; (iv) increased expression 
of genes associated with lipid catabolism, i.e. hydrolases and esterases; and (v) an increase in 
expression of the retinoid-catabolizing CYP, CYP2S1.  Our data suggest that there is 
heterogeneity in the HSC population in normal, uninjured liver.  A subset of the HSC population 




















Table 2-1.  ABI primers used for qRT-PCR analysis.  
























Commercially available primers purchased from Applied Biosystems (ABI) are shown with the 
















Table 2-2.  Summary of differentially expressed genes. 
 
Method p-value Cutoff Total Changed Increased Decreased 
Student’s t-test 0.05 5363* 2676 2687 
 0.01 3563 1901 1662 
 0.001 1673 825 848 
Welch’s t-test 0.05 5074 2361 2713 
 0.01 2674 1064 1610 
 0.001 985 230 755 
 
Affymetrix Mouse 430 2.0 microarray chips were used to search for gene expression differences 
between AF- and GFP-HSCs.  Lists of differentially expressed genes were generated using 
Student’s t-tests or Welch’s t-tests, each with three p-value cut-offs, including 0.05, 0.01 and 
0.001.  For each comparison, the number of total, increased and decreased differentially expressed 
genes is shown. 
































Table 2-3.  KEGG Pathway Enrichment. 
 




Up Down z-score 
UP Cell adhesion molecules 
(CAMs) 
131 51 34 17 5.64 
 Cytokine-cytokine receptor 
interaction 
232 74 48 26 4.95 
 Leishmaniasis 66 30 19 11 4.72 
 Type I diabetes mellitus 44 19 14 5 4.50 
 Leukocyte transendothelial 
migration 
114 44 26 18 4.16 
 ECM-receptor interaction 76 27 18 9 3.63 
 Maturity onset diabetes of 
the young 
25 10 8 2 3.41 
 Steroid biosynthesis 17 6 6 0 3.25 
 Glycine, serine and 
threonine metabolism 
30 9 8 1 2.80 
DOWN Axon guidance 127 54 24 30 4.76 
 Focal adhesion 189 70 33 37 4.01 
 Gap junction 83 25 7 18 3.25 
 Cell cycle 123 27 4 23 2.89 
 ErbB signaling pathway 84 22 6 16 2.48 
 Chemokine signaling 
pathway 
173 47 20 27 2.11 
 
Tests of KEGG pathway enrichment were conducted on the set of 5363 differentially expressed 
genes identified by the Student’s t-test as having a p-value equal to or less than 0.05.  The tests 
were performed using the GeneSifter software.  A pathway is defined as enriched if it has a 



















Table 2-4.  Markers of HSC Activation. 
 
AFFY ID Gene Name Gene ID FC p-value 
1449254_at Secreted phosphoprotein 1 Spp1 115.5 0.000001 








1456658_at Actin, alpha 2, smooth muscle Acta2 5.5 0.001718 
1456156_at Leptin receptor Lepr 4.2 0.007139 
1451924_a_at Endothelin 1 Edn1 4.2 0.000544 
1416454_s_at Actin, alpha 2, smooth muscle Acta2 3.5 0.016302 
1438303_at Transforming growth factor, beta 2 Tgfb2 2.7 0.002149 
1448729_a_at Septin 4 Sept4 0.49 0.003582 
1443434_s_at Plexin C1 Plxnc1 0.45 0.000309 
1455851_at Bone morphogenetic protein 5 Bmp5 0.40 0.000004 
 

















Table 2-5.  Retinoid- and Lipid-related Nuclear Receptors.  
 
AFFY ID Gene Name Gene ID FC p-value 
1454773_at Retinoid X receptor alpha Rxra 0.5 0.005977 
1450180_a_at Retinoic acid receptor, alpha Rara 0.4 0.002350 
1419416_a_at Retinoic acid receptor, gamma Rarg 0.4 0.003971 
1425762_a_at Retinoid X receptor alpha Rxra 0.4 0.000323 
1439675_at 
Peroxisome proliferator 
activated receptor alpha Ppara 0.3 0.004452 
 





















Table 2-6.  Retinol and Fatty Acid Binding Proteins. 
 
AFFY ID Gene Name Gene ID FC p-value 
1451263_a_at Fatty acid binding protein 4 Fabp4 10.9 0.001481 
1417023_a_at Fatty acid binding protein 4 Fabp4 4.9 0.003252 
1416022_at Fatty acid binding protein 5 Fabp5 3.4 0.002208 
1426225_at Retinol binding protein 4 Rbp4 3.0 0.022103 
1416021_a_at Fatty acid binding protein 5 Fabp5 2.8 0.000799 
1450779_at Fatty acid binding protein 7  Fabp7 2.1 0.014394 
1425105_at Retinol binding protein 3, interstitial Rbp3 0.5 0.024528 
1448754_at Retinol binding protein 1, cellular Rbp1 0.5 0.010727 
 




































Table 2-7.  Lipases. 
 
AFFY ID Gene Name Gene ID FC p-value 
1430550_at Lipase, family member M Lipm 6.1 0.047718 
1452398_at Phospholipase C, epsilon 1 Plce1 3.9 0.000029 
1417785_at Phospholipase A1 member A Pla1a 3.5 0.001223 
1430700_a_at 
Phospholipase A2, group VII (platelet-
activating factor acetylhydrolase, plasma) Pla2g7 3.5 0.002280 
1457157_at Phospholipase C-eta1a Plch1 2.6 0.007681 
1425338_at Phospholipase C beta 4  Plcb4 2.5 0.007491 
1436821_at 
Phosphatidylinositol-specific 
phospholipase C, X domain containing 3  Plcxd3 2.4 0.031885 
1437872_at 
NAPE-PLD mRNA for N-acyl-
phosphatidylethanolamine-hydrolyzing 
phospholipase D Napepld 2.3 0.017539 
1451970_at Diacylglycerol lipase, beta  Daglb 2.3 0.011264 
1435771_at Phospholipase C beta 4  Plcb4 2.1 0.002450 
1448558_a_at Phospholipase A2, group IVA  Pla2g4a 2.0 0.001474 
1424259_at Lipase maturation factor 1  Lmf1 0.5 0.042273 
1454619_at Lipase maturation factor 2 Lmf2 0.5 0.000238 
1416013_at Phospholipase D family, member 3  Pld3 0.4 0.000290 
1421261_at Lipase, endothelial Lipg 0.4 0.008316 
1432928_at Phospholipase C, delta 4  Plcd4 0.4 0.039780 
1450188_s_at Lipase, endothelial Lipg 0.4 0.002089 
1455448_at Diacylglycerol lipase, alpha Dagla 0.4 0.000027 
1417433_at Lysophospholipase 2  Lypla2 0.2 0.003292 
1433949_x_at Soluble PLA2-Ib precursor  Pla2g1b 0.2 0.018829 
1450128_at Phospholipase A2, group IIA  - 0.1 0.038422 
 


















Table 2-8.  Esterases. 
 
AFFY ID Gene Name Gene ID FC p-value 
1449081_at Carboxylesterase 3 Ces3 82.2 0.000234 
1435370_a_at Carboxylesterase 3 Ces3 67.4 0.000011 
1421218_at Butyrylcholinesterase  Bche 45.9 0.001056 
1436098_at Butyrylcholinesterase  Bche 26.2 0.007839 
1435371_x_at Carboxylesterase 3 Ces3 17.4 0.000000 
1436090_at 
Ectonucleotide 
pyrophosphatase/phosphodiesterase 6 Enpp6 13.7 0.014343 
1448813_at Arylacetamide deacetylase (esterase) Aadac 10.9 0.003532 
1417300_at 
Sphingomyelin phosphodiesterase, acid-
like 3B  Smpdl3b 5.3 0.000398 
1438665_at 
Sphingomyelin phosphodiesterase 3, 
neutral  Smpd3 5.1 0.002101 
1438785_at 
Ectonucleotide 
pyrophosphatase/phosphodiesterase 6 Enpp6 4.8 0.004224 
1452202_at 
Phosphodiesterase 2A, cGMP-
stimulated Pde2a 4.5 0.006551 
1422779_at 
Sphingomyelin phosphodiesterase 3, 
neutral  Smpd3 4.3 0.041569 
1447707_s_at 
Phosphodiesterase 2A, cGMP-
stimulated - 3.6 0.026599 
1416913_at Esterase 1 Es1 3.4 0.044153 
1417626_at 
Phosphodiesterase 4D interacting 
protein (myomegalin) - 2.8 0.001982 
1448136_at 
Ectonucleotide 
pyrophosphatase/phosphodiesterase 2 Enpp2 2.8 0.004744 
1424150_at 
Glycerophosphodiester 
phosphodiesterase domain containing 5 Gdpd5 2.6 0.030611 
1451857_a_at Notum pectinacetylesterase homolog  Notum 2.5 0.015403 
1417667_a_at Phosphotriesterase related Pter 2.4 0.000644 
1427302_at 
Ectonucleotide 
pyrophosphatase/phosphodiesterase 3 Enpp3 2.3 0.000140 
1415894_at 
Ectonucleotide 
pyrophosphatase/phosphodiesterase 2 Enpp2 2.2 0.001248 
1437341_x_at 
2',3'-cyclic nucleotide 3' 
phosphodiesterase - 0.5 0.000609 
1431913_a_at Phosphodiesterase 3A, cGMP inhibited - 0.5 0.000050 
1435096_at 
Resistance to inhibitors of 
cholinesterase 8 homolog B  Ric8b 0.5 0.001273 
1422635_at Acetylcholinesterase  Ache 0.5 0.004425 
1437989_at Phosphodiesterase 8B - 0.5 0.000826 
1421353_at CAMP specific phosphodiesterase 7B  Pde7b 0.4 0.015231 
1423810_at Protein phosphatase methylesterase 1 Ppme1 0.4 0.000273 
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1418302_at Palmitoyl-protein thioesterase 2 Ppt2 0.4 0.000061 
1452897_at 
Cell division cycle 2-like 5 
(cholinesterase-related cell division 
controller) Cdc2l5 0.4 0.000532 
1438949_at 
Resistance to inhibitors of 
cholinesterase 8 homolog  - 0.4 0.001225 
1421535_a_at Phosphodiesterase 4A, cAMP specific Pde4a 0.4 0.002163 
1432490_a_at Phosphodiesterase 10A - 0.4 0.046869 
1450453_a_at 
CGMP-phosphodiesterase 6 gamma 
subunit Pde6g 0.4 0.035910 
1442700_at Phosphodiesterase 4B, cAMP specific Pde4b 0.4 0.000132 
1451615_at Carboxylesterase 8  Ces8 0.3 0.012629 
 


































Table 2-9.  Cytochrome P450 enzymes. 
 
AFFY ID Gene Name Gene ID FC p-value 
1416612_at 
Cytochrome P450, family 1, subfamily b, 
polypeptide 1 Cyp1b1 100.9 0.000175 
1428283_at 
Cytochrome P450, family 2, subfamily s, 
polypeptide 1 Cyp2s1 32.0 0.004925 
1460604_at Cytochrome b reductase 1 Cybrd1 23.6 0.000016 
1421075_s_at 
Cytochrome P450, family 7, subfamily b, 
polypeptide 1 Cyp7b1 17.1 0.000044 
1417507_at Cytochrome b-561 Cyb561 13.2 0.000421 
1421074_at 
Cytochrome P450, family 7, subfamily b, 
polypeptide 1 Cyp7b1 10.2 0.000009 
1425040_at Cytochrome b reductase 1 Cybrd1 9.2 0.000095 
1416613_at 
Cytochrome P450, family 1, subfamily b, 
polypeptide 1 Cyp1b1 8.9 0.000029 
1419559_at 
Cytochrome P450, family 4, subfamily f, 
polypeptide 14 Cyp4f14 8.4 0.000002 
1417531_at 
CDNA fis, clone TRACH2008112,highly 
similar to CYTOCHROME P450 2J5 (EC 
1.14.14.1) Cyp2j5 5.3 0.002609 
1422533_at Cytochrome P450, family 51 Cyp51 4.7 0.000374 
1436778_at Cytochrome b-245, beta polypeptide Cybb 4.4 0.000743 
1417532_at 
CDNA fis, clone TRACH2008112,highly 
similar to CYTOCHROME P450 2J5 (EC 
1.14.14.1) Cyp2j5 4.3 0.00797 
1422978_at Cytochrome b-245, beta polypeptide Cybb 4.0 0.001173 
1444138_at 
Cytochrome P450, family 2, subfamily r, 
polypeptide 1 Cyp2r1 3.9 0.016331 
1436779_at Cytochrome b-245, beta polypeptide Cybb 3.8 0.003131 
1450646_at Cytochrome P450, family 51 Cyp51 3.4 0.001651 
1415994_at 
Cytochrome P450, family 2, subfamily e, 
polypeptide 1 Cyp2e1 2.9 0.006021 
1422534_at Cytochrome P450, family 51 Cyp51 2.8 0.010709 
1418780_at 
Cytochrome P450, family 39, subfamily a, 
polypeptide 1 Cyp39a1 2.2 0.03874 
1418709_at Cytochrome c oxidase, subunit VIIa 1  Cox7a1 2.1 0.017825 
1440211_at 
Cytochrome P450, family 2, subfamily j, 
polypeptide 11 Cyp2j11 0.5 0.026833 
1416933_at P450 (cytochrome) oxidoreductase Por 0.5 0.002868 
1430452_at 
Cytochrome P450, family 20, subfamily 
A, polypeptide 1 Cyp20a1 0.5 0.000408 
1416112_at Cytochrome c oxidase, subunit VIIIa Cox8a 0.4 0.000037 
 







Figure 2-1.  Quality assessment of samples used in microarray analysis.  Gene microarray 
analysis was conducted on populations of AF-HSCs isolated from 6 mice and GFP-HSCs 
isolated from 5 mice.  cDNA purified from these populations was run on Affymetrix Mouse 
Genome 430 2.0 Arrays, and data was analyzed using GeneSifter software.  (A) Levels of 
desmin mRNA normalized to 18S. A Student’s t-test was used to analyze for statistically 
significant differences between groups.  Groups were considered to be significantly different 
when p < 0.05.  (B) Boxplot summary showing the maximum and minimum values, 1st and 3rd 
quartiles, and medians of the AF and GFP groups.  (C) Scatter plot summary showing the spread 
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of the data points around the line of identity.  All genes over-expressed in the GFP group are 


























Figure 2-2.  Co-localization of GFP expression with expression of the HSC marker desmin.  
Immunohistochemistry was performed on sections of liver from collagen-GFP mice using 
antibodies to the HSC marker desmin (A) and GFP (B).  Merged image shows colocalization of 
desmin and GFP expression (C).  DAPI (blue) staining of nuclei is also shown in the merged 
image.  Micrographs are at 40X magnification.  Scale bars, 15 µm.  Arrows point to a hepatic 
















Figure 2-3.  mRNA and protein expression of markers of HSC activation.  (A) Relative 
mRNA expression levels of Col1a1, Acta2, Pdgfc, Tgfb, and Edn1 in AF-HSCs (solid bars) and 
GFP-HSCs (stripped bars) are shown.  Values are normalized to 18S and given as the mean ± 1 
S.D. for 5 AF and 5 GFP HSC isolations.  Significance was determined by a Student’s t-test, *** 
p-value < 0.001.  ND means “not detected.”  (B) Protein levels of ACTA2 in AF-HSCs and 













Figure 2-4.  Total Retinyl Ester and Triglyceride Levels in Liver and HSCs.  (A)  Retinyl 
ester (RE) levels in livers from WT and collagen-GFP mice, expressed as µg RE per gram liver 
weight.  (B)  Retinyl ester levels in AF-HSCs and GFP-HSCs, expressed as µg RE per million 
cells.  (C)  Triglyceride (TG) levels in livers from WT and collagen-GFP mice, expressed as µg 
TG per gram liver weight.  Mice were fasted for 4 hours prior to sacrifice and tissue collection.  
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(D)  TG levels in AF-HSCs and GFP-HSCs, expressed as µg TG per million cells.  Significance 
was determined by a Student’s t-test, * p-value < 0.05.  (E)  Protein levels of LRAT in AF-HSCs 

























Figure 2-5.  Assessment of lipid droplet content in AF-HSCs and GFP-HSCs after 
overnight culture.  AF-HSCs and GFP-HSCs were isolated by FACS and incubated at 37 ºC 
overnight on glass bottom dishes.  Phase contrast and fluorescent images were captured at 60X 
magnification for both AF-HSCs (A) and GFP-HSCs (B).  Scale bars represent 30 µm.  Average 
number of lipid droplets (C), average diameter (µm) of lipid droplets (D) and total lipid droplet 
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volume (µm3) (E) per HSC are shown.  (F)  Protein levels of ADRP in AF-HSCs and GFP-


























Figure 2-6.  mRNA levels of retinoid- and lipid-related nuclear receptors.  Relative mRNA 
expression levels of Rxra, Rara, Rarg, and Ppara in AF-HSCs (solid bars) and GFP-HSCs 
(stripped bars) are shown.  Values are normalized to 18S and given as the mean ± 1 S.D. for 5 














Figure 2-7.  mRNA levels of retinol and fatty acid binding proteins.  Relative mRNA 
expression levels of Fabp4, Rbp4, and Rbp1 in AF-HSCs (solid bars) and GFP-HSCs (stripped 
bars) are shown.  Values are normalized to 18S and given as the mean ± 1 S.D. for 5 AF and 5 














Figure 2-8.  mRNA levels of lipid hydrolases.  Relative mRNA expression levels of Ces3 and 
LpL in AF-HSCs (solid bars) and GFP-HSCs (stripped bars) are shown.  Values are normalized 
to 18S and given as the mean ± 1 S.D. for 5 AF and 5 GFP HSC isolations.  Significance was 














Figure 2-9.  mRNA and protein expression of retinoid-metabolizing cytochrome P450 
enzymes.  (A) Relative mRNA expression levels of Cyp2s1 and Cyp2e1 in AF-HSCs (solid bars) 
and GFP-HSCs (stripped bars) are shown.  Values are normalized to 18S and given as the mean 
± 1 S.D. for 5 AF and 5 GFP HSC isolations.  Significance was determined by a Student’s t-test, 
** p-value < 0.01.  (B) Protein levels of CYP2S1 and CYP2E1 in AF-HSCs and GFP-HSCs.  













Figure 2-10.  Cyp2s1 is a retinoid-catabolizing CYP both highly expressed in HSCs and 
induced in hepatic fibrosis.  (A)  HSCs and hepatocytes were isolated from male WT C57 mice 
at 3 months age.  Relative mRNA expression levels of Cyp26a1, Cyp2e1, Cyp2c37, and Cyp2c39 
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(left panel) and Cyp26b1 and Cyp2s1 (right panel) are shown.  (B)  WT C57 male mice were 
given weekly injections of either corn oil or 0.5ul CCl4/g B.W. administered in corn oil for 4 
weeks and then sacrificed.  Relative Cyp mRNA levels in whole liver homogenates were 
measured.  Values are normalized to 18S and given as the mean ± 1 S.D.  Significance was 










































































































































Figure 2-11.  Increased retinyl ester hydrolysis in HSCs transfected with a recombinant 
adenovirus overexpressing CYP2S1.  HSCs were isolated from female WT mice in a mixed 
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genetic background at approximately 200 days of age.  The cells were seeded on plastic dishes, 
infected with the recombinant adenoviruses 24 h later and then cultured for an additional 48 h 
before harvesting.  Retinoids were extracted, and concentrations of retinyl ester (RE) and retinol 
(ROH) in the cells were quantified by comparing integrated peak areas for those of each retinoid 
against those of known amounts of purified standards.  (A)  Relative mRNA expression levels of 
Cyp2s1 in HEK293 cells, HEK293 cells infected with AdGFP (empty vector control), and 
HEK293 cells infected with AdCYP2S1 are shown.  Values are normalized to 18S.  N is 1 for 
each group.  (B)  Levels of RE (left panel) and ROH (right panel) expressed as nmol per 106 
HSCs are shown.  Significance was determined by a Student’s t-test, * p-value < 0.05, *** p-

















A DNA Microarray Study in LRAT Knockout Mice to Identify Key Genes and Pathways 
Involved in Hepatic Stellate Cell Lipid Droplet Formation and Maintenance 
 
ABSTRACT 
The expression and activity of lecithin:retinol acyltransferase (LRAT) plays a central role in the 
storage of retinoid, in the form of retinyl ester, in hepatic stellate cell (HSC) lipid droplets.  The 
importance of this enzyme is underscored by the findings that the HSCs of LRAT knockout 
(KO) mice, despite being morphologically normal, are completely devoid of retinyl ester and 
their characteristic lipid droplets.  The objective of this study was to use the LRAT KO mouse 
model to identify key genes and pathways involved in HSC lipid droplet formation and 
maintenance.  Wild type (WT) and Lrat-/- mice in the C57BL/6 genetic background were bred 
into collagen-green fluorescent protein (GFP) mice, and HSCs were isolated by fluorescence 
activated cell sorting (FACS) based on GFP expression.      DNA microarrays were performed on 
these two populations of cells to access differences in gene transcriptional expression.  Our 
findings indicate that, while there are not global differences in the expression of genes related to 
retinoid metabolism, the LRAT KO HSCs have significant differences in expression of genes 
related to lipid metabolism.  Overall, lipid biosynthesis is down-regulated and lipid catabolism is 
up-regulated in LRAT KO HSCs, which likely contributes to the complete absence of lipid 







 The role of hepatic stellate cells (HSCs) in retinoid storage in the body has been firmly 
established in previous chapters.  The expression and activity of lecithin:retinol acyltransferase 
(LRAT) in these cells plays a central role in this process.  In the late 1980s, two enzymatic 
activities capable of esterifying retinol were found in the liver, including acyl-CoA:retinol 
acyltransferase (ARAT) and LRAT [225].  Accompanying these activities was also a high 
concentration of cellular retinol-binding protein, type I (CRBPI) [31].  Subsequent studies 
showed that CRBPI-bound retinol is esterified by LRAT in liver and that this reaction resulted in 
the formation of retinyl esters [226, 227].  The importance of CRBPI in the esterification of 
retinol by LRAT was also demonstrated in the eye [228].  The first concrete connection between 
hepatic LRAT expression with storage of retinyl esters in the liver was shown in vitamin A 
depletion and repletion studies in rats, in which hepatic LRAT activity and serum retinol levels 
decreased with vitamin A depletion [229].  Upon vitamin A repletion, hepatic LRAT activity and 
serum retinol increased, along with deposition of retinyl ester in the liver, thereby implicating 
LRAT as a mediator of hepatic retinyl ester stores [229]. 
 The cloning and biochemical characterization of LRAT in the late 1990s revealed that 
LRAT is a 25-kDa protein and, when transfected into HEK293 cells, was able to convert all-
trans-retinol to all-trans-retinyl palmitate, the predominant retinyl ester form present in HSCs 
[230].  A number of dietary studies, thereafter, elucidated the role of LRAT in maintaining 
vitamin A homeostasis in response to changes in dietary retinoid status.  The first of these studies 
demonstrated that LRAT mRNA was absent from the livers of rats maintained on a vitamin A-
deficient diet (with no effect on intestinal levels, another site of LRAT expression), suggesting 
that, under conditions of vitamin A insufficiency, hepatic LRAT expression is curtailed to 
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maintain retinol availability for secretion and delivery to peripheral tissues [231].  This same 
study reported that, in vitamin A-deficient mice, hepatic LRAT mRNA was induced by retinoic 
acid supplementation, suggesting that when vitamin A is replenished, retinoic acid serves as a 
signal for LRAT to redirect retinol into storage pools.  Later studies by the Gudas laboratory 
reported on the effects of vitamin A dietary status in LRAT knockout (KO) mice [82].  This 
group first showed that LRAT KO mice are more susceptible to vitamin A-deficiency, as retinol 
levels were undetectable in most tissues from mice maintained of a vitamin A-deficient diet for 6 
weeks.  These authors proposed LRAT KO mice as a novel model of vitamin A-deficiency.  
They later showed that LRAT KO mice fed a high retinol diet exhibited a greater and faster 
increase in serum retinol concentration and higher levels of retinol in adipose tissue [232].  This 
data suggested that when overloaded with excess retinol, the LRAT KO mice, unable to store the 
excess in the liver, will redirect it into the serum so that it may be carried to and stored in 
extrahepatic tissues. 
 The most compelling evidence that LRAT plays an essential role in retinoid metabolism 
and storage in the liver came from a study also in LRAT KO mice reported by O’Byrne et al. in 
2005 [29].  A major finding of this study was that the HSCs of LRAT KO mice, despite being 
morphologically normal, are completely devoid of retinyl ester and their characteristic lipid 
droplets.  Furthermore, despite the absence of significant retinyl ester stores and HSC lipid 
droplets, these mice showed no signs of hepatic fibrosis, as determined by histological analysis 
of liver sections.  This study high-lighted two important aspects of hepatic retinoid physiology: 
(i) the synthesis and storage of retinyl ester is essential for the presence of HSC lipid droplets, 
and (ii) LRAT is the only enzyme capable of retinol esterification in the liver in vivo, disproving 
the existence of an unidentified hepatic ARAT, which was inferred from in vitro data.   
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 With LRAT having such a prominent role in hepatic retinoid homeostasis and HSC lipid 
droplet biology, we were interested in employing the LRAT KO mice in the study of HSC lipid 
droplet formation and maintenance to identify key genes and pathways involved in these 
processes.  The LRAT KO mice serve as a model system where lipid droplets do not form (in 
contrast to disease models, where HSC lipid droplets form, but are subsequently lost in response 
to hepatic injury).  For this study, we have bred wild type (WT) and Lrat-/- mice in the C57BL/6 
genetic background into the collagen-green fluorescent protein (GFP) mice described and 
characterized in Chapter 2.  We conducted DNA microarray analysis on HSCs isolated from 
these two strains of mice to parallel the study presented in Chapter 2, with a focus on changes in 
















MATERIALS AND METHODS 
Animals.  WT and Lrat-/- mice in the C57BL/6 genetic background were bred into the collagen-
green fluorescent protein (GFP) mice described in Chapter 2 [188].  All mice used in the study 
were males between 90 and 120 days of age at the time of sacrifice.  Animals were allowed ad 
libitum access to water and a standard nutritionally complete rodent chow diet (W. F. Fisher and 
Sons, Inc., Somerville, NJ).  All mice were maintained on a 12-h dark-light cycle, with the 
period of darkness between 7:00 a.m. and 7:00 p.m. in a conventional barrier facility.  The 
animal experiments described in this report were conducted in accordance with the National 
Research Council's Guide for the Care and Use of Laboratory Animals and were approved by the 
Columbia University Institutional Committee on Animal Care.   
HSC Isolations.  Primary mouse HSCs were isolated according to established protocols [84, 
193, 194] with some modification.  Livers were perfused in situ with EGTA for 5 min, pronase E 
(0.4 mg/ml, EMD Chemicals Inc., Gibbstown, NJ) for 5 min and collagenase D (0.5 mg/ml, 
Roche Diagnostics) for 8 min, respectively, at a flow rate of 5 ml/min.  After excision of the liver 
from the body, the liver digests were filtered through a cell strainer and washed with Gey’s 
Balanced Salt Solution (Sigma, St. Louis, MO) containing DNase I (2mg/ml, Roche 
Diagnostics).  Parenchymal cells and debris were separated from non-parenchymal cells by 
centrifugation at 50g for 2 minutes.  The remaining non-parenchymal cell suspension was then 
separated by fluorescence activated cell sorting (FACS) using FACS Calibur (Becton Dickinson, 
Franklin Lakes, NJ), and FITC-positive cells were collected based on their emission at 530 nm.  
This method of HSC isolation yields approximately 10% of the total HSCs estimated to be in the 
liver from both WT-GFP and LRAT KO-GFP mice.     
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Isolation of RNA and cDNA synthesis.  Total RNA was isolated from HSCs using the Qiagen 
RNeasy kit (Qiagen, Valencia, CA).  cDNA synthesis and amplification were performed using 
the NuGEN WT-Ovation Pico RNA Amplification kit (NuGEN, San Carlos, CA).  The resulting 
cDNA was then purified using the Qiagen QIAquick PCR Purification kit (Qiagen).  cDNA 
fragmentation and labeling were performed using the NuGEN FL-Ovation cDNA Biotin Module 
V2 kit (NuGEN).         
DNA Microarray Analysis.  Array analysis was conducted on the Affymetrix Mouse Genome 
430 2.0 Array (Affymetrix, Santa Clara, CA) and analyzed using the GeneSifter gene expression 
analysis suite (Geospiza, Seattle, WA).  Individual gene expression values were normalized to 
the median.  Significant changes in gene expression between sample sets were identified by a 
Student’s t-test and subsequent Benjamini–Hochberg correction, with a p-value of 0.05 as the 
criterion for statistical significance.   
Quantitative Real-Time PCR.  Differential gene expression was confirmed by quantitative real-
time polymerase chain reaction (qRT-PCR) using commercially available primer-probe sets 
(Table 1, Applied Biosystems, Foster City, CA).  qRT-PCR was performed on a LightCycler 
480 (Roche Diagnostics).   
Western Blot Protein Analysis.  HSC proteins were analyzed by Western blot assay.  For all 
proteins analyzed, 20 µg of total protein was separated on 10% SDS–PAGE gels and transferred 
onto polyvinylidene fluoride membrane (Millipore Immunobilon-P Transfer Membrane) at 100V 
for 1 h at 4°C.  The membranes were then incubated with 10% milk blocking buffer for 1 h at 
room temperature (RT), followed by overnight incubation at 4°C with the following primary 
antibodies: perilipin (1:500, rabbit polyclonal, Abcam, Cambridge, MA, ab3526), adipose 
differentiation-related protein (1:500, rabbit polyclonal, Abcam, ab52356), and mannose-6-
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phosphate receptor binding protein 1 (1:500, rabbit polyclonal, Abcam, ab47639).  The 
secondary antibody incubations were for 1 h at RT with a donkey horseradish peroxidase-
conjugated anti-rabbit IgG antiserum (1:10,000, GE Healthcare, Piscataway, NJ, cat# NA934V).  
Immunoblots were developed using the ECL system (Thermo Scientific, Rockford, IL).  
Statistical Analysis.  All data are presented as means ± S.D.  A Student’s t-test was used to 
analyze for statistically significant differences between groups.  Groups were considered to be 


































RESULTS   
Method of HSC Isolation.  To obtain HSCs from the livers of LRAT KO mice, WT and Lrat-/- 
mice in the C57BL/6 genetic background were bred into the collagen-green fluorescent protein 
(GFP) mice described in Chapter 2 [188].  These two strains will be referred to subsequently as 
WT-GFP and LRAT KO-GFP.  As previously described, GFP expression in these mice is driven 
by the Col1a1 promoter [188], and expression of collagen I in the liver is thought to be solely in 
the HSCs [189, 190].  Thus, the use of these transgenic mice allows the isolation of HSCs 
independent of the presence of lipid droplets in the cells.  We performed FACS on digests of 
non-parenchymal cells and collected GFP-positive cells based on their emission at 530nm.  The 
purity of these populations was analyzed by qRT-PCR using desmin mRNA expression as a 
marker of HSC purity [195].  We show that the isolation of HSCs from WT-GFP and LRAT KO-
GFP mice yields cell populations with equivalent desmin expression (Figure 1A).        
Microarray Analysis Overview.  For this study, we performed gene microarray analysis on 
populations of WT-GFP HSCs isolated from 5 mice and LRAT KO-GFP HSCs isolated from 5 
mice.  cDNA purified from these populations was run on Affymetrix Mouse Genome 430 2.0 
Arrays, covering over 45,000 transcripts in the mouse genome, and data was analyzed using 
GeneSifter software.  The quality of the samples used is demonstrated by the box plot and scatter 
plot summaries of the WT- and LRAT KO-GFP groups, which show that the spread of all the 
array data points is identical in both groups (Figure 1B and 1C).  Six hundred ninety one probe 
sets were more than 2-fold up- or down-regulated in the LRAT KO-GFP HSCs compared to 
WT-GFP HSCs (Table 2).  This set of transcripts differentially expressed between WT- and 
LRAT KO-GFP-HSCs is enriched for 10 KEGG pathways (Table 3), with enrichment defined as 
a z-score up or down of greater than 2 (see Chapter 2 for a more detailed description of z-score).  
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The differential FACS sorting patterns of the LRAT KO-GFP HSCs compared to WT-GFP 
HSCs is shown in Figure 2, which reveals that the LRAT KO-GFP HSCs are overall larger in 
size and less granular.   
Changes in retinoid- and lipid-related gene expression.  With the goal of identifying the genes 
and/or pathways that may account for the absence of vitamin A-containing lipid droplets in the 
LRAT KO-GFP HSCs, we focused our array analysis on retinoid- and lipid-related gene 
expression.  The retinoid and lipid nuclear receptors were of high interest, as this group of genes 
represents a major route of gene regulation with many downstream effectors.  The array data 
indicated that the peroxisome proliferator activated receptor alpha and gamma (Ppara and 
Pparg), retinoid X receptor alpha, beta and gamma (Rxra, Rxrb and Rxrg), and retinoic acid 
receptor alpha, beta and gamma (Rara, Rarb and Rarg) are not differentially expressed in the 
LRAT KO-GFP HSCs (Table 4).  qRT-PCR analysis confirmed that there is not significant 
differential expression of these nuclear receptors in this population of cells (Figure 3).  
Similarly, the array indicated that the retinol- and fatty acid binding proteins, including members 
of the Rbp and fatty acid binding protein (Fabp) families, are not differentially expressed in the 
LRAT KO-GFP HSCs (Table 5).  One exception, however, is Fabp4, which the array showed to 
be 2-fold elevated in the LRAT KO group.  However, qRT-PCR analysis shows that Fabp4, 
along with the other retinol and fatty acid binding proteins, is not differentially expressed in the 
LRAT KO-GFP HSCs (Figure 4).  We were also interested in whether differences in gene 
expression might indicate altered levels of retinoic acid in the LRAT KO-GFP HSCs, so we 
looked at levels of hepatic retinoic acid-synthesizing enzymes, the aldehyde dehydrogenases 
(Aldh’s), and hepatic retinoic acid-catabolizing cytochromes (Cyp’s).  The array showed no 
differences in expression in Aldh1a1, Aldh1a2 and Aldh1a3 (Table 6; also known as Raldh1, 
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Raldh2, and Raldh3, respectively) or in Cyp26a1, Cyp26b1, Cyp2e1 and Cyp2s1 (Table 7).  
qRT-PCR analysis confirmed that there is not differential expression of these specific Aldh’s 
(Figure 5) or Cyp’s (Figure 6) in the LRAT KO-GFP HSCs.             
The array data suggest that there may be significant gene transcriptional changes relating 
to lipid metabolism underlying the altered lipid droplet content in LRAT KO-GFP HSCs.  The 
lipid biosynthesis KEGG pathway is down-regulated: 7 genes were found to have significant 
differential expression, and all 7 were 2-fold or more decreased in the LRAT KO-GFP HSCs 
(Table 8).  Among these genes are the liver master regulator hepatic nuclear factor 4 alpha 
(Hnf4a) and a few proteins that play a role in long chain fatty acid synthesis, including 
elongation of very long chain fatty acids family members 2 and 7 (Elovl2 and Elovl7) and acyl-
coA synthetase long-chain family member 1 (Acsl1) (Table 8).  qRT-PCR confirmed that these 
lipid biosynthetic enzymes are trending towards decreased levels in the LRAT KO-GFP HSCs, 
but these changes were not found to be statistically significant (Figure 7).  Conversely, the array 
indicates that long chain fatty acid breakdown is up-regulated: 4 lipases were found to have 
significant differential expression, and all 4 were 2-fold or more increased in the LRAT KO-GFP 
HSCs (Table 9).  Interestingly, the two most elevated of these enzymes, pancreatic lipase (Pnlip; 
elevated 24-fold) and colipase (Clps; elevated nearly 7-fold), work in conjunction to hydrolyze 
dietary long-chain triglycerides in the intestinal lumen, but are not known to act in the liver [233, 
234].  qRT-PCR shows that Clps mRNA is elevated in the LRAT KO-GFP HSCs, but, again, this 
difference was not found to be statistically significant (Figure 8).  We also measured mRNA 
levels of lipoprotein lipase (LpL) and carboxylesterase 3 (Ces3), lipases previously shown to play 
a role in retinoid and lipid catabolism in HSCs (see Chapter 2), but no statistically significant 
differences were found for these enzymes (Figure 8).     
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A group of proteins that was of high interest in this study is the lipid droplet-associated 
proteins, which play a crucial role in the stabilization of lipid droplets and in the control of 
lipolysis [210].  We focused our analysis on the PAT family proteins, including perilipin (Plin), 
adipose differentiation-related protein (Adfp), TIP47 (also known as mannose-6-phosphate 
receptor binding protein 1; M6prbp1), and S3-12, which are the major structural proteins of lipid 
droplets [210, 235, 236], and additionally considered the lipid-anchored, GTPase protein Rab18 
[237, 238].  The array (Table 10) and qRT-PCR (Figure 9A) both indicated that these proteins 
are present at equivalent levels in the LRAT KO-GFP HSCs relative to WT-GFP HSCs.  
Western blot analysis, however, revealed that ADFP protein is completely absent in LRAT KO-
GFP HSCs (Figure 9B).  Unexpectedly, M6PRBP1 was undetectable in both WT- and LRAT 




























The standard method of HSC isolation employs a Nycodenz density gradient to separate 
non-parenchymal cells from a liver digest where hepatocytes have been destroyed by exposure to 
pronase [84, 193, 194].  The low buoyant density of the numerous lipid droplets present in the 
HSCs allows these cells to float to the top of the gradient and thereby be separated from the other 
less lipid-rich cell types present in the liver.  The dependence of this method on the presence of 
lipid droplets poses a technical barrier to the isolation of HSCs from a liver where lipid droplets 
are either significantly depleted, as is the case for activated HSCs, or completely absent, in the 
case of LRAT KO mice.  Thus, the study of primary isolates of HSCs from LRAT KO mice has, 
to date, not been possible.  To overcome this barrier, we employed a FACS-based method to 
isolate HSCs from LRAT KO mice.  This involved the use of collagen-GFP mice in which GFP 
expression is driven by the Col1a1 promoter [188].  Hepatic expression of collagen I is solely in 
HSCs [189, 190], and its expression is increased as the cells become activated [191, 192].  Thus, 
GFP expression from this transgene can be used to identify and isolate HSCs from both LRAT 
KO mice and activated HSCs (which will be further discussed in Chapter 4).  Our data confirm 
that the GFP-based method of HSC isolation yields a population of cells with equivalent desmin 
expression in both WT- and LRAT KO-GFP HSCs.  Thus, we demonstrate for the first time a 
novel method of HSC isolation that allows the isolation of HSCs independent of the presence of 
lipid droplets.  Furthermore, the absence of lipid droplets in LRAT KO HSCs makes these cells a 
high-priority model in the study of HSC lipid droplet biology, and we demonstrate for the first 
time the ability to utilize this system. 
To gain insight into global differences in gene expression in the LRAT KO-GFP HSCs 
compared to WT, we first performed KEGG pathway enrichment analysis on both microarray 
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sample sets.  A number of the enriched KEGG pathways play a role in the structure of the 
extracellular matrix (ECM), including glycosaminoglycan biosynthesis (keratin sulfate), gap 
junctions, and adherens junctions, which indicates that there may be structural alterations to the 
cells themselves that may be either a cause or consequence of the lack of lipid droplets in the 
LRAT KO HSCs.  This idea is further supported by the differential FACS sorting patterns of the 
LRAT KO-GFP HSCs compared to WT-GFP HSCs, which shows that the LRAT KO HSCs are 
overall larger in size and less granular.  This finding was unexpected because one would 
hypothesize a priori that, with the absence of lipid droplets in the LRAT KO HSCs, these cells 
would be smaller in size.  Enrichment of ErbB signaling is notable because this pathway plays a 
significant role in cell proliferation, differentiation, motility, and survival [239].  It is also 
interesting that folate metabolism is seemingly altered in the LRAT KO-GFP HSCs because 
deregulated folate metabolism has been linked to disrupted retinoid metabolism in the liver both 
in retinol-binding protein (RBP)-null mice, where hepatic stores of retinol can not be mobilized 
(unpublished data from Loredana Quadro and William Blaner), and in alcoholic liver disease 
[240]. 
 As discussed previously in Chapter 2, there is a strong correlation between the 
predominant lipid species present in a lipid droplet and the enzyme(s) responsible for synthesis 
of the lipid.  HSC lipid droplets have a unique retinoid content, not found in other cell types in 
the body [83, 84].  This retinoid, in the form of retinyl ester, comprises approximately 40% of 
total HSC lipid content and is dependent on the expression of LRAT, which is the only hepatic 
enzyme capable of retinyl ester synthesis in vivo [29].  Consistent with the idea above, our lab 
has shown that when LRAT expression is absent, HSC lipid droplets do not form [29].  Thus, we 
hypothesized that LRAT KO HSCs would have a global deregulation in retinoid metabolism, in 
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addition to the absence of retinyl ester synthesis.  Surprisingly, both the array and qRT-PCR data 
indicated that there are no differences in expression in the retinoid nuclear receptors, retinoid 
binding proteins, or genes associated with retinoic acid signaling in LRAT KO-GFP HSCs.  
These findings suggest that the formation and maintenance of HSC lipid droplets may be 
regulated entirely by the synthesis of retinyl ester and not by more profound changes in retinoid 
metabolism.  This also high-lights the significance of the specialization of lipid droplets in 
different cell types in the storage of different lipid species: for reasons yet unknown, evolution 
has driven different cell types to specialize in the storage of different lipid species and when that 
particular lipid is absent, due to either decreased synthesis, increased degradation or increased 
mobilization, the lipid droplet in that cell type will not form. 
 Both the array and qRT-PCR data indicated that there are also no differences in gene 
expression in the lipid droplet-associated proteins, including Plin, Rab18, M6prbp1, Adfp and 
S3-12.  This finding was unexpected because there is seemingly no reason for lipid droplet-
associated proteins to be present if there are no lipid droplets in the cell.  The presence of lipid 
droplet-associated protein mRNA expression in LRAT KO HSCs led us to hypothesize that lipid 
droplets may actually form in these cells, but are subsequently degraded due to the absence of 
retinyl ester.  More specifically, in the absence of retinyl ester in the LRAT KO, there is no 
signal for the lipid droplet-associated proteins to form the scaffolding for the droplet and the 
other lipids in the cell, including triglyceride, cholesterol ester, cholesterol and phospholipids, 
must be degraded.  However, this model was disproved by western blot analysis showing that 
ADFP protein is completely absent in LRAT KO-GFP HSCs.  These proteins likely undergo 
post-transcriptional processing, and thus, message and protein levels do not correspond.           
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 The array data did, however, indicate that there are global changes in lipid metabolism in 
the LRAT KO-GFP HSCs.  A number of genes in the lipid biosynthesis pathway are down-
regulated, including Hnf4a, Elovl2 and 7, and Acsl1.  Moreover, a number of genes in the lipid 
catabolic pathway are up-regulated, including Pnlip, Clps, and phospholipase A2 group X 
(Pla2g10).  These results are consistent with the absence of lipid droplets in LRAT KO-GFP 
HSCs and suggest that the cells respond by decreasing lipid synthesis and increasing lipid 
degradation, since there is no storage depot for this lipid.  It is interesting that pancreatic lipase 
and colipase are elevated in the LRAT KO-GFP HSCs because a role for these two enzymes in 
the liver has been suggested, but not well-studied.  These enzymes are known to be secreted by 
the pancreas into the intestinal lumen, where they act together to hydrolyze dietary long-chain 
triglycerides.  More recently, data from the Zhang laboratory suggested these enzymes are 
activated in the liver in a circadian manner under conditions of light illumination deficiency 
(dark-dark cycle) [241], and they subsequently showed that this regulation occurs through 
adenosine receptors [242].  More compelling is the finding that inhibition of pancreatic-related 
protein 2 (Plrp2) and Clps expression in mice in vivo resulted in decreased levels of circulating 
retinol and in decreased hydrolysis of retinyl esters in vitro in HSC-T6 cells [243].  Our data is 
consistent with this group and suggests that PNLIP and its co-enzyme CLPS may be significant 
lipid hydrolases in HSCs.     
Although qRT-PCR analysis indicated that expression of these lipid synthesis enzymes 
are trending toward decreased levels in the LRAT KO HSCs, these differences did not reach 
statistical significance.  This is also the case for Clps mRNA, which is trending towards an 
elevation in LRAT KO-GFP HSCs, but is not significant.  These results are worth pursuing, but a 
different approach is required.  Rather than trying to access changes in the expression of 
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significant enzymes in these lipid pathways, it would be more efficient to measure directly the 
lipid products of interests.  This could be accomplished by utilizing LC/MS/MS to conduct a 
lipidomics study in LRAT KO-GFP HSCs to create a profile of the individual lipid classes 
present in these cells; instead of analyzing message and protein levels of enzymes responsible for 
long chain fatty acid synthesis, i.e. Elovl’s, we can directly measure long chain fatty acyl content 
in LRAT KO-GFP HSCs.  In addition to being a more direct method of analysis, LC/MS/MS is a 
highly sensitive and specific tool that far surpasses the limitations of qRT-PCR and western blot 































Table 3-1.  ABI primers used for qRT-PCR analysis.  
 
































Commercially available primers purchased from Applied Biosystems (ABI) are shown with the 






Table 3-2.  Summary of differentially expressed genes.   
 
 p-value Cutoff Total Changed Increased Decreased 
No Statistics - 45,101 21,814 23,287 
Student’s t-test 0.05 691 344 347 
0.01 179 94 85 
0.001 35 17 18 
Welch’s t-test 0.05 541 266 275 
0.01 125 62 63 
0.001 18 7 11 
 
Affymetrix Mouse 430 2.0 microarray chips were used to search for gene expression differences 
between WT-GFP and LRAT KO-GFP HSCs.  Lists of differentially expressed genes were 
generated using Student’s t-tests or Welch’s t-tests, each with three p-value cut-offs, including 
0.05, 0.01 and 0.001.  For each comparison, the number of total, increased and decreased 


















Table 3-3.  KEGG Pathway Enrichment.   
 
z-score UP 




Up Down z-score 
MAPK signaling pathway 266 39 27 12 4.40 
Glycosaminoglycan biosynthesis – 
keratan sulfate 
15 4 4 0 4.07 
Fatty acid biosynthesis 6 2 2 0 3.35 
ErbB signaling pathway 84 16 10 6 3.20 
Wnt signaling pathway 149 23 14 9 2.81 
Protein digestion and absorption 75 11 8 3 2.51 
Gap junction 83 11 8 3 2.19 
z-score DOWN 




Up Down z-score 
One carbon pool by folate 16 4 1 3 3.12 
Adherens junctions 73 8 1 7 2.59 
Folate biosynthesis 11 2 0 2 2.49 
 
Tests of KEGG pathway enrichment were conducted on the set of 691 differentially expressed 
genes identified by the Student’s t-test as having a p-value equal to or less than 0.05.  The tests 
were performed using the GeneSifter software.  A pathway is defined as enriched if it has a 














Table 3-4.  Retinoid- and Lipid-related Nuclear Receptors.   
 
AFFY ID Gene Name Gene ID FC p-value 
1419416_a_at Retinoic acid receptor, gamma Rarg 1.5 0.057644 
1439675_at 
Peroxisome proliferator 
activated receptor alpha Ppara 1.5 0.048561 
1425762_a_at Retinoid X receptor alpha Rxra 1.5 0.010843 
1420715_a_at 
Peroxisome proliferator 
activated receptor gamma Pparg 1.4 > 0.1 
1450180_a_at Retinoic acid receptor, alpha Rara 1.4 0.030931 
1418782_at Retinoid X receptor gamma  Rxrg 1.2 > 0.1 
1416990_at Retinoid X receptor beta Rxrb 1.1 > 0.1 
1454773_at Retinoid X receptor alpha Rxra 1.0 > 0.1 
1454906_at Retinoic acid receptor, beta Rarb 1.0 > 0.1 
1430497_at Retinoid X receptor alpha Rxra 0.9 > 0.1 
1457721_at 
Peroxisome proliferator 
activated receptor alpha Ppara 0.9 > 0.1 
1449051_at 
Peroxisome proliferator 
activated receptor alpha Ppara 0.9 > 0.1 
1419415_a_at Retinoic acid receptor, gamma Rarg 0.8 > 0.1 
 















Table 3-5.  Retinol and Fatty Acid Binding Proteins.   
 
AFFY ID Gene Name Gene ID FC p-value 
1417023_a_at 
Fatty acid binding protein 4, 
adipocyte  Fabp4 2.1 0.029292 
1426225_at 
Retinol binding protein 4, 
plasma Rbp4 1.4 > 0.1 
1451263_a_at 
Fatty acid binding protein 4, 
adipocyte  Fabp4 1.4 > 0.1 
1424155_at 
Fatty acid binding protein 4, 
adipocyte  Fabp4 1.3 > 0.1 
1444844_at 
Fatty acid binding protein 3, 
muscle and heart Fabp3 1.2 > 0.1 
1425105_at 
Retinol binding protein 3, 
interstitial Rbp3 1.1 > 0.1 
1416023_at 
Fatty acid binding protein 3, 
muscle and heart Fabp3 1.1 > 0.1 
1416022_at 
Fatty acid binding protein 5, 
epidermal Fabp5 1.1 > 0.1 
1448754_at 
Retinol binding protein 1, 
cellular Rbp1 1.0 > 0.1 
1416021_a_at 
Fatty acid binding protein 5, 
epidermal Fabp5 0.9 > 0.1 
1450682_at Fatty acid binding protein 6 Fabp6 0.9 > 0.1 
1448764_a_at 
Fatty acid binding protein 1, 
liver Fabp1 0.9 > 0.1 
1449461_at 
Retinol binding protein 7, 
cellular - 0.9 > 0.1 
1422846_at 
Retinol binding protein 2, 
cellular  Rbp2 0.8 > 0.1 
1418438_at 
Fatty acid binding protein 2, 
intestinal Fabp2 0.8 > 0.1 
1450779_at 
Fatty acid binding protein 7, 
brain  Fabp7 0.8 > 0.1 
1457855_at 
Retinol binding protein 3, 
interstitial Rbp3 0.7 > 0.1 
1417556_at 
Fatty acid binding protein 1, 
liver Fabp1 0.7 > 0.1 
 






Table 3-6.  Retinoic Acid-synthesizing Enzymes.   
 
AFFY ID Gene Name Gene ID FC p-value 
1422789_at 
Aldehyde dehydrogenase family 1, 
subfamily A2 Aldh1a2 1.2 > 0.1 
1416468_at 
Aldehyde dehydrogenase family 1, 
subfamily A1 Aldh1a1 0.9 > 0.1 
1417642_at 
Aldehyde dehydrogenase family 1, 
subfamily A3 Aldh1a3 0.9 > 0.1 
1448789_at 
Aldehyde dehydrogenase family 1, 
subfamily A3 Aldh1a3 0.7 > 0.1 
1427395_a_at 
Aldehyde dehydrogenase family 1, 
subfamily A3 Aldh1a3 0.7 > 0.1 
 



















Table 3-7.  Retinoic acid-catabolizing Cytochromes.    
 
AFFY ID Gene Name Gene ID FC p-value 
1460011_at 
Cytochrome P450, family 26, 
subfamily b, polypeptide 1 Cyp26b1 1.9 > 0.1 
1419430_at 
Cytochrome P450, family 26, 
subfamily a, polypeptide 1 Cyp26a1 1.1 > 0.1 
1415994_at 
Cytochrome P450, family 2, 
subfamily e, polypeptide 1 Cyp2e1 1.1 > 0.1 
1428283_at 
Cytochrome P450, family 2, 
subfamily s, polypeptide 1 Cyp2s1 1.1 > 0.1 
1421363_at 
Cytochrome P450, family 2, 
subfamily c, polypeptide 39  Cyp2c39 0.9 > 0.1 
 



















Table 3-8.  Lipid Biosynthesis.   
 
AFFY ID Gene Name Gene ID FC p-value 
1421983_s_at Hepatic nuclear factor 4, alpha Hnf4a 0.5 0.029831 
1416444_at 
Elongation of very long chain fatty acids 
(FEN1/Elo2, SUR4/Elo3, yeast)-like 2  Elovl2 0.5 0.022637 
1417561_at Apolipoprotein C-I Apoc1 0.5 0.030074 
1456147_at 
ST8 alpha-N-acetyl-neuraminide alpha-
2,8-sialyltransferase 6  St8sia6 0.5 0.006100 
1460316_at 
Acyl-CoA synthetase long-chain family 
member 1 Acsl1 0.4 0.018952 
1441891_x_at 
ELOVL family member 7, elongation of 
long chain fatty acids  Elovl7 0.4 0.017288 
1424097_at 
ELOVL family member 7, elongation of 
long chain fatty acids  Elovl7 0.4 0.018966 
1444453_at 
Transformation related protein 53 
regulating kinase Trp53rk 0.2 0.003407 
 




















Table 3-9.  Lipases.   
 
AFFY ID Gene Name Gene ID FC p-value 
1421868_a_at Pancreatic lipase  Pnlip 24.3 0.017304 
1438612_a_at C57BL/6J colipase  Clps 6.7 0.048900 
1421261_at Lipase, endothelial Lipg 2.3 0.005677 
1451502_at Phospholipase A2, group X Pla2g10 2.0 0.003341 
 






















Table 3-10.  Lipid Droplet-Associated Proteins.   
 
AFFY ID Gene Name Gene ID FC p-value 
1436453_at Perilipin Plin 1.7 > 0.1 
1420899_at Ras-related protein  Rab18 1.1 > 0.1 
1420900_a_at Ras-related protein  Rab18 1.0 > 0.1 
1416424_at 
Mannose-6-phosphate receptor 
binding protein 1 M6prbp1 0.9 > 0.1 
1448318_at 
C57BL/6J adipose 
differentiation-related protein Adfp 0.9 > 0.1 
1418595_at 
Plasma membrane associated 
protein, S3-12  S3-12 0.8 > 0.1 
 




















































Figure 3-1.  Quality assessment of samples used in microarray analysis.  Gene microarray 
analysis was conducted on populations of WT-GFP HSCs isolated from 5 mice and LRAT KO-
GFP HSCs isolated from 5 mice.  cDNA purified from these populations was run on Affymetrix 
Mouse Genome 430 2.0 Arrays, and data was analyzed using GeneSifter software.  (A) Levels of 
desmin mRNA normalized to 18S. A Student’s t-test was used to analyze for statistically 
significant differences between groups.  Groups were considered to be significantly different 
when p < 0.05.  (B) Boxplot summary showing the maximum and minimum values, 1st and 3rd 
quartiles, and medians of the WT- and LRAT KO-GFP groups.  (C) Scatter plot summary 
  
126
showing the spread of the data points around the line of identity.  All genes over-expressed in the 
LRAT KO-GFP group are shown in red; genes over-expressed in the WT-GFP group are shown 
























Figure 3-2.  Differential FACS sorting pattern of WT-GFP and LRAT KO-GFP HSCs.  
FACS was performed on digests of non-parenchymal cells, and GFP-positive cells were 
collected based on their emission at 530 nm.  The above panels are representative FACS output 
for WT-GFP HSCs (left) and LRAT KO-GFP HSCs (right), with GFP-positive cells in red.  












































































Figure 3-3.  mRNA levels of retinoid- and lipid-related nuclear receptors.  Relative mRNA 
expression levels of Ppara, Rxra, and Rara in WT-GFP HSCs (solid bars) and LRAT KO-GFP 
HSCs (stripped bars) are shown.  Values are normalized to 18S and given as the mean ± 1 S.D. 
























































































Figure 3-4.  mRNA levels of retinol and fatty acid binding proteins.  Relative mRNA 
expression levels of Fabp4, Rbp4, and Rbp1 in WT-GFP HSCs (solid bars) and LRAT KO-GFP 
HSCs (stripped bars) are shown.  Values are normalized to 18S and given as the mean ± 1 S.D. 
























































































Figure 3-5.  mRNA levels of retinoic acid-synthesizing enzymes.  Relative mRNA expression 
levels of Aldh1a1, Aldh1a2, and Aldh1a3 in WT-GFP HSCs (solid bars) and LRAT KO-GFP 
HSCs (stripped bars) are shown.  Values are normalized to 18S and given as the mean ± 1 S.D. 


























































































Figure 3-6.  mRNA levels of retinoic acid-catabolizing enzymes.  Relative mRNA expression 
levels of Cyp26b1, Cyp26a1, Cyp2e1, and Cyp2s1 in WT-GFP HSCs (solid bars) and LRAT 
KO-GFP HSCs (stripped bars) are shown.  Values are normalized to 18S and given as the mean 


















































Figure 3-7.  mRNA levels of genes involved in lipid biosynthesis.  Relative mRNA expression 
levels of Hnf4α, Elovl2, Elovl7, Apoc1, Acsl1, and Agpat2 in WT-GFP HSCs (solid bars) and 
LRAT KO-GFP HSCs (stripped bars) are shown.  Values are normalized to 18S and given as the 






















































Figure 3-8.  mRNA levels of lipases.  Relative mRNA expression levels of Clps, LpL, Ces3, and 
Lipa in WT-GFP HSCs (solid bars) and LRAT KO-GFP HSCs (stripped bars) are shown.  
Values are normalized to 18S and given as the mean ± 1 S.D. for 5 WT and 5 LRAT KO HSC 
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Figure 3-9.  mRNA and protein expression of lipid droplet-associated proteins.  (A) Relative 
mRNA expression levels of Plin, Rab18, M6prbp1, Adfp, and S3-12 in WT-GFP HSCs (solid 
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bars) and LRAT KO-GFP HSCs (stripped bars) are shown.  Values are normalized to 18S and 
given as the mean ± 1 S.D. for 5 WT and 5 LRAT KO HSC isolations.  ND means “not 
detected.”  (B) Protein levels of PLIN, M6PRBP1, and ADFP in WT-GFP HSCs and LRAT KO-
GFP HSCs.  20 µg protein loaded per lane as follows: Lane 1, Adipose fat pad; Lane 2, Adipose 























Altered Retinoid and Lipid Storage in Hepatic Stellate Cell Lipid Droplets in Various 
Models of Hepatic Fibrosis 
 
ABSTRACT 
The objective of these studies was to determine the factors that regulate the loss of hepatic 
stellate cell (HSC) lipid droplets when these cells activate, with an emphasis on transcriptional 
changes in key genes associated with retinoid and lipid metabolism and changes in the lipidome 
of activated HSCs.  For this purpose, we employed two standard models of HSC activation, the 
in vivo model of carbon tetrachloride (CCl4) treatment and the in vitro model, the culture of 
purified HSCs on plastic cell culture dishes.  Additionally, we studied the effects of 
hypervitaminosis A since there is evidence in the literature that dietary vitamin A toxicity can 
cause hepatic fibrosis.  Using these three models of hepatic fibrosis, we investigated the 
following questions: (i) are LRAT KO mice, which are unable to store vitamin A, more 
susceptible to diet-induced hepatic fibrosis; (ii) are LRAT KO mice, which are unable to form 
HSC lipid droplets, more susceptible to CCl4-induced hepatic fibrosis; (iii) does culture-
activation of HSCs elicit the same response in these cells as observed in vivo; (iv) how is 
retinoid- and lipid-related gene expression regulated in HSC activation; and (v) how is the 
lipidome altered in activated HSCs, specifically with regard to the potent lipid signaling 







 In Chapter 2, we investigated the heterogeneity of hepatic stellate cells (HSCs) and their 
lipid droplets in healthy, uninjured liver.  In Chapter 3, we investigated HSC lipid droplet 
formation and maintenance in healthy, but genetically-modified liver: specifically, we studied 
HSC lipid droplets in the LRAT KO mouse model, a system where HSC lipid droplets do not 
form.  In the present chapter, we investigated HSC lipid droplet dissolution in HSC activation 
and hepatic fibrosis, systems where HSC lipid droplets form, but are subsequently lost.  The 
objective of these studies was to gain a better understanding of the factors that regulate the loss 
of HSC lipid droplets when these cells activate, with an emphasis on transcriptional changes in 
key genes associated with retinoid and lipid metabolism and changes in the lipidome of activated 
HSCs.  Furthermore, we employed various models of HSC activation to understand whether all 
types of hepatic injury lead to the same conserved response in HSCs or if different insults signal 
unique responses. 
 There are a number of accepted models of HSC activation.  The two most commonly-
employed in vivo models include bile duct ligation (BDL) and carbon tetrachloride (CCl4) 
treatment [244, 245].  In BDL, the common bile duct is surgically ligated, leading to cholestasis, 
a condition where flow of bile from the liver is blocked.  These animals will present with marked 
fibrosis after 12 days, and liver cirrhosis is usually present within 4-8 weeks [246].  CCl4 
treatment is a type of chemically induced fibrosis, which is generally highly reproducible and 
robust.  CCl4 is a hepatotoxin that causes acute liver injury, and, when given repetitively at a low 
dose, induces liver fibrosis through the formation of CCl3 radicals [244].  A third commonly-
used model of HSC activation is an in vitro model, the culture of purified HSCs on plastic cell 
culture dishes [247].  All three models up-regulate the activation markers α-smooth muscle actin 
  
138
and collagen 1a1 and induce the loss of retinoids from the HSCs [244].  For our studies, we 
choose to use one of the in vivo models, CCl4 treatment (more practical because BDL requires 
special surgical skills) and the in vitro model, the culture of primary HSCs on plastic.   
We additionally wanted to study the effects of diet-induced hepatic fibrosis, since there is 
a literature on a role for hypervitaminosis A in the development of hepatic fibrosis.  This 
connection was first made in the early 1970s, when it was reported that hepatocellular damage, 
portal fibrosis and eventual cirrhosis may result from chronic vitamin A intoxication in humans 
[248].  Ensuing clinical case reports over the following couple decades revealed that chronic 
hypervitaminosis A in various patients has resulted in perisinusoidal fibrosis and an increase in 
basement membrane-like material and collagen in the perisinusoidal space, in association with 
the lipocyte-like cells in the liver (then, referred to as Ito cells; now, referred to as HSCs) [249-
251].  As a result of the deposition of extracellular matrix material in the liver, blood flow is 
ultimately obstructed and hepatic function declines.  In more recent years, clinical studies in 
human patients have shown that hypervitaminosis A is also associated with the hypertrophy and 
hyperplasia of HSCs and that these cells display enhanced spontaneous autofluorescence due to 
their accumulation of vitamin A [252, 253].  Most cases of hypervitaminosis A result from either 
over-ingestion of vitamin A supplements (10-100 times excess of the recommended daily dose, 
5000 IU) or the misuse of prescription, retinoid-based medicines.                  
   Because such a strong association of hypervitaminosis A with hepatic fibrosis has been 
made in human patients, one objective of this study was to confirm in mouse models that excess 
retinol intake can cause hepatic fibrosis.  There have been several studies in animal models 
assessing how dietary modifications of retinoids affect hepatic fibrosis, but these studies report 
conflicting findings and thus, are inconclusive.  Some studies report that retinoids promote 
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fibrosis [254-256], while others report retinoids act protectively preventing fibrosis development 
[257-259].  Another important question we wanted to address is whether the effects observed in 
human patients are directly mediated by retinol, or if the effects are mediated by its biologically 
active metabolite and potent transcriptional regulator, retinoic acid.  We were also very 
interested in studying the effects of hypervitaminosis A in LRAT KO mice.  Because the 
literature suggests that hepatic fibrosis results when the liver’s capacity to store vitamin A is 
exceeded, we hypothesized that LRAT KO mice, which are unable to store retinol, will be more 
susceptible to diet-induced fibrosis.  Furthermore, since there is a strong association of loss of 
vitamin A-containing lipid droplets with HSC activation, we hypothesized that LRAT KO mice, 
which genetically have no lipid droplets, will be more susceptible to CCl4-induced fibrosis. 
 Lastly, in addition to gaining a better understanding of the altered gene expression 
patterns in hepatic fibrosis, we also wanted to elucidate the changes that may occur in the 
lipidome of HSCs as they activate.  Endocannabinoids, sphingolipids, and ceramides are potent 
lipid signaling molecules that play a role in diverse cellular processes, including cell 
proliferation, differentiation, and apoptosis, events that reflect the restructuring occurring in an 
injured liver.  Though these lipids are not known to be present in the HSC lipid droplets 
themselves, we want to study the role they may play in regulating the loss of these droplets in 
HSC activation.  Furthermore, there is an emerging literature associating the disregulated 
metabolism of these lipids with various types of metabolic disease, including cardiomyopathy, 
cancer, and alcoholic liver disease [260].  It has been shown that treatment of cultured primary 
HSCs with the endogenous endocannabinoids, anandamide (AEA) and 2-arachidonyl glycerol 
(2-AG), at lower concentrations, blocked HSC proliferation and, at higher concentrations, 
induced HSC apoptosis [162, 163].  These effects were reported to be specific to HSCs, with no 
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effect on primary cultures of hepatocytes, and are similar to necrosis, involving the rapid 
depletion of ATP and induction of ROS production.  Furthermore, one of these studies directly 
measured hepatic 2-AG levels in BDL- and CCl4-induced fibrosis, and they found that 2-AG is 
elevated 3-fold in both models [163].  Both studies conclude that AEA and 2-AG are potential 
anti-fibrogenic tools in the treatment of hepatic fibrosis. 
 The literature on sphingolipids in hepatic fibrosis is limited and inconclusive.  
Sphingolipids encompass a large and essential group of lipids, including sphingosine, 
sphinganine, ceramide, and various phosphorylated and glycosylated derivatives.  They serve as 
structural components of lipid membranes and also act as signaling molecules.  Most of the 
studies reported in the literature regarding sphingolipid metabolism in hepatic fibrosis focus on 
only sphinogsine-1-phosphate (SO-1P), and these studies report conflicting findings: a few, 
earlier studies report that SO-1P inhibits the growth of activated HSCs and induces apoptosis 
[261-263]; while other studies report that SO-1P triggers survival signals and induces 
proliferation, migration, and motility of HSCs [264-269].  It has also been shown that treatment 
of HSCs in culture with a synthetic, cell-permeable analogue of ceramide caused a 57% decrease 
in collagen 1a1 protein (elevated levels of which are associated with HSC activation) [270]. 
The limited literature indicates that we are only in the early stages of understanding the 
role of these lipids in HSC activation and hepatic fibrosis.  Many unanswered questions remain, 
including how endogenous levels of these lipids change in response to HSC activation, how 
levels may be different in hepatocytes, HSCs and whole liver, and how levels may change in 
shorter- versus longer-term models of HSC activation.  The ultimate goal of this lipidomics study 
is to determine the effects of acute HSC activation on select lipid classes in these cells using 
liquid chromatography tandem mass spectrometer (LC/MS/MS).  We will measure, for the first 
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time, levels of endogenous endocannabinoids, sphingolipids, ceramides and free fatty acids 
specifically in HSCs, as opposed to whole liver, and we will study the immediate response of 
HSCs to CCl4, as opposed to chronic, longer-term injury.  This cell-focused approach is 
important because HSCs are central to the development and progression of hepatic fibrosis.  
Moreover, because LC/MS/MS identifies a compound not only by its molecular weight, but 
additionally by its unique fragmentation pattern (a consequence of the stability of its carbon 



















MATERIALS AND METHODS 
Animals.  WT, Lrat-/- and collagen-green fluorescent protein (GFP) mice were used, with all 
strains congenic for the C57BL/6 genetic background.  The collagen-GFP mice have been 
previously described in both Chapters 2 and 3.  All mice used were males between 90 and 120 
days of age at the time of sacrifice.  Animals were allowed ad libitum access to water and a 
standard nutritionally complete rodent chow diet (W. F. Fisher and Sons, Inc., Somerville, NJ).  
For the 4-week diet study, WT and Lrat-/- mice were maintained on the American Institute of 
Nutrition 93M purified diet (AIN-93M) used for maintenance of mature rodents.  An unmodified 
AIN-93M diet containing 6.7 µg/g retinol (ROH) served as the basal, control diet (DSM 
Nutritional Products, Inc., Parsippany, NJ).  Two additional diets were used: a high ROH diet, 
which was an AIN-93M diet containing 167.5 µg/g ROH (25X ROH), and a high retinoic acid 
(RA) diet, which was an AIN-93M diet containing no pre-formed ROH and supplemented with 
100 µg/g RA.  All mice were maintained on a 12-h dark-light cycle, with the period of darkness 
between 7:00 a.m. and 7:00 p.m. in a conventional barrier facility.  The animal experiments 
described in this report were conducted in accordance with the National Research Council's 
Guide for the Care and Use of Laboratory Animals and were approved by the Columbia 
University Institutional Committee on Animal Care (IACUC Protocol # AC-AAAA9687).      
HSC Isolations.  Primary mouse HSCs were isolated according to established protocols [84, 
193, 194].  Briefly, livers were perfused in situ with EGTA for 5 min, pronase E (0.4 mg/ml, 
EMD Chemicals Inc., Gibbstown, NJ) for 5 min and collagenase D (0.5 mg/ml, Roche 
Diagnostics) for 8 min, respectively, at a flow rate of 5 ml/min.  After excision of the liver from 
the body, the liver digests were filtered through a cell strainer and washed with Gey’s Balanced 
Salt Solution (Sigma, St. Louis, MO) containing DNase I (2mg/ml, Roche Diagnostics).  For the 
  
143
WT mice, HSCs were purified from the remainder of non-parenchymal cells and hepatocyte-
derived debris by floatation through 9% (w/v) Nycodenz (Axis-Shield PoC AS, Oslo, Norway) 
in Gey’s Balanced Salt Solution (without NaCl).  Subsequently, the cells were separated by 
FACS using FACS Calibur (Becton Dickinson, Franklin Lakes, NJ), and vitamin A auto-
fluorescent cells were collected based on their emission at 460 nm.  This method of HSC 
isolation yields approximately 10% of the total HSCs estimated to be in the liver.  For the 
collagen-GFP mice, parenchymal cells and debris were separated from non-parenchymal cells by 
centrifugation at 50g for 2 minutes.  The remaining non-parenchymal cell suspension was then 
separated by FACS, and GFP-positive cells were collected based on their emission at 530 nm.  
This method of HSC isolation yields approximately 10% of the total HSCs estimated to be in the 
liver.     
In Vivo HSC Activation.  Two studies were conducted, a longer-term HSC activation study 
carried out over 4 weeks and a shorter-term HSC activation study carried out over 72 hours.  For 
the longer-term study, WT and Lrat-/- mice were given weekly injections of either 0.5 µl carbon 
tetrachloride (CCl4) per gram body weight administered in corn oil or an equivalent volume of 
corn oil alone for 4 weeks and then sacrificed.  Liver tissue was collected and stored immediately 
at –80 °C prior to analysis.  For the shorter-term study, WT-GFP mice were given 2 injections, 
separated by 48h, of either 1.0 µl CCl4 per gram body weight administered in corn oil or an 
equivalent volume of corn oil alone.  HSCs were isolated 24h after the last injection by FACS; 
mice were fasted 12h prior to HSC isolation.     
In Vitro HSC Activation.  HSCs were isolated from WT mice by flotation in a Nycodenz 
density gradient, and 1x106 cells were seeded on 100 mm polystyrene cell culture dishes 
(Corning Inc., Corning, NY).  HSCs were cultured in Dulbecco’s Modified Eagle Medium 
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(DMEM; Gibco, Grand Island, NY) containing 10% fetal bovine serum and 1% 
penicillin/streptomycin either overnight (O/N), 3 days or 6 days.  Phase contrast images were 
captured on an Olympus IX71 microscope (Olympus, Tokyo, JPN) with a Retiga Exi Fast 1394 
camera (Q Imaging, Surrey, CAN).     
Isolation of RNA and cDNA synthesis.  Total RNA was isolated from liver tissue and HSCs 
using the Qiagen RNeasy kit (Qiagen, Valencia, CA) and reverse transcribed to cDNA using the 
Invitrogen SuperScript III First-Strand Synthesis kit (Invitrogen, Carlsbad, CA).   
Quantitative Real-Time PCR.  Differential gene expression was analyzed by quantitative real-
time polymerase chain reaction (qRT-PCR) using commercially available primer-probe sets 
(Table 1, Applied Biosystems, Foster City, CA).  qRT-PCR was performed on an ABI Prism 
7000 Sequence Detection System (Applied Biosystems).   
Reverse-phase HPLC Analysis.  Liver retinyl ester levels were determined by procedures 
described previously [29].  Briefly, 200 mg liver tissue was homogenized in 2 ml of PBS (10 mM 
sodium phosphate, pH 7.2, 150 mM sodium chloride) using a Polytron homogenizer (Brinkmann 
Instruments, Westbury, NY) and 200 µl aliquots were taken for further analysis.  All samples 
were then treated with an equal volume of absolute ethanol containing a known amount of retinyl 
acetate as an internal standard, and the retinoids present in the homogenates were extracted into 
hexane.  The extracted retinoids were separated on a 4.6 × 250 mm Ultrasphere C18 column 
(Beckman, Fullerton, CA) preceded by a C18 guard column (Supelco, Bellefonte, PA), using 70% 
acetonitrile, 15% methanol, 15% methylene chloride as the running solvent flowing at 1.8 
ml/min.  Retinol and retinyl esters (retinyl palmitate, oleate, linoleate, and stearate) were 
detected at 325 nm and identified by comparing the retention times and spectral data of 
experimental compounds with those of authentic standards.  Concentrations of retinol and retinyl 
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esters in the tissues were quantified by comparing integrated peak areas for each retinoid against 
those of known amounts of purified standards.  Loss during extraction was accounted for by 
adjusting for the recovery of the internal standard added immediately after homogenization of 
the cells and tissues. 
Histology.  At the time of sacrifice, liver was placed into 10% formaldehyde for 24hr and then 
transferred to 70% ethanol.  Liver sections of 5µm were obtained and then analyzed by Masson 
trichrome stain for collagen deposition.   
Liquid Chromatography Tandem Mass Spectrometry (LC/MS/MS).  All solvents employed 
for sample extractions and liquid chromatography were LC/MS grade or LC grade when LC/MS 
grade was not available and were purchased from Fisher Scientific (Pittsburgh, PA, USA).  All 
measurements were carried out on a Waters Xevo TQ MS ACQUITY UPLC system (Waters, 
Milford, MA).  The system was controlled by Mass Lynx Software version 4. 1 (Waters).   
For all lipids classes analyzed, including endocannabinoids, sphingolipids, ceramides, 
and free fatty acid, HSCs were extracted using chloroform:methanol.  Briefly, 3 ml of pre-cooled 
2:1 chloroform:methanol (v/v) and 20 µl of internal standards cocktail in methanol containing 
100 µM deuterated palmitic acid, 2 µM C17 sphingosine, 2 µM C17 sphinganine, 2 µM C17 
sphingosine-1-phosphate, 2 µM C17 sphinganine-1-phosphate, 2 µM C12 ceramide, 2 µM C25 
ceramide, 1 µM AEA-d8 and 5 µM 2-AG-d8 were added to 100 µL of HSC homogenate 
containing 0.5x106 cells in a clean glass tube.  The mixture was mixed well in a vortex mixer.  
One half milliliter of water was added to the mixture to allow for phase separation, and the 
mixture was vortexed well again and centrifuged at 3,000 g at 4 °C for 10 min to separate phases.  
The lower chloroform phase was transferred to another clean glass tube using a Pasteur pipette.  
Two milliliters of pre-cooled chloroform was added to the remaining upper aqueous phase, and 
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this was mixed well and again centrifuged at 3,000 g at 4 °C for 10 min to separate phases.  The 
chloroform phases were pooled and evaporated to dryness under N2.  The lipid extract was 
reconstituted in 50 µl acetonitrile and transferred to an autosampler vial (Waters) for processing 
by liquid chromatography mass spectrometry.  For these analyses, free fatty acid standards were 
purchased from Nu-Chek Prep Inc. (Elysian, MN, USA) and deuterated palmitic acid-d31 (C16-
D31 fatty acid) was purchased from C/D/N Isotopes Inc.(Quebec, Canada).  Sphingolipid and 
ceramide standards were purchased from Avanti Polar Lipids, Inc. (Alabaster, AL, USA).  
Endoannabinoid standard and deuterated endocannabinoids were purchased from Cayman 
Chemical Co. (Ann Arbor, MI, USA).  Samples in autosampler vials were maintained at 4 °C in 
the autosampler until 5 µl was injected onto a Waters ACQUITY UPLC column.  A BEH C18 
column (2.1 × 100 mm, 1.7 µm particle size, Waters), preceded by a 2.1 × 5 mm guard column 
using the same packing material, was employed for free fatty acid.  A BEH Phenyl column (3 
mm inner diameter × 100 mm with 1.7 µm particles), preceded by a 2.1 × 5 mm guard column 
containing the same packing, was used for sphingolipid and ceramide.  An HSS C18 column (2.1 
mm inner diameter × 100 mm with 1.8 µm particles), preceded by a 2.1 × 5 mm guard column 
containing the same packing, was used for endocannabinoid.  All columns were maintained at 40 
°C.  All the flow rates were 300 µl/min in a binary gradient mode. 
For fatty acid analyses, the mobile phases were initiated using 15% solvent A [100% 
H2O] and 85% solvent B [100% methanol].  The concentration of solvent B was increased 
linearly to 100% over 8 min and maintained at 100% until 10 min.  The gradient was then re-
equilibrated to 15% solvent A and 85% solvent B over 2 min before the next sample was 
injected.  Negative ESI-MS using the selected ion recording (SIR) mode was performed, 
employing the following parameters: capillary voltage -3.8 kV; source temperature 150 °C; 
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desolvation temperature 500 °C; and desolvation gas flow 1000 l/hr.  Optimized cone voltages 
ranged from 36 to 52 V and the following mass (m/z) were employed: Myristic acid 227.2, 
Myristoleic acid  225.2, Palmitic acid 255.2, Palmitoleic acid 253.2, Stearic acid 283.3, Oleic 
acid 281.3, Linoleic acid 279.2, Linolenic  acid 277.2, Eicosanoic acid 311.2, Eicosenoic acid 
309.3, Eicosadienoic acid 307.3, Arachidonic acid 303.2, Eicosapentaenoic acid 301.2, 
Docasanoic acid 339.3, Docasenoic acid 337.3, Docasahexaenoic 327.2, Tetracosanoic acid 
367.4, Tetracosenoic acid 365.3 and Palmitic acid-d31 286.5. 
For endocannabinoid analyses, the UPLC flow rate was isocratic composed of 17% 
solvent A (H2O containing 0.1% formic acid) and 83% solvent B (acetonitrile containing 0.1% 
formic acid).  The UPLC running time was 4 minutes and endocannabinoids of interest eluted 
between 2 and 3.5 min.  Positive ESI-MS/MS was performed employing the following 
parameters: capillary voltage, 3.8 kV; source temperature, 150 °C; desolvation temperature, 500 
°C; desolvation gas flow, 1000 l/hr; and collision gas flow, 0.18 ml/min.  The optimized cone 
voltage was 22 V, collision energy for multiple reaction monitoring (MRM) mode was 14 eV.  
The following transitions (m/z) were employed: AEA 348.3→62.0, AEA-d8 356.3→63.0, 2-AG 
379.3→287.3, 2-AG-d8 387.3→294.2.  
For sphingolipid analyses, the initial UPLC flow conditions were 50% solvent A (H2O, 
containing 0.2% formic acid and 1 mM ammonium formate) and 50% solvent B (methanol, 
containing 0.2% formic acid and 1 mM ammonium formate) and was maintained for 2 minutes.  
Then solvent B was increased to 95% over a 0.1 min period and maintained till 6.5 minute.  This 
was followed by a reduction of solvent B to 50% and continuing through 7 min.  Sphingolipids 
of interest eluted between 4.0 and 5.5 min.  Positive ESI-MS/MS was performed using the 
following parameters: capillary voltage, 3.8 kV; source temperature, 150 °C; desolvation 
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temperature, 500 °C; desolvation gas flow, 1000 l/hr; and collision gas flow, 0.18 ml/min.  The 
optimized cone voltage was 22 V, collision energy for MRM mode was 26 eV.  The following 
transitions (m/z) were employed: C17 sphingosine 286.3→238.2, C17 Sphinganine 
288.3→240.2, C18 sphingosine 300.3→252.3, C18 Sphinganine 302.3→254.3, C17 
Sphingosine-1-phosphate 366.3→250.2, C17 Sphinganine-1-phosphate 368.3→252.2, C18 
sphingosine-1-phosphate 380.3→264.3, C18 Sphinganine-1-phosphate 382.3→266.3. 
For ceramide analyses, initial flow conditions were 20% solvent A (H2O, containing 
0.2% formic acid and 1 mM ammonium formate) and 80% solvent B (methanol, containing 0.2% 
formic acid and 1 mM ammonium formate).  Solvent B was increased linearly to 95% over a 2 
min period and to 98% in the subsequent 6 min.  This was followed by a reduction of solvent B 
to 80% starting at 8.2 min and continuing through 9 min.  Ceramides of interest eluted between 
4.0 and 7.5 min.  Positive ESI-MS/MS was performed using the following parameters: capillary 
voltage, 3.8 kV; source temperature, 150 °C; desolvation temperature, 500 °C; desolvation gas 
flow, 1000 l/hr; and collision gas flow, 0.18 ml/min.  The optimized cone voltage was 22 V, 
collision energy for MRM mode was 26 eV.  The following transitions (m/z) were employed: 
C12 ceramide 482.55→264.2, C14 ceramide 510.45→264.2, C16 ceramide 538.48→264.2, 
C18:1 ceramide 564.5→264.2, C18 ceramide 566.51→264.2, C20:1 ceramide 592.6→264.2, 
C20 ceramide 594.54→264.2, C22:1 ceramide 620.7→264.2, C22 ceramide 622.64→264.2, 
C24:1 ceramide 648.59→264.2, C24 ceramide 650.61→264.2, C25 ceramide 664.68→264.2, 
C26 ceramide 678.8→264.2. 
Statistical Analysis.  All data are presented as means ± S.D.  A Student’s t-test was used to 
analyze for statistically significant differences between groups.  Groups were considered to be 




Susceptibility of Lrat-/- mice to diet-induced hepatic fibrosis.  WT and LRAT KO mice in the 
C57BL/6 genetic background were maintained on one of the three following experimental diets 
for 4 weeks: basal (AIN-93M containing 6.7 µg/g ROH), high ROH (AIN-93M containing 167.5 
µg/g ROH), or high RA (AIN-93M containing no pre-formed ROH and supplemented with 100 
µg/g RA).  We conducted qRT-PCR analysis of αSMA and Col1a1 mRNA levels in WT and 
LRAT KO livers, as both are markers of HSC activation and hepatic fibrosis [206].  We found 
no significant difference in αSMA mRNA levels in either WT or LRAT KO livers on the high 
ROH or high RA diets (Figure 1A).  While Col1a1 mRNA levels in WT livers are trending 
towards elevation in response to the high ROH diet, this difference was not found to be 
significant (Figure 1B).  However, in LRAT KO livers, Col1a1 levels were found to be 
significantly decreased in response to the high ROH diet (Figure 1B), suggesting that the 
absence of LRAT expression might actually make mice less susceptible to diet-induced fibrosis.  
Interestingly, Col1a1 levels were significantly increased in the LRAT KO livers in response to 
the high RA diet (Figure 1B), suggesting that the toxic effects of hypervitaminosis A may be 
mediated by retinoic acid.  Trichrome staining of liver sections shows no exacerbation of fibrotic 
lesions in the livers of LRAT KO mice relative to WT livers (Figure 1C). 
 To understand how the livers of LRAT KO mice might compensate for the lack of a 
storage depot for incoming dietary ROH, we additionally analyzed liver and adipose ROH and 
retinyl ester (RE) levels in both WT and LRAT KO mice in response to the high ROH and high 
RA diets.  In WT mice on a basal diet, the majority of retinoid is found in the liver in the form of 
RE, with very low levels of hepatic ROH (Figure 2A).  There is very little RE, and even less 
ROH, present in the adipose tissues of these mice (Figure 2B).  In LRAT KO mice on a basal 
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diet, hepatic RE levels are undetectable (Figure 2C), and adipose ROH levels are approximately 
25-fold higher than hepatic ROH levels (Figures 2C and 2D).  While adipose ROH levels in the 
LRAT KO mice are approximately 20-fold higher than WT, adipose RE levels are very similar 
(Figures 2B and 2D).  In both WT and LRAT KO mice, both liver and adipose ROH and RE 
levels are elevated in response to the high ROH diet compared to the basal diet, but no 
significant change is seen in ROH and RE levels in response to the high RA diet (Figure 2).      
Susceptibility of Lrat-/- mice to experimentally-induced hepatic fibrosis.  WT and LRAT KO 
mice in the C57BL/6 genetic background were given weekly injections of either 0.5 µl carbon 
tetrachloride (CCl4) per gram body weight administered in corn oil or an equivalent volume of 
corn oil alone for 4 weeks.  As expected, CCl4  treatment caused a significant decrease in both 
ROH and RE levels in WT livers (Figure 3A).  CCl4 treatment did not significantly alter hepatic 
αSMA mRNA expression in either WT or LRAT KO mice (Figure 3B).  However, marked 
changes were observed in Col1a1 mRNA levels.  CCl4 treatment significantly increased hepatic 
Col1a1 mRNA expression in both WT and LRAT KO mice (Figure 3B); however, interestingly, 
Col1a1 mRNA was still significantly lower in LRAT KO liver compared to WT liver.  Again, 
our data suggests that the absence of LRAT expression may make mice less susceptible to 
experimentally-induced hepatic fibrosis.  Trichrome staining of liver sections showed early signs 
of fibrosis in both WT and LRAT KO mice (Figure 3C).  Blue areas, representing fibrotic 
lesions, were observed mainly around the blood vessels, but no discernable difference between 
WT and LRAT KO livers could be determined (Figure 3C).                   
Culture-induced activation of HSCs on plastic.  To better understand gene transcription 
changes occurring during HSC activation, we employed the in vitro model of HSC activation, the 
culture of primary isolates on plastic.  HSCs were isolated from WT C57BL/6 mice by flotation 
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in a Nycodenz density gradient and then cultured on plastic dishes overnight and for 3 and 6 
days.  Phase contrast images show that after overnight culture the cells retain their lipocyte-like 
phenotype; the cells are relatively small, round and filled with cytoplasmic lipid droplets (Figure 
4).  After 3 days in culture, the HSCs were showing signs of activation; the cells were beginning 
to flatten-out, enlarge and grow myofibroblastic processes.  These HSCs also had less lipid 
droplet content than after overnight culture (Figure 4).  After 6 days in culture, the process of 
activation had progressed further, with very little to no lipid droplets remaining in the cells 
(Figure 4).  The loss of lipid droplets was accompanied by the loss of retinoid stores, as 
determined by RP-HPLC analysis of total retinol (ROH + RE) levels.  Representative RP-HPLC 
profiles show that the peak associated with retinyl palmitate, the predominant lipid species 
present in HSC lipid droplets, progressively decreases with days in culture (Figure 5A).  The 
quantification of total retinol levels confirmed this progressive depletion of HSC retinoid content 
(Figure 5B).  qRT-PCR analysis of Col1a1 mRNA levels confirmed successful induction of 
HSC activation; as expected, mRNA levels of Col1a1, a marker of HSC activation, progressively 
increased in HSCs with days in culture (Figure 6).  However, Lrat mRNA expression initially 
dropped after overnight culture and then continued to progressively increase at 3 and 6 days in 
culture (Figure 6), inconsistent with the decrease in total retinol content.  We were additionally 
interested in Dgat1, because a previous study suggested that this enzyme plays a role in the 
development of hepatic fibrosis [91], and in Cyp2s1, because our own data has shown Cyp2s1 to 
play a role in the hydrolysis of retinyl esters in activated HSCs (data presented in Chapter 2).  
However, Dgat1 mRNA expression did not change with HSC activation in culture (Figure 6), 
and Cyp2S1 levels, unexpectedly, decreased after overnight culture and decreased further at 3 
days in culture (Figure 6).                           
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LC/MS/MS analysis of lipid profiles in HSCs after short-term activation.  In addition to 
understanding gene expression changes in activated HSCs, we were also interested in the 
changes that might occur in the lipid content in these cells.  There is an expanding literature 
suggesting a role for endocannabinoids, sphingolipids, and ceramides in various types of 
metabolic disease, including cardiomyopathy, cancer and alcoholic liver disease [260]; thus, the 
objective of this study was to determine how endogenous levels of these lipid classes might be 
altered in HSCs in the early events of HSC activation and hepatic fibrosis.  Representative 
LC/MS/MS profiles for endocannabinoids, sphingolipids, ceramides and free fatty acids (FFAs) 
in uninduced, WT HSCs isolated by flotation in a Nycodenz density gradient are shown in Figure 
7.  These profiles demonstrate that we are capable of detecting levels of each lipid class in as few 
as 0.5x106 HSCs, and the prominent peaks indicate a high level of sensitivity (Figure 7).  To 
study the acute effects of CCl4 on the lipid profile of HSCs, WT-GFP mice were given 2 
injections, separated by 48h, of either 1.0 µl CCl4 per gram body weight administered in corn oil 
or an equivalent volume of corn oil alone, and HSCs were isolated 24 hours after the last 
injection.  Our data show that endocannabinoid levels are overall decreased in HSCs from CCl4-
treated mice: AEA and total AG (2-AG+1-AG) levels are decreased, but only the decrease in 
AEA is significant (Figure 8).  Levels of sphingolipids are also overall decreased in HSCs from 
CCl4-treated mice, with both SO and SA found to be significant (Figure 9).  Levels of the major 
ceramides (i.e. ceramides found at higher endogenous concentrations in the liver) are trending 
towards elevation in HSCs from CCl4-treated mice, but only C24 was found to be significant 
(Figure 10).  We were additionally interested in FFA levels, since FFAs serve as precursors to 
many lipids found in HSCs.  The predominant FFAs found in HSCs from both corn-oil and 
CCl4-treated mice are palmitic, stearic, oleic, and linoleic acid, respectively, reflecting the 
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predominant retinyl ester forms in these cells (Table 2).  FFAs of all chain lengths are trending 
towards decreased levels in HSCs from CCl4-treated mice, though only levels of myristic, 
























Because the literature suggests that hepatic fibrosis can result when liver storage 
capacities of vitamin A are exceeded [248-253], we undertook studies in LRAT KO mice, a 
system where the liver’s ability to store vitamin A has been ablated.  We hypothesized that 
LRAT KO mice will be more susceptible to diet-induced hypervitaminosis A since they will, 
theoretically, exceed hepatic vitamin A storage capacity much faster than WT mice on the same 
diet.  Furthermore, we wanted to determine whether any effects of hypervitaminosis A are a 
direct result of ROH overload or if the effects are mediated through RA, the biologically active 
metabolite of ROH and potent regulator of gene transcription.  Surprisingly, the LRAT KO mice 
did not show signs of hepatic fibrosis on either the high ROH or high RA diets.  Hepatic α-SMA 
mRNA levels were not significantly altered by either experimental diet; whereas, hepatic Col1a1 
mRNA levels were actually significantly decreased in response to the high ROH diet.  Trichrome 
staining of liver sections showed some fibrotic lesions developing around periportal areas in both 
WT and LRAT KO mice, but in neither case was this substantial.  The fact that WT mice did not 
have elevated α-SMA and Col1a1 levels or significant trichrome staining suggests that, in our 
mouse model of hypervitaminosis A, diet alone is not enough to induce hepatic fibrosis.  These 
findings contradict the clinical case reports in human patients, or it may be that our regimen was 
simply too mild and did not match the level of vitamin A toxicity observed in those patients.  RE 
levels were approximately 4.5-fold elevated in the livers of WT mice on the high ROH diet, but, 
while this is a significant elevation, it is not as impressive as one might expect with a diet 
containing 25X ROH.  Future studies would benefit from increasing the duration of the study 
and/or the amount of ROH that is supplemented in the diet (this could be increased to 50 or 
100X).  Nevertheless, the absence of HSC lipid droplets and hepatic retinoid storage capacity do 
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not appear to promote diet-induced hepatic fibrosis is LRAT KO mice.  This may be accounted 
for by the liver and adipose ROH and RE levels, which suggests that the LRAT KO mice 
compensate for their inability to store dietary ROH by shuttling it to adipose tissue.  Our data 
show that the liver of WT mice contain substantially more ROH and RE than the adipose tissue 
of these mice; whereas, the opposite is observed in LRAT KO mice, which have no RE in their 
livers but appromixtaely 3-fold increased RE levels in their adipose compared to WT adipose.             
It is also well-established that in HSC activation and hepatic fibrosis HSC retinyl ester-
containing lipid droplets are lost [86, 87].  Though it is not yet known whether this loss is a cause 
or consequence of disease, there remains a strong correlation between loss of HSC lipid droplets 
and the progression of hepatic disease.  Thus, we hypothesized that LRAT KO mice, which are 
unable to form HSC lipid droplets, will be more susceptible to experimentally-induced hepatic 
fibrosis.  However, the LRAT KO mice did not show signs of increased susceptibility to CCl4 
treatment.  Hepatic α-SMA mRNA levels were not significantly altered by CCl4 treatment in 
either WT or LRAT KO mice.  Hepatic Col1a1 mRNA levels were significantly increased in 
response to CCl4 treatment in both WT and LRAT KO mice, but in LRAT KO mice Col1a1 was 
still significantly lower than in WT.  Trichrome staining of liver sections, again, showed some 
fibrotic lesions developing around periportal areas in both WT and LRAT KO mice, but in 
neither case was this substantial.  Our data suggest that the absence of HSC lipid droplets does 
not promote CCl4-induced hepatic fibrosis in LRAT KO mice.  These findings are supported by a 
recently published study, which reports that the absence of HSC lipid droplets does not enhance 
hepatic fibrosis but decreases hepatic carcinogenesis [271].  Specifically, these studies showed 
that the absence of HSC lipid droplets did not predispose LRAT KO mice to spontaneous, CCl4-
induced or BDL-induced hepatic fibrosis.  Conversely, tumor load was decreased in response to 
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diethylnitrosamine-induced hepatocellular carcinoma in LRAT KO mice, and this was 
accompanied by increased expression of retinoic acid-responsive genes that act to inhibit cell 
proliferation.  The authors concluded that LRAT deficiency increases the level of bioactive 
retinoids by increased channeling of retinol into retinoic acid (and decreased conversion to the 
storage form retinyl ester).  Thus, future studies will need to focus on the role retinoic acid-
responsive genes play in different types of liver injury, as it appears that any retinoid-mediated 
effects on disease development are through retinoic acid and not retinol or retinyl ester. 
To study changes in the gene transcription pattern of activated HSCs, we choose to 
employ the in vitro model of HSC activation, the culture of purified HSCs on plastic cell culture 
dishes.  The primary motivation for using this model is that it is an easily-manipulable and 
versatile system and, thus, allows for a high degree of flexibility in the kind of experiments we 
could ultimately conduct.  Other advantages are that it requires the least amount of technical skill 
and generally induces HSC activation faster than the in vivo models (HSCs activate within days 
in culture, whereas the in vivo models often require weeks of hepatic insult).  Our data show that 
culturing primary isolates of HSCs caused the phenotypic changes that are hallmarks of HSC 
activation, including conversion to a myofibroblast-like phenotype and the progressive loss of 
lipid droplets.  Furthermore, culture-induced activation resulted in the biochemical hallmarks of 
HSC activation, including loss of total retinol and an increase in Col1a1 mRNA expression.  
Interestingly, however, expression of other retinoid- and lipid-related genes was not regulated as 
expected.  Lrat mRNA levels initially dropped after overnight culture, but levels progressively 
increased with days in culture.  An increase in expression of Lrat, the only hepatic enzyme 
capable of synthesizing retinyl ester, is irreconcilable with the decrease in retinyl esters 
confirmed by RP-HPLC and the loss of retinyl ester-containing lipid droplets.  We were also 
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interested in mRNA expression of Dgat1, since a previously published study reported that 
DGAT1 antisense oligonucleotides (ASO) inhibited HSC activation in mice with methionine 
choline-deficient diet-induced non-alcoholic steatohepatitis [91].  DGAT1 ASO also inhibited 
the loss of total vitamin A content and repressed collagen 1a2 promoter activities in 4-day 
cultured primary HSCs.  Contrary to these published findings, our data show that Dgat1 mRNA 
expression does not change as HSCs activate in culture.  Furthermore, previously-presented data 
in Chapter 2 shows elevated Cyp2s1 mRNA and protein in both GFP-HSCs (“pre-activated” 
HSCs) and in the livers of CCl4-treated mice.  Thus, it was expected that Cyp2s1 mRNA levels 
would progressively increase in HSCs with increasing days in culture.  However, Cyp2s1 mRNA 
drops after overnight culture and decreases further after 3 days in culture.  Levels seem to be on 
the rise after 6 days in culture, so it might be that Cyp2s1 is only increased in the later stages of 
culture-induced HSC activation.  Only one other group has studied the changes in CYP2S1 
protein expression in culture, and their findings suggest that CYP2S1 does not begin to become 
elevated until 14 days in culture and that its expression increases gradually thereafter [203].  
Thus, while it seems that the culture of HSCs on plastic results in the typical hallmark events of 
HSC activation, including the up-regulation of Col1a1, the decrease in retinyl esters and the loss 
of lipid droplets, it does not cause the gene expression changes expected based on the in vivo 
models.   
These findings are similar to those reported by De Minicis et al., who conducted a 
microarray study comparing the gene expression profiles of BDL- and CCl4-induced hepatic 
fibrosis with that of culture-activated HSCs [88].  These investigators found a strong correlation 
in the gene expression patterns between the two in vivo models; whereas, there was a very weak 
correlation in the gene expression pattern of these two in vivo models with the in vitro model of 
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culture activation.  The authors attribute this finding to the fact that the microenvironment of 
HSCs in the liver is complex and influenced by numerous cellular and humoral interactions, 
including interaction with Kupffer cells, which have been shown to play an important role in 
HSC activation and hepatic fibrosis in vivo [272-274].  In contrast, the environment of the cells 
in culture is artificial and thus, can not properly regulate gene expression as the disease does in 
vivo.  This study, along with our own findings, provide strong evidence that not all types of HSC 
activation lead to the same conserved response in these cells. 
  Though we initially intended to conduct a lipidomics study in culture-activated HSCs, 
our findings discussed above made it clear that this would not be an informative and useful 
model.  Thus, we decided to study a select part of the lipidome of primary isolates of HSCs 
induced in vivo by CCl4 treatment.  For this purpose, we employed the collagen-GFP mice 
discussed in detail in Chapter 2.  Because it is expected that HSC activation will lead to the loss 
of lipid droplets, we wanted to avoid using the Nycodenz-based method of HSC isolation since 
this method would be biased towards the isolation of quiescent, lipid droplet-rich cells.  Using 
the collagen-GFP mice allowed us to purify HSCs by FACS based on their GFP expression, and 
thus, we were able to isolate HSCs independent of their lipid droplet content.  It is also important 
to emphasize that this lipidomics study is a “proof-of-principle” study.  Endogenous levels of 
endocannabinoids, sphingolipids, and ceramides in quiescent and activated HSCs have not been 
widely-reported in the literature; thus, one objective of this study is to simply show that we are 
able to detect levels of these lipids in primary isolates of HSCs.  Additionally, we chose to study 
the effects of acute CCl4 treatment on HSCs and thereby are studying the immediate response of 
HSCs to activation.  This study is not meant to be conclusive, but rather, hypothesis-generating. 
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Our data show that we are able to detect levels of endocannabinoids, sphingolipids, 
ceramides and free fatty acids (FFAs) in as few as 0.5x106 HSCs, which represents 
approximately 5% of the total HSC population in the liver.  This demonstrates the sensitivity of 
our LC/MS/MS instrument over other methods reported in the literature, including LC/MS and 
HPTLC.  In HSCs from CCl4-treated mice, levels of AEA and 2-AG are decreased; however, 
only decreased levels of AEA were found to be significant.  This data suggests that endogenous 
AEA levels are initially low/decreased in the early stages of HSC activation (i.e. in this case, in 
the first 72 h).  We hypothesize that, with decreased AEA levels, HSCs are allowed to proliferate 
and thus activate, thereby promoting the development and progression of hepatic fibrosis.  And 
possibly, as hepatic disease progresses, AEA and 2-AG levels progressively rise in an attempt to 
counteract proliferation and fibrogenesis by inducing cell death, which would account for the 
elevated 2-AG levels observed in longer-term HSC activation studies reported by Siegmund et 
al. [163].  Levels of both sphingosine and sphinganine are significantly lower in HSCs from 
CCl4-activated mice.  This data likely parallels what we observed with endocannabinoid levels: if 
sphingolipids function mainly in regulating programmed cell death in HSCs, then the low levels 
in activated cells may allow for the proliferation of HSCs and thus, promote the early events of 
HSC activation.  In contrast to endocannabinoids and sphingolipids, levels of the major 
ceramides (i.e. those expressed at higher endogenous levels in the liver) in HSCs from CCl4-
activated mice are trending towards elevation, though only C24 was found to be significant.  We 
hypothesize that, as ceramides have a very well-defined role in apoptosis in various cell types, 
they be may the first-responders in an injured liver, such that levels rise earlier than 
endocannabinoids and sphingolipids in an attempt to inhibit proliferation.  Since an important 
part of the reparative process in a fibrotic liver involves the apoptosis of injured cells, it is 
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conceivable that ceramides will prove to play a critical role in this process.  Lastly, our data 
show that levels of all FFAs measured are decreased in HSCs from CCl4-activated mice.  This 
finding was expected given that FFAs are the precursors for many lipids in the liver, and we 
know that these lipids are lost upon activation.   
This study gives a unique first insight into the role endocannabinoids, sphingolipids and 
ceramides may play in HSCs within the first few days of activation.  The regulation of these 
lipids at the various stages of HSC activation and hepatic fibrosis development may be more 
complex than originally thought, where lower levels at earlier stages may promote the activation 
process and elevated levels at later stages may inhibit/counteract the activation process.  It will 
be important for future studies to integrate the changes in these lipid levels with transcriptional 
changes in the key genes involved in the synthesis and degradation pathways of these lipids.  Of 
high interest would be the endocannabinoid receptors, CB1 and CB2, as CB2 specifically has 
been suggested to have an antifibrogenic role in liver injury [165], and the sphingolipid receptor, 
sphingosine-1-phosphate receptor 2, inactivation of which has been shown to ameliorate CCl4-
induced hepatic fibrosis [267].         
           











Table 4-1.  ABI primers used for qRT-PCR analysis.   
 








Commercially available primers purchased from Applied Biosystems (ABI) are shown with the 



















Table 4-2.  Free fatty acid levels in HSCs after short-term activation.   
 
Free Fatty Acid Carbon # nmol/10^6 HSC p-value
Corn Oil CCl4 
Myristoleic acid 14:1 ND ND -
Myristic acid 14:0 1.36 ± 0.94 0.34 ± 0.10 0.045
Palmitoleic acid 16:1 1.98 ± 1.99 0.62 ± 0.26 0.167
Palmitic acid 16:0 317.37 ± 276.92 106.45 ± 79.49 0.144
Linolenic acid 18:3 0.21 ± 0.17 0.07 ± 0.02 0.104
Linoleic acid 18:2 12.83 ± 18.83 1.37 ± 0.42 0.208
Oleic acid 18:1 38.16 ± 57.22 2.84 ± 0.97 0.203
Stearic acid 18:0 62.92 ± 51.60 11.34 ± 2.35 0.057
Eicosapentaenoic acid 20:5 0.20 ± 0.17 0.10 ± 0.05 0.244
Arachidonic acid 20:4 2.15 ± 2.49 0.90 ± 0.26 0.293
Eicosenoic acid 20:1 0.28 ± 0.28 0.06 ± 0.03 0.111
Eicosanoic acid 20:0 0.54 ± 0.35 0.14 ± 0.07 0.039
Docasahexaenoic acid 22:6 0.73 ± 0.84 0.47 ± 0.22 0.525
Docasenoic acid 22:1 0.06 ± 0.03 0.02 ± 0.00 0.014
Docasanoic acid 22:0 0.26 ± 0.20 0.01 ± 0.01 0.029
Tetracosenoic acid 24:1 0.04 ± 0.03 0.02 ± 0.00 0.182
Tetracosanoic acid 24:0 0.26 ± 0.34 0.01 ± 0.02 0.135
TOTAL 439.35 ± 407.67 124.74 ± 79.81 0.130
 
 
Collagen-green fluorescent protein (GFP) mice in the C57BL/6 genetic background between 90 
and 120 d old were given 2 injections, separated by 48 h, of either 1.0 µl carbon tetrachloride 
(CCl4) per gram body weight administered in corn oil or an equivalent volume of corn oil alone.  
HSCs were isolated 24 h after the last injection; mice were fasted 12 h prior to HSC isolation.  
HSCs were isolated from pronase digests of non-parenchymal cells by FACS, and GFP-positive 
cells were collected.  Lipids were extracted by the Folch method from aliquots of 0.5x106 cells, 


























































































































































































































































































































Figure 4-1.  Susceptibility of Lrat-/- mice to diet-induced hepatic fibrosis.  Three-month-old 
male WT and Lrat-/- mice were maintained on a basal, high retinol (ROH) or high retinoic acid 
(RA) diet for 4 weeks.  The mice were then sacrificed, and liver tissues were immediately placed 
into liquid nitrogen.  (A and B)  Total RNA was extracted and qRT-PCR was performed using 
custom-made taqman primer sets.  Relative mRNA expression levels of αSMA (A) and Col1a1 
(B) in WT and LRAT KO livers are shown.  Values are normalized to 18S and given as the mean 
± 1S.D.  (C)  At the time of sacrifice, liver was placed into 10% formaldehyde for 24 h and then 
transferred to 70% ethanol.  Liver sections of 5 µm were obtained and then analyzed by Masson 
trichrome stain for collagen deposition (indicated by the area of blue staining).  Significance was 
determined by a Student’s t-test, * p-value < 0.05, ** p-value < 0.01, *** p-value < 0.001.  N = 







































































































































































































































































































































































































Figure 4-2.  Redistribution of retinol and retinyl ester in Lrat-/- mice in response to diet-
induced hepatic fibrosis.  Three-month-old male WT and Lrat-/- mice were maintained on a 
basal, high retinol (ROH) or high retinoic acid (RA) diet for 4 weeks.  The mice were then 
sacrificed, and liver and adipose tissues were immediately placed into liquid nitrogen.  Retinoids 
were extracted and concentrations of ROH and retinyl esters (RE) in the tissues were quantified 
by comparing integrated peak areas for those of each retinoid against those of known amounts of 
purified standards.  (A) Levels of ROH (left panel) and RE (Right panel) in WT liver.  (B) 
Levels of ROH (left panel) and RE (right panel) in WT adipose.  (C) Levels of ROH in LRAT 
KO liver.  RE was not detected in LRAT KO livers, data not shown.  (D) Levels of ROH (left 
panel) and RE (right panel) in LRAT KO adipose.  Significance was determined by a Student’s t-

























































































































































































































































































Figure 4-3.  Susceptibility of Lrat-/- mice to experimentally-induced hepatic fibrosis.   Three-
month-old male WT and Lrat-/- mice were maintained on a purified basal diet and were given 
weekly injections of either 0.5 µl carbon tetrachloride (CCl4) per gram body weight administered 
in corn oil or an equivalent volume of corn oil alone for 4 weeks.  The mice were then sacrificed, 
and liver tissues were immediately placed into liquid nitrogen.  (A)  Retinoids were extracted and 
concentrations of retinol (ROH) and retinyl ester (RE) in the tissues were quantified by 
comparing integrated peak areas for those of each retinoid against those of known amounts of 
purified standards.  Levels of ROH (left panel) and RE (right panel) in WT and LRAT KO livers 
are shown.  ND means “not detected.”  (B)  Total RNA was extracted and qRT-PCR was 
performed using custom-made taqman primer sets.  Relative mRNA expression levels of αSMA 
(left panel) and Col1a1 (right panel) in WT and LRAT KO livers are shown.  Values are 
normalized to 18S and given as the mean ± 1S.D.  (E)  At the time of sacrifice, liver was placed 
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into 10% formaldehyde for 24 h and then transferred to 70% ethanol.  Liver sections of 5 µm 
were obtained and then analyzed by Masson trichrome stain for collagen deposition.  
Significance was determined by a Student’s t-test, * p-value < 0.05, *** p-value < 0.001.  N = 4-





















Figure 4-4.  Culture-induced activation of HSCs on plastic.  HSCs were isolated from 3-
month-old male WT mice in the C57BL/6 genetic background by flotation in a Nycodenz density 
gradient, and 1x106 cells were seeded on 100 mm polystyrene cell culture dishes.  HSCs were 
cultured in DMEM + 10% FBS + 1% PS either overnight (O/N), 3 days or 6 days.  Phase 
contrast images were captured on an Olympus IX71 microscope at 4X (upper panel) and 10X 
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Figure 4-5.  Activation of HSCs on plastic is accompanied by the loss of retinoid stores.  
HSCs were isolated from 3-month-old male WT mice in the C57BL/6 genetic background by 
flotation in a Nycodenz density gradient, and 1x106 cells were seeded on 100 mm polystyrene 
cell culture dishes.  HSCs were cultured in DMEM + 10% FBS + 1% PS either overnight (O/N), 
3 days or 6 days.  Retinoids were extracted and concentrations of retinol (ROH) and retinyl ester 
(RE) in the cells were quantified by comparing integrated peak areas for those of each retinoid 
against those of known amounts of purified standards.  (A)  Representative RP-HPLC profiles 
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for each time point are shown.  Arrows point to the peak associated with retinyl palmitate.  (B)  
Levels of total retinol (ROH+RE) per plate are shown.  Significance was determined by a 



























































































Figure 4-6.  Gene expression profiles during culture-induced activation of HSCs on plastic.  
HSCs were isolated from 3-month-old male WT mice in the C57BL/6 genetic background by 
flotation in a Nycodenz density gradient, and 1x106 cells were seeded on 100 mm polystyrene 
cell culture dishes.  HSCs were cultured in DMEM + 10% FBS + 1% PS either overnight (O/N), 
3 days or 6 days.  Total RNA was extracted and qRT-PCR was performed using custom-made 
taqman primer sets.  Relative mRNA expression levels of Col1a1, Dgat1, Lrat, and Cyp2s1 are 
shown.  Values are normalized to 18S.  N for each time point is 2, thus statistical analysis is not 






























































Figure 4-7.  Representative LC/MS/MS profiles of endocannabinoids, sphingolipids, 
ceramides and free fatty acids in HSCs.  HSCs were isolated from WT C57BL/6 mice by 
flotation in a Nycodenz density gradient, and lipids were extracted by the Folch method from 
aliquots of 0.5x106 cells.  Representative LC/MS/MS profiles of endocannabinoids (A), 
sphingolipids (B), ceramides (C) and free fatty acids (D) in HSCs are shown.  Red lines indicate 







































Figure 4-8.  Endocannabinoid levels in HSCs after short-term activation.  Collagen-green 
fluorescent protein (GFP) mice in the C57BL/6 genetic background between 90 and 120 d old 
were given 2 injections, separated by 48 h, of either 1.0 µl carbon tetrachloride (CCl4) per gram 
body weight administered in corn oil or an equivalent volume of corn oil alone.  HSCs were 
isolated 24 h after the last injection; mice were fasted 12 h prior to HSC isolation.  HSCs were 
isolated from pronase digests of non-parenchymal cells by FACS, and GFP-positive cells were 
collected.  Lipids were extracted by the Folch method from aliquots of 0.5x106 cells, and 
endocannabinoid levels were determined by LC/MS/MS analysis.  Quantification of anandamide 
(AEA) and total arachidonoyl glycerol (1-AG and 2-AG) levels is shown.  Significance was 
determined by a Student’s t-test, ** p-value < 0.01.       











































Figure 4-9.  Sphingolipid levels in HSCs after short-term activation. Collagen-green 
fluorescent protein (GFP) mice in the C57BL/6 genetic background between 90 and 120 d old 
were given 2 injections, separated by 48 h, of either 1.0 µl carbon tetrachloride (CCl4) per gram 
body weight administered in corn oil or an equivalent volume of corn oil alone.  HSCs were 
isolated 24 h after the last injection; mice were fasted 12 h prior to HSC isolation.  HSCs were 
isolated from pronase digests of non-parenchymal cells by FACS, and GFP-positive cells were 
collected.  Lipids were extracted by the Folch method from aliquots of 0.5x106 cells, and 
sphingolipid levels were determined by LC/MS/MS analysis.  Quantification of sphingosine 
(SO), sphinganine (SA), and sphingosine-1-phosphate (S-1-P) levels is shown.  Sphinganine-1-
phosphate was not detected in HSCs.  Significance was determined by a Student’s t-test, * p-
















































Figure 4-10.  Ceramide levels in HSCs after short-term activation.  Collagen-green 
fluorescent protein (GFP) mice in the C57BL/6 genetic background between 90 and 120 d old 
were given 2 injections, separated by 48 h, of either 1.0 µl carbon tetrachloride (CCl4) per gram 
body weight administered in corn oil or an equivalent volume of corn oil alone.  HSCs were 
isolated 24 h after the last injection; mice were fasted 12 h prior to HSC isolation.  HSCs were 
isolated from pronase digests of non-parenchymal cells by FACS, and GFP-positive cells were 
collected.  Lipids were extracted by the Folch method from aliquots of 0.5x106 cells, and 
ceramide levels were determined by LC/MS/MS analysis.  Quantification of levels of the major 
and minor ceramide species and of total ceramide is shown.  Significance was determined by a 






Summary and Future Directions 
 
 The ultimate goal of this dissertation was to further elucidate the factors that regulate 
HSC retinoid storage as retinyl esters in lipid droplets and to define the factors that regulate HSC 
lipid droplet genesis and dissolution.  The first aim was to characterize the HSC population 
present in a healthy adult mouse liver.  Previous reports in the literature suggested that there is a 
lipocyte-like population in the liver that is vitamin A-deficient and that this population could be 
induced to an activated, myofibroblastic phenotype [204, 205].  We wanted to further investigate 
this idea of heterogeneity and to address the question of whether the HSC population in a healthy 
adult mouse liver is phenotypically heterogeneous with regard to capacity for retinoid and lipid 
storage and lipid droplet content.  To this end, we employed two FACS-based methods of HSC 
isolation: vitamin A autofluorescence and GFP expression driven by the collagen 1a1 (Col1a1) 
promoter.  The first method leverages HSC lipid droplet vitamin A content, a feature of 
quiescent HSCs, and the second method leverages HSC collagen type I expression, a feature of 
activated HSCs.  The hypotheses addressed were as follows.  If the HSC population is 
homogenous, such that the every cell has equivalent lipid droplet vitamin A content and 
equivalent expression of Col1a1, then both methods of isolation will yield populations with the 
same biochemical features (Figure 1).  Alternatively, if the HSC population is heterogeneous, 
such that the cells have different lipid droplet vitamin A content and different levels of Col1a1 
expression, then the use of these two isolation methods will capitalize on this: the isolation of 
cells by vitamin A autofluorescence will be biased towards the isolation of lipid droplet vitamin 
A-rich cells, and isolation based on GFP expression will be biased towards the isolation of cells 
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with higher expression of Col1a1 (Figure 1).  Our findings provide strong evidence for the 
second hypothesis.  We show that the GFP-based method of HSC isolation yields cells that are 
biochemically different from those isolated by vitamin A autofluorescence and that the 
characteristics of the GFP-HSCs overlap almost completely with the known characteristics of 
activated HSCs, as summarized in Table 1.  Because the livers of these mice have not been 
experimentally injured, we conclude that the HSC population in a healthy, uninjured liver is 
heterogeneous, and there exists a population of “pre-activated” HSCs in the liver that may act as 
first-responders to acute liver injury. 
 In addition to confirming heterogeneity in the HSC population under normal, 
physiological conditions in the liver and characterizing these two populations of cells, this study 
reported a number of novel findings.  One of these findings concerns the changes in HSC lipid 
droplets in the very early stages of activation.  We show that the lipid droplets in the pre-
activated HSC population are greater in number and smaller in size, suggesting that the first step 
of HSC activation involves the fragmentation and dispersion of the lipid droplets into 
microdroplets.  An advantage of this response is that it provides increased surface area for lipase 
action, which is supported by the finding that this population has elevated levels of a number of 
lipases and esterases.  It will be necessary for future studies to confirm this sequence of events in 
HSCs directly with real-time tracking of lipid droplet remodeling in response to HSC activation.  
This may involve capturing the changes in these lipid droplets at varying time points within the 
first 24 hours of activation.  It will also be necessary to define the contribution of the lipid 
droplet-associated proteins, such as ADRP, to these processes.  Our data show that ADRP 
protein expression is not different in the two populations of HSCs, but its distribution in the cell 
and on the lipid droplets might be changed as a consequence of the beginning stages of lipolysis.   
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 In fact, the lipid droplet-associated proteins have not been widely studied in HSCs and, 
even less so, in activated HSCs.  Quiescent HSCs have been found to express ADRP and TIP47 
[275, 276, 235], but little else is known with regard to HSC lipid droplet-associated proteins.  
Proteomic analysis of lipid droplets in other cell types has shown that the proteins associated 
with lipid droplets in a basal state is very different from those associated with the droplets in 
pathogenesis.  In 3T3-L1 adipocytes, perilipin, TIP47 and S3-12 have been associated with the 
basal state; whereas, ADRP and a number of Rab GTPases have been associated exclusively 
with lipolytically-stimulated adipocytes [212].  It has also been reported that perilipin, which 
under normal conditions is only found in adipocytes and steroidogenic cells, becomes de novo 
expressed in hepatocytes in steatotic livers [277, 278].  The reorganization of lipid droplet-
associated proteins in response to activation leads to the recruitment of other proteins, such as 
hormone sensitive lipase, that ultimately control lipolysis in these droplets [279].  Thus, future 
studies of HSC lipid droplet biology should focus on the isolation of these droplets from basal 
and activated HSCs and the charactization of their proteome by SDS-PAGE and mass 
spectroscopy analysis.           
 Another novel finding of this study was the identification of Ces3 and LpL as potential 
retinyl ester hydrolases in activated HSCs.  We observed a large increase in expression of Ces3 
in the pre-activated HSC population.  This is interesting in light of the fact that other 
carboxylesterases have recently been proposed as potential retinyl ester hydrolases in mouse 
HSCs, including ES-4 and -10 [71, 216].  Similarly, we find elevated levels of LpL in the GFP-
HSC population.  Mello et al. have shown that LpL is expressed at very low levels in hepatocytes 
and HSCs, but its expression is induced 32-fold in activated HSCs [71].  These findings suggest 
that Ces3 and LpL might be retinyl ester hydrolases in activated HSCs, but more work will need 
  
184
to be done to confirm their HSC expression and role in retinyl ester hydrolysis.  LpL is less 
likely to be a physiologically significant retinyl ester hydrolase because it is a secreted enzyme, 
and there is no evidence for it acting intracellularly.  However, these two enzymes could be 
studied in the same manner we pursued potential retinyl ester hydrolase activity in CYP2S1 in 
activated HSCs.  This would involve the determination of Ces3 and LpL mRNA and protein 
levels in hepatocytes and HSCs to establish their hepatic expression.  Each protein could also be 
overexpressed as a recombinant adenovirus in primary isolates of HSCs to assess their ability to 
hydrolyze retinyl ester to retinol and their effects on HSC lipid droplet content.   
 Arguably the most exciting finding of this study is the identification of CYP2S1 as a 
mediator of HSC activation that possesses retinyl ester hydrolase activity.  Specifically, our data 
shows CYP2S1 to be elevated on the array, by qRT-PCR and by western blot in the pre-activated 
HSC population compared to the quiescent population of cells.  We also show that CYP2S1 
mRNA is elevated in vivo in response to CCl4-mediated hepatic fibrosis induction, and CYP2S1 
expression is enriched in purified HSCs relative to hepatocytes.  Furthermore, we show that 
cultured primary isolates of HSCs transfected with a recombinant adenovirus overexpressing 
CYP2S1 undergo increased retinyl ester hydrolysis, thereby directly proving this cytochrome 
plays a role in the loss of retinyl ester in the early stages of HSC activation.  It will be necessary 
for future studies to confirm the exact retinoid substrates of CYP2S1, namely retinol, retinyl 
ester and retinoic acid, and the contribution of the retinoid binding proteins, the CRBPs (cellular 
retinol-binding proteins) and CRABPs (cellular retinoic acid-binding proteins), to these 
processes.  The recombinant adenovirus we created can be further utilized for these studies.  A 
cell line with a clean background for retinoid metabolism and CYP2S1 expression would be 
infected with AdCYP2S1 or AdGFP vector control, and microsomal protein would be isolated, 
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since CYP2S1 is a membrane-associated protein.  In vitro assays could then be conducted, in 
which tritiated retinol, retinyl ester or retinoic acid would be added to the microsomal protein 
fractions and the catabolism of each would be tracked by the amount of counts associated with 
the aqueous, soluble phase (containing polar metabolites) versus the counts remaining in the 
organic phase (containing retinol, retinyl ester, and retinoic acid) after a retinoid extraction.  The 
experiment would be performed in the presence and absence of CRBP-I and -II and CRABP-I 
and -II to determine if and how these binding proteins affect catabolism of their respective 
substrates by CYP2S1. 
 In a separate, but parallel, study we investigated HSC lipid droplet biology in genetically-
modified mice that do not express LRAT, a model system where HSC lipid droplets do not form.  
The purpose of this study was to identify the key genes and pathways involved in HSC lipid 
droplet formation and maintenance by comparing the gene expression profile of HSCs isolated 
from WT mice to that of HSCs isolated from LRAT KO mice.  Unexpectedly, the array and 
accompanying qRT-PCR data indicated no statistically significant differential expression in a 
number of retinoid- and lipid-related parameters in the LRAT KO HSCs, including the nuclear 
receptors Ppar-α and -γ, Rxr-α,-β and -γ, and RAR-α, -β and –γ, and the binding proteins of the 
Rbp and Fabp families.  The array and qRT-PCR data also indicated no statistically significant 
differential expression in the retinoic acid-synthesizing enzymes, the Aldh’s, or in the retinoic 
acid-catabolizing enzymes, the Cyp’s.  These findings were taken to indicate that the formation 
and maintenance of HSC lipid droplets may be regulated entirely by the synthesis of retinyl ester 
and not by more profound changes in retinoid metabolism.   
Surprisingly, the array and qRT-PCR data also showed no differential expression in the 
lipid droplet-associated proteins in the LRAT KO HSCs, unexpected since there is seemingly no 
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reason for the lipid droplet proteins to be present if there are no lipid droplets in the cell.  
However, western blot analysis showed that ADFP (also known as ADRP) is not present at the 
protein level in LRAT KO HSCs.  This is an important and novel finding because we show for 
the first time, to our knowledge, that the lipid droplet-associated proteins may undergo 
posttranscriptional processing.  To confirm this finding, it would be helpful to conduct 
complementary, side-by-side in situ hybridizations and immunohistochemistry to localize these 
proteins at the RNA and protein levels, respectively, within HSCs isolated from WT-GFP and 
LRAT KO-GFP mice.  Success would be most likely if primary isolates of HSCs were used 
because the small percentage of HSCs in the liver will make detection in whole liver sections 
very difficult.  This experiment would directly confirm that the lipid droplet-associated proteins 
are present at the mRNA and protein levels in WT HSCs, but only at the mRNA level in LRAT 
KO HSCs.   
The array data did suggest differential expression in a number of lipid-related parameters 
in the LRAT KO-GFP HSCs.  Overall, lipid biosynthesis appears to be down-regulated and lipid 
catabolism is up-regulated in the LRAT KO-GFP HSCs, consistent with the absence of lipid 
droplets in these cells.  These findings are also consistent with the idea that when the 
predominant lipid species found in a particular droplet is absent (in this case, retinyl ester), the 
other lipids in the cell (triglycerides, cholesterol, cholesterol ester and phospholipids) are 
targeted for degradation, and the droplets will no longer be formed.  Unfortunately, we were 
unable to confirm differences in expression of the many genes identified by the array by qRT-
PCR analysis.  mRNA levels of the lipid synthetic genes were trending towards decreased levels 
in the LRAT KO-GFP HSCs, and levels of the lipid catabolic genes were trending towards 
elevated levels in the LRAT KO-GFP HSCs; however, in all cases, these differences were not 
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found to be significant.  A possible explanation for this is the difficulty in obtaining highly pure 
and adequate quantities of HSCs.  Both the Nycodenz density gradient and the FACS-based 
method employed for this study are subject to contamination by other hepatic cell types, and 
even the small presence of these other cells could confound the data.  It seems likely that the 
global changes in lipid metabolism in LRAT KO-HSCs suggested by the array and qRT-PCR 
data are real, but we will need to change our approach to confirm these differences and gain a 
better understanding of the altered lipid content in these cells.  Our lab has recently developed 
the methods for LC/MS/MS analysis of various classes of lipids, including endocannabinoids, 
sphingolipids, ceramides, free fatty acids, and fatty acyl-CoA’s.  Rather than using changes in 
gene expression as an indicator of altered lipid content, in future studies we can directly assess 
the lipid content of LRAT KO HSCs.  It would be particularly interesting to determine free fatty 
acid and fatty acyl-CoA levels because the decreased expression of many genes involved in long 
chain fatty acid synthesis in LRAT KO HSCs on the array indicates there is a shift towards 
shorter-chain fatty acids in these cells.  
 A final component of this dissertation research was the study of HSC lipid droplet 
dissolution with HSC activation and the progression of hepatic disease.  To this end, we 
employed a number of different experimental models of HSC activation, including 
hypervitaminosis, CCl4 exposure and the culture of primary isolates of HSCs on plastic cell 
culture dishes.  Specifically, we wanted to determine: the role LRAT may play in the 
development and progression of diet- and chemically-induced hepatic fibrosis; if these different 
types of hepatic injury elicit different responses in HSCs; and the changes occurring in the 
expression of genes associated with retinoid and lipid metabolism and in the lipidome of 
activated HSCs.   
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Our studies suggest that, despite being unable to synthesize and store retinyl ester in lipid 
droplets, LRAT KO mice are not more susceptible than WT to the development of diet- or 
chemically-induced hepatic fibrosis.  In both these models, hepatic levels of α-SMA and Col1a1, 
two established markers of HSC activation, are not significantly elevated in the LRAT KO mice 
compared to WT.  Furthermore, trichrome staining of liver sections shows that, in LRAT KO 
mice, the area of fibrotic lesions is small and equivalent to staining in WT mice.  One point of 
contention is that the WT mice on the high retinol diet did not have significantly elevated levels 
of α-SMA and Col1a1 compared to WT mice on the basal diet, suggesting that either diet alone 
is not enough to induce hepatic fibrosis, contrary to published reports in human patients [248-
253], or our diet regimen was too mild.  Future studies would benefit from increasing the 
duration of the study and/or the amount of retinol that is supplemented in the diet.  Vitamin 
toxicity in human patients occurs between 10- and 100-fold excess of the recommended daily 
dosage of 5000 IU.  We designed a relatively mild diet regimen of 25X retinol over 4 weeks 
since this is the first time a study of this nature is being carried out in mice, and we did not know 
how the mice would respond.  Our findings indicate that the amount of retinol can be increased 
anywhere from 50- to 100-X, and the study could be carried out over 8-12 weeks.  Pushing the 
system in this manner will either force the phenotype or confirm our findings that 
hypervitaminosis A does not induce hepatic fibrosis in mice.  
Furthermore, repeating both of these studies using harsher dietary and CCl4 regimens will 
clarify the role of LRAT in these different types of hepatic injury.  A recently-published study 
reports that the absence of lipid droplets does not predispose LRAT KO mice to spontaneous, 
CCl4-induced or BDL-induced hepatic fibrosis; however, LRAT deficiency seemingly is 
protective in chemically-induced hepatocellular carcinoma [271].  Our data shows that Col1a1 is 
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significantly decreased in LRAT KO mice in response to the high retinol diet and is significantly 
decreased in response to CCl4 exposure relative to WT mice.  These findings suggest that, as in 
hepatocellular carcinoma, LRAT deficiency may be protective in both diet- and CCl4-induced 
hepatic fibrosis.  The report by Kluwe et al. used a very similar CCl4 regimen to our study, 
consisting of 0.5 µl CCl4/g B.W. injected approximately twice a week for one month [271].  
Models of CCl4-induced hepatic fibrosis in the literature range in dosage from 0.5-2 µl/g B.W. 
from 4-12 weeks [244, 245].  Both Kluwe et al. and our own study used a relatively mild 
regimen, so it is possible that if we push this system further, we will see a clear phenotype in the 
LRAT KO mice.   
Another aim of this study was to investigate the changes in the gene expression profile of 
activated HSCs.  The use of CCl4 exposure, as described in the experiments above, for this 
purpose would be problematic, because once the cells are activated in the animal, they lose their 
lipid droplets, thereby making the isolation of cells by Nycodenz difficult.  The Nycodenz 
method relies on lipid droplet content in the cells, so use of this method would bias us towards 
the isolation of quiescent, lipid droplet-rich HSCs.  To avoid this complication, we isolated 
primary HSCs and activated them in vitro by culturing on plastic.  In addition to studying gene 
expression changes at various stages of HSC activation, we also wished to determine whether 
different types of activation lead to the same conserved response in HSCs.  We found that, while 
the culture of HSCs on plastic results in the typical hallmark events of HSC activation, including 
the upregulation of Col1a1, the decrease in retinyl ester and the loss of lipid droplets, it does not 
regulate gene expression as HSC activation does in vivo.  These findings are consistent with a 
published study comparing the gene expression profiles of three models of HSC activation by 
DNA microarray analysis [88].  Specifically, these investigators found a strong correlation in the 
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gene expression patterns between the two in vivo models of CCl4 and BDL, but a weak 
correlation in the gene expression pattern of these two in vivo models with the in vitro model of 
culture activation [88].  This published report, along with our data, provide strong grounds for 
the rejection of the in vitro model as a useful and applicable model of HSC activation and its 
effects on retinoid storage, and thus, all future work in this area ought to be conducted in vivo. 
As a final arm of these studies, we conducted a preliminary, proof-of-principle lipidomics 
study in primary isolates of in vivo-activated HSCs.  To our knowledge, a study of this nature has 
yet to be reported in the literature, so two goals of our study were: (i) to show this can be done 
and (ii) to generate hypotheses that will allow for the design of more profound and conclusive 
experiments in the future.  Our data show that we can simultaneously and successfully measure 
levels of endocannabinoids, sphingolipids, ceramides and free fatty acids in as little as 0.5x106 
HSCs, with prominent LC/MS/MS peaks indicating a high level of detection.  We were 
particularly interested in these lipid classes because they are potent lipid signaling molecules that 
play a role in cell proliferation and cell death, events reflective of the remodeling occurring in an 
injured liver, and additionally, because they have each been implicated in a number of metabolic 
diseases, including alcoholic liver disease, a case in which HSCs are known to activate and lose 
their retinoid content, as well [260].  We found that, after two injections of 1.0 µl CCl4/g B.W. 
spaced 48 h apart, the HSCs have significantly decreased levels of the endocannabinoid, 
anandamide (AEA), and of the sphingolipids, sphingosine (SO) and sphinganine (SA).  Levels of 
many of the major ceramides are trending towards elevation, though only C24 was found to be 
significant.   
Based on these findings, we hypothesize that endocannabinoids and sphingolipids may 
function in HSCs as mediators of apoptosis.  The low levels of these lipids in the very early 
  
191
stages of HSC activation allow the cells to proliferate and thereby, promote activation and 
hepatic fibrosis development.  As the cells become further activated and disease progresses, we 
predict levels will rise in an effort to induce injured/activated HSCs to apoptose.  This hypothesis 
is supported by a published report showing that, after long-term HSC activation, induced by 
BDL and CCl4, hepatic levels of the endocannabinoid 2-AG were significantly elevated [163].  
The elevated levels of ceramides are inconsistent with these data.  However, ceramides are 
known to be very potent inducers of cell apoptosis; therefore, it may be that levels rise sooner 
than endocannabinoids and sphingolipids in an attempt to inhibit proliferation.  
In addition to giving a novel first glimpse at the role lipid signaling molecules may play 
in the early stages of HSC activation, this study lays the foundation upon which all future studies 
may be built.  This study should first be repeated with a larger sample size to ensure any 
differences will reach statistical significance.  The study should also be expanded to include 
more time points, so we can track the changes in these lipids at early, intermediate and advanced 
stages of HSC activation and hepatic fibrosis.  Thus, we can firmly establish the time-frame in 
which these lipids act.  One very important application of these data would be the use of one or 
more of these lipid signaling molecules as biomarkers of hepatic disease stage and/or therapeutic 
targets.   
It will also be important to integrate the changes in these lipid levels with gene 
transcription changes in the enzymes involved in their synthesis and catabolism.  Among the 
genes of interest are phospholipase D and diacylglycerol lipase, which are involved in the 
synthesis of AEA and 2-AG, respectively (Figure 2).  Also important are fatty acid amide 
hydrolase and monoglyceride lipase, involved in the catabolism of AEA and AG, respectively 
(Figure 2).  Of high interest in the endocannabinoid pathway are the endocannabinoid receptors, 
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CB1 and CB2.  These cell membrane receptors, containing transmembrane spanning domains, 
mediate the binding and trafficking of endocannabinoids into and out of cells in various tissues, 
and they have also been implicated as mediators of hepatic fibrosis.  Interestingly, CB1 has been 
suggested to have a fibrogenic role in liver injury [164]; whereas, CB2 has been suggested to be 
antifibrogenic [165].  In regard to sphingolipid and ceramide metabolism, genes of interest 
would include 3-keto sphinganine reductase, sphinganine kinase, sphinganine-1P phosphatase, 
ceramide synthase, ceramidase, sphingosine-1P phosphatase, and sphingosine-1P lyase, the roles 
of which are summarized in Figure 3.  Furthermore, inactivation of the sphingolipid receptor, 
sphingosine-1-phosphate receptor 2, has been shown to ameliorate CCl4-induced hepatic fibrosis 
[267]. 
    The ultimate goal of this dissertation research was to further elucidate the factors 
regulating lipid droplet formation and dissolution in HSCs.  The major findings of this research 
and significant contributions to the field are discussed herein.  Previous work from our lab has 
established that HSC lipid droplets are specialized organelles for the storage of vitamin A in the 
form of retinyl ester, such that when retinyl ester is not synthesized, these droplets will not form.  
This work extended these findings and showed that the formation of HSC lipid droplets is likely 
regulated entirely by the synthesis and storage of retinyl ester in these cells and not by more 
profound changes in retinoid or lipid metabolism.  It has also been long-debated whether the loss 
of HSC lipid droplets is a cause or a consequence of hepatic disease.  Our findings that the 
absence of lipid droplets does not predispose mice to developing hepatic fibrosis argue against a 
causative role of HSC lipid droplet loss in the development of hepatic disease.  Rather, it appears 
that the loss of retinoids and lipid droplets is a response to disease, perhaps to allow the HSCs to 
function more readily in injury repair.  This idea connects with our finding that there is a 
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population of pre-activated HSCs in a healthy liver.  These HSCs, which have already begun to 
“dump” their vitamin A content, are primed and ready to respond to acute hepatic injury (for 
example, alcohol consumption).  Lastly, we report a novel method of HSC isolation that is not 
dependent on lipid droplet content, which promises to have a significant impact on the field in 
the study of in vivo-activated HSCs.  HSC lipid droplets are proven to be dynamic and complex 
organelles; therefore, despite these gains, much remains to be learned about their role in retinoid 





















Table 5-1.  Summary of differences found between AF- and GFP-HSCs and comparison to 
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HSC Population is Homogeneous
Hypothesis 2:
HSC Population is Heterogeneous
AF GFP AF GFP
= HSC with higher lipid droplet vitamin A content, less Col1a1 expression
= HSC with higher Col1a1 expression, less lipid droplet vitamin A content
= HSC with equivalent lipid droplet vitamin A content and Col1a1 expression
 
 
Figure 5-1.  Hypotheses underlying the use of the two FACS-based methods of HSC 
isolation.  If the HSC population is homogenous, such that every cell has equivalent lipid droplet 
vitamin A content and equivalent expression of Col1a1, then both methods of isolation will yield 
populations with the same biochemical features.  Alternatively, if the HSC population is 
heterogeneous, such that the cells have different lipid droplet vitamin A content and different 
levels of Col1a1 expression, then the use of these two isolation methods will capitalize on this: 
the isolation of cells by vitamin A autofluorescence (AF) will be biased towards the isolation of 
lipid droplet vitamin A-rich cells, and isolation based on GFP expression will be biased towards 





















Figure 5-2.  Overview of endocannabinoid metabolism.  A simplified scheme of 
endocannabinoid metabolism is shown.  Endocannabinoids are formed within various 
mammalian cell types from membranous fatty-acid precursors via the activity of the 
phosphodiesterase enzyme, phospholipase D (anandamide), and diacylglycerol (DAG) lipase (2-
AG).  After their extracellular release, the endocannabinoids can either bind to cannabinoid 
receptors or be degraded.  The endocannabinoids are degraded through reuptake by a diffusion 
facilitated transport molecule and then hydrolytically cleaved by enzymes such as fatty-acid-
amide hydrolase and monoglyceride lipase to break down the endocannabinoids to molecules 
such as arachidonic acid and ethanolamine.  Figure was modified from an original created by 





























Figure 5-3.  Overview of sphingolipid metabolism.  A simplified scheme of sphingolipid 
metabolism is shown.  Serine: palmitoyl transferase is the initial and rate-limiting enzyme in the 
de novo sphingolipid biosynthesis cascade.  This enzyme catalyzes the condensation of 
palmitoyl-CoA with serine to form 3-keto-sphinganine, which is further metabolized to generate 
sphinganine and, ultimately, ceramide.  Ceramide can then be acted on by a number of enzymes 
to generate molecules known to be important in both intra- and intercellular signaling.  
Ceramidase converts ceramide to sphingosine, and sphingosine serves as the substrate for 
sphingosine kinase to generate sphingosine-1-phosphate.  Figure was modified from an original 
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